10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM  TO  

COMMISSION FILE NUMBER 1-11846

AptarGroup, Inc.

DELAWARE	36-3853103
(State of Incorporation)	(I.R.S. Employer Identification No.)

265 EXCHANGE DRIVE, SUITE 100, CRYSTAL LAKE, ILLINOIS 60014

815-477-0424

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $.01 par value	ATR	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ◻ No þ

The number of shares outstanding of common stock, as of July 24, 2020, was 64,473,805 shares.

AptarGroup, Inc.

Form 10-Q

Quarter Ended June 30, 2020

INDEX

Part I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Statements of Income – Three and Six Months Ended June 30, 2020 and 2019	1
	Condensed Consolidated Statements of Comprehensive Income – Three and Six Months Ended June 30, 2020 and 2019	2
	Condensed Consolidated Balance Sheets – June 30, 2020 and December 31, 2019	3
	Condensed Consolidated Statements of Changes in Equity – Three and Six Months Ended June 30, 2020 and 2019	5
	Condensed Consolidated Statements of Cash Flows - Six Months Ended June 30, 2020 and 2019	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	43
Item 4.	Controls and Procedures	43
Part II.	OTHER INFORMATION
Item 1A.	Risk Factors	44
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 5.	Other Information	45
Item 6.	Exhibits	45
	Signature	46

i

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

In thousands, except per share amounts
	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Sales	$	699,305	$	742,661	$	1,420,858	$	1,487,121
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)		441,702		469,441		892,958		938,573
Selling, research & development and administrative		123,365		113,752		249,557		234,967
Depreciation and amortization		56,429		47,867		107,235		95,356
Restructuring initiatives		7,331		1,737		12,170		11,267
		628,827		632,797		1,261,920		1,280,163
Operating Income		70,478		109,864		158,938		206,958
Other (Expense) Income:
Interest expense		(8,734)		(8,756)		(17,122)		(17,970)
Interest income		175		1,033		350		2,781
Equity in results of affiliates		(328)		9		(1,127)		(86)
Miscellaneous, net		(923)		(49)		(2,335)		417
		(9,810)		(7,763)		(20,234)		(14,858)
Income before Income Taxes		60,668		102,101		138,704		192,100
Provision for Income Taxes		18,808		28,180		41,594		55,180
Net Income	$	41,860	$	73,921	$	97,110	$	136,920
Net Income Attributable to Noncontrolling Interests	$	(21)	$	(6)	$	(18)	$	(1)
Net Income Attributable to AptarGroup, Inc.	$	41,839	$	73,915	$	97,092	$	136,919
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic	$	0.65	$	1.16	$	1.51	$	2.17
Diluted	$	0.63	$	1.12	$	1.47	$	2.08
Average Number of Shares Outstanding:
Basic		64,262		63,471		64,135		63,219
Diluted		66,384		66,232		66,246		65,842
Dividends per Common Share	$	0.36	$	0.36	$	0.72	$	0.70

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

1

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

In thousands
	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Income	$	41,860	$	73,921	$	97,110	$	136,920
Other Comprehensive Income (Loss):
Foreign currency translation adjustments		19,096		9,414		(23,133)		(197)
Changes in derivative (losses) gains, net of tax		(733)		(479)		750		(872)
Defined benefit pension plan, net of tax
Amortization of prior service cost included in net income, net of tax		72		83		143		167
Amortization of net loss included in net income, net of tax		1,368		633		2,933		1,270
Total defined benefit pension plan, net of tax		1,440		716		3,076		1,437
Total other comprehensive income (loss)		19,803		9,651		(19,307)		368
Comprehensive Income		61,663		83,572		77,803		137,288
Comprehensive (Income) Loss Attributable to Noncontrolling Interests		(22)		2		(19)		(1)
Comprehensive Income Attributable to AptarGroup, Inc.	$	61,641	$	83,574	$	77,784	$	137,287

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

2

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

In thousands
		June 30,		December 31,
		2020		2019
Assets
Current Assets:
Cash and equivalents	$	247,656	$	241,970
Accounts and notes receivable, less current expected credit loss ("CECL") of $6,080 in 2020 and $3,626 in 2019		575,655		558,428
Inventories		381,939		375,795
Prepaid and other		138,321		115,048
		1,343,571		1,291,241
Property, Plant and Equipment:
Buildings and improvements		521,312		504,328
Machinery and equipment		2,578,354		2,521,737
		3,099,666		3,026,065
Less: Accumulated depreciation		(2,028,101)		(1,963,520)
		1,071,565		1,062,545
Land		26,355		25,133
		1,097,920		1,087,678
Other Assets:
Investments in equity securities		44,193		8,396
Goodwill		861,928		763,461
Intangible assets, net		352,740		291,084
Operating lease right-of-use assets		68,665		72,377
Miscellaneous		44,999		47,882
		1,372,525		1,183,200
Total Assets	$	3,814,016	$	3,562,119

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

3

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

In thousands, except share and per share amounts
		June 30,		December 31,
		2020		2019
Liabilities and Stockholders’ Equity
Current Liabilities:
Notes payable, revolving credit facility and overdrafts	$	150,831	$	44,259
Current maturities of long-term obligations, net of unamortized debt issuance costs		66,248		65,988
Accounts payable, accrued and other liabilities		612,688		573,028
		829,767		683,275
Long-Term Obligations, net of unamortized debt issuance costs		1,082,742		1,085,453
Deferred Liabilities and Other:
Deferred income taxes		39,414		41,388
Retirement and deferred compensation plans		108,896		101,225
Operating lease liabilities		52,036		55,276
Deferred and other non-current liabilities		55,175		23,250
Commitments and contingencies		—		—
		255,521		221,139
Stockholders’ Equity:
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 69.0 and 68.6 million shares issued as of June 30, 2020 and December 31, 2019, respectively		690		686
Capital in excess of par value		803,511		770,596
Retained earnings		1,573,392		1,523,820
Accumulated other comprehensive loss		(361,256)		(341,948)
Less: Treasury stock at cost, 4.7 and 4.8 million shares as of June 30, 2020 and December 31, 2019, respectively		(370,706)		(381,238)
Total AptarGroup, Inc. Stockholders’ Equity		1,645,631		1,571,916
Noncontrolling interests in subsidiaries		355		336
Total Stockholders’ Equity		1,645,986		1,572,252
Total Liabilities and Stockholders’ Equity	$	3,814,016	$	3,562,119

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

4

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

In thousands
Three Months Ended	AptarGroup, Inc. Stockholders’ Equity
June 30, 2020 and 2019			Accumulated
			Other		Common				Capital in		Non-
	Retained		Comprehensive		Stock		Treasury		Excess of		Controlling		Total
	Earnings		(Loss) Income		Par Value		Stock		Par Value		Interest		Equity
Balance - March 31, 2019	$	1,413,453	$	(319,795)	$	676	$	(327,871)	$	700,933	$	318	$	1,467,714
Net income		73,915		—		—		—		—		6		73,921
Foreign currency translation adjustments		—		9,422		—		—		—		(8)		9,414
Changes in unrecognized pension gains (losses) and related amortization, net of tax		—		716		—		—		—		—		716
Changes in derivative gains (losses), net of tax		—		(479)		—		—		—		—		(479)
Stock awards and option exercises		—		—		7		14,587		42,399		—		56,993
Cash dividends declared on common stock		(22,761)		—		—		—		—		—		(22,761)
Treasury stock purchased		—		—		—		(4,096)		—		—		(4,096)
Balance - June 30, 2019	$	1,464,607	$	(310,136)	$	683	$	(317,380)	$	743,332	$	316	$	1,581,422
Balance - March 31, 2020	$	1,554,665	$	(381,058)	$	689	$	(372,573)	$	785,567	$	333	$	1,587,623
Net income		41,839		—		—		—		—		21		41,860
Foreign currency translation adjustments		—		19,095		—		—		—		1		19,096
Changes in unrecognized pension gains (losses) and related amortization, net of tax		—		1,440		—		—		—		—		1,440
Changes in derivative gains (losses), net of tax		—		(733)		—		—		—		—		(733)
Stock awards and option exercises		—		—		1		1,867		17,944		—		19,812
Cash dividends declared on common stock		(23,112)		—		—		—		—		—		(23,112)
Balance - June 30, 2020	$	1,573,392	$	(361,256)	$	690	$	(370,706)	$	803,511	$	355	$	1,645,986

In thousands
Six Months Ended	AptarGroup, Inc. Stockholders’ Equity
June 30, 2020 and 2019			Accumulated
			Other		Common				Capital in		Non-
	Retained		Comprehensive		Stock		Treasury		Excess of		Controlling		Total
	Earnings		(Loss) Income		Par Value		Stock		Par Value		Interest		Equity
Balance - December 31, 2018	$	1,371,826	$	(310,504)	$	673	$	(318,208)	$	678,769	$	315	$	1,422,871
Net income		136,919		—		—		—		—		1		136,920
Foreign currency translation adjustments		—		(197)		—		—		—		—		(197)
Changes in unrecognized pension gains (losses) and related amortization, net of tax		—		1,437		—		—		—		—		1,437
Changes in derivative gains (losses), net of tax		—		(872)		—		—		—		—		(872)
Stock awards and option exercises		—		—		10		19,924		64,563		—		84,497
Cash dividends declared on common stock		(44,138)		—		—		—		—		—		(44,138)
Treasury stock purchased		—		—		—		(19,096)		—		—		(19,096)
Balance - June 30, 2019	$	1,464,607	$	(310,136)	$	683	$	(317,380)	$	743,332	$	316	$	1,581,422
Balance - December 31, 2019	$	1,523,820	$	(341,948)	$	686	$	(381,238)	$	770,596	$	336	$	1,572,252
Net income		97,092		—		—		—		—		18		97,110
Adoption of CECL standard		(1,377)		—		—		—		—		—		(1,377)
Foreign currency translation adjustments		—		(23,134)		—		—		—		1		(23,133)
Changes in unrecognized pension gains (losses) and related amortization, net of tax		—		3,076		—		—		—		—		3,076
Changes in derivative gains (losses), net of tax		—		750		—		—		—		—		750
Stock awards and option exercises		—		—		4		10,532		32,915		—		43,451
Cash dividends declared on common stock		(46,143)		—		—		—		—		—		(46,143)
Balance - June 30, 2020	$	1,573,392	$	(361,256)	$	690	$	(370,706)	$	803,511	$	355	$	1,645,986

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

5

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

In thousands, brackets denote cash outflows
Six Months Ended June 30,		2020		2019
Cash Flows from Operating Activities:
Net income	$	97,110	$	136,920
Adjustments to reconcile net income to net cash provided by operations:
Depreciation		86,901		82,968
Amortization		20,334		12,388
Stock-based compensation		17,603		12,978
Provision for CECL		1,089		312
(Gain) loss on disposition of fixed assets		(46)		368
Deferred income taxes		9		679
Defined benefit plan expense		11,550		7,699
Equity in results of affiliates		1,127		86
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables		(25,625)		(28,772)
Inventories		(13,241)		(18,503)
Prepaid and other current assets		(16,936)		546
Accounts payable, accrued and other liabilities		63,256		14,590
Income taxes payable		(8,446)		1,840
Retirement and deferred compensation plan liabilities		(5,916)		(4,652)
Other changes, net		(1,083)		1,693
Net Cash Provided by Operations		227,686		221,140
Cash Flows from Investing Activities:
Capital expenditures		(122,986)		(124,774)
Proceeds from sale of property, plant and equipment		4,130		1,082
Acquisition of business, net of cash acquired and release of escrow		(159,570)		(49,131)
Acquisition of intangible assets, net		(3,612)		(602)
Investment in equity securities		(34,044)		—
Proceeds from sale of investment in equity securities		—		16,487
Notes receivable, net		(1,045)		(220)
Net Cash Used by Investing Activities		(317,127)		(157,158)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts		14,464		31,022
Repayments of notes payable and overdrafts		(27,788)		(35,490)
Proceeds and repayments of short term revolving credit facility, net		125,000		(38,685)
Proceeds from long-term obligations		1,316		10,446
Repayments of long-term obligations		(4,067)		(6,546)
Payment of contingent consideration obligation		(1,500)		—
Dividends paid		(46,143)		(44,138)
Proceeds from stock option exercises		30,058		70,712
Purchase of treasury stock		—		(19,096)
Net Cash Provided (Used) by Financing Activities		91,340		(31,775)
Effect of Exchange Rate Changes on Cash		8,522		3,920
Net Increase in Cash and Equivalents and Restricted Cash		10,421		36,127
Cash and Equivalents and Restricted Cash at Beginning of Period		246,973		266,823
Cash and Equivalents and Restricted Cash at End of Period	$	257,394	$	302,950

Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow related to the Noble and Fusion Acquisitions (as defined herein).

Six Months Ended June 30,		2020		2019
Cash and equivalents	$	247,656	$	302,950
Restricted cash included in prepaid and other		9,738		—
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$	257,394	$	302,950

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

6

AptarGroup, Inc.

Notes to Condensed Consolidated Financial Statements

(Dollars in Thousands, Except per Share Amounts, or as Otherwise Indicated)

(Unaudited)

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.

In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.

Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. For the six months ended June 30, 2020, our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues.

There are many uncertainties regarding the current COVID-19 pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic and the extent of local and worldwide social, political and economic disruption it may cause. The pandemic has impacted our business, operations and financial results during the six months ended June 30, 2020 including an overall reduction to net sales. No impairments were recorded as of June 30, 2020. While the disruption is currently expected to be temporary, there is uncertainty around the duration. Due to significant uncertainty surrounding the situation, our judgment regarding future results could change and therefore our results could be materially impacted.

ADOPTION OF RECENT ACCOUNTING STANDARDS

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.

Effective January 1, 2020, we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, issued by the FASB in June 2016, as well as the clarifying amendments subsequently issued. We applied the guidance using a modified retrospective approach and accordingly recognized an amount of $1.4 million as the cumulative adjustment to opening retained earnings in the first quarter of 2020. This is based on management's best estimates of specific losses on individual exposures particularly on current trade receivables, as well as the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. On an ongoing basis, we will contemplate forward-looking economic conditions in recording lifetime expected credit losses for our financial assets measured at cost, such as our trade receivables and certain other assets.

7

In January 2017, the FASB issued ASU 2017-04, which provides guidance to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As a result, impairment charges are required for the amount by which a reporting unit’s carrying amount exceeds its fair value up to the amount of its allocated goodwill. We adopted the standard on January 1, 2020 and did not record any impairment charges.

In August 2018, the FASB issued ASU 2018-15 to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted the standard on January 1, 2020 and no material impacts were noted.

In August 2018, the FASB issued ASU 2018-13, which amends disclosure requirements for fair value measurements. The new standard modifies disclosure requirements including removing requirements to disclose the valuation process for Level 3 measurements and adding requirements to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements and the range and weighted average of significant unobservable inputs used to develop Level 3 measurements. We adopted the standard on January 1, 2020 and no material impacts were noted.

Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.

INCOME TAXES

We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested.  Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and the global cash management goals of the Company.

We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition.

The Company is subject to taxation and files income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. The Company believes that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in the Company’s tax audits are resolved in a manner inconsistent with its expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.

NOTE 2 – REVENUE

At contract inception, we assess the goods and services promised in our contracts with customers and identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product and tooling sales; however, we also receive revenues from service, license, exclusivity and royalty arrangements, which collectively are not material to the quarterly and year-to-date results. Revenue by segment and geography for the three and six months ended June 30, 2020 and 2019 is as follows:

8

	For the Three Months Ended June 30, 2020
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	152,412	$	94,349	$	29,893	$	23,132	$	299,786
Pharma		201,813		81,098		6,987		11,361		301,259
Food + Beverage		27,841		54,478		6,489		9,452		98,260
Total	$	382,066	$	229,925	$	43,369	$	43,945	$	699,305

	For the Three Months Ended June 30, 2019
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	202,541	$	73,973	$	41,449	$	24,117	$	342,080
Pharma		190,654		76,042		7,078		8,165		281,939
Food + Beverage		32,336		65,160		9,211		11,935		118,642
Total	$	425,531	$	215,175	$	57,738	$	44,217	$	742,661

	For the Six Months Ended June 30, 2020
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	339,362	$	176,194	$	66,074	$	42,716	$	624,346
Pharma		391,943		172,063		13,566		20,883		598,455
Food + Beverage		56,610		112,068		14,523		14,856		198,057
Total	$	787,915	$	460,325	$	94,163	$	78,455	$	1,420,858

	For the Six Months Ended June 30, 2019
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	418,774	$	160,952	$	84,091	$	45,922	$	709,739
Pharma		374,828		147,814		14,734		17,264		554,640
Food + Beverage		63,297		120,280		17,095		22,070		222,742
Total	$	856,899	$	429,046	$	115,920	$	85,256	$	1,487,121

We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the receipt of the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance.

The opening and closing balances of our contract asset and contract liabilities are as follows:

	Balance as of		Balance as of		Increase/
	December 31, 2019		June 30, 2020		(Decrease)
Contract asset (current)	$	16,245	$	15,113	$	(1,132)
Contract asset (long-term)	$	—	$	—	$	—
Contract liability (current)	$	79,305	$	70,708	$	(8,597)
Contract liability (long-term)	$	9,779	$	20,662	$	10,883

The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the customer’s payment. The total amount of revenue recognized during the current year against contract liabilities is $27.3 million, including $21.6 million relating to contract liabilities at the beginning of the year.

Determining the Transaction Price

In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled.

9

Product Sales

We primarily manufacture and sell dispensing, sealing and active packaging solutions. The amount of consideration is typically fixed for such customers. At the time of delivery, the customer is invoiced the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer.

To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. A majority of product sales are sold free on board (“FOB”) shipping point. For FOB shipping point shipments, control of the goods transfers to the customer at the time of shipment of the goods. Therefore, our performance obligation is satisfied at the time of shipment. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale.

There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the Output Method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks.

As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties.

Tooling Sales

We also build, or contract to build molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the Input Method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any material significant payment terms as payment is typically either received during the mold-build process or shortly after completion.

In certain instances, we offer extended warranties on tools sold to our customers above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. At December 31, 2019, $515 thousand of unearned revenue associated with outstanding contracts was reported in Accounts Payable, Accrued and Other Liabilities. At June 30, 2020, the unearned amount was $410 thousand. We expect to recognize approximately $111 thousand of the unearned amount during the remainder of 2020, $125 thousand in 2021, and $174 thousand thereafter.

Credit Risk

We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review.

We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.

At June 30, 2020, we reported $576 million of accounts receivable, net of CECL of $6.1 million. Changes in the allowance were not material for the six months ended June 30, 2020. Current uncertainty in credit and market conditions due to the COVID-19 pandemic may slow our collection efforts if customers experience significant difficulty accessing credit and paying their obligations, which may lead to higher than normal accounts receivable and increased CECL charges.

10

NOTE 3 - INVENTORIES

Inventories, by component, consisted of:

	June 30,		December 31,
	2020		2019
Raw materials	$	112,287	$	111,653
Work in process		123,710		123,750
Finished goods		145,942		140,392
Total	$	381,939	$	375,795

NOTE 4 – GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by reporting segment since December 31, 2019 are as follows:

	Beauty +				Food +		Corporate
	Home		Pharma		Beverage		& Other		Total
Goodwill	$	221,658	$	413,650	$	128,153	$	1,615	$	765,076
Accumulated impairment losses		—		—		—		(1,615)		(1,615)
Balance as of December 31, 2019	$	221,658	$	413,650	$	128,153	$	—	$	763,461
Acquisition		99,644		463		—		—		100,107
Foreign currency exchange effects		(473)		(1,175)		8		—		(1,640)
Goodwill	$	320,829	$	412,938	$	128,161	$	1,615	$	863,543
Accumulated impairment losses		—		—		—		(1,615)		(1,615)
Balance as of June 30, 2020	$	320,829	$	412,938	$	128,161	$	—	$	861,928

The table below shows a summary of intangible assets as of June 30, 2020 and December 31, 2019.

		June 30, 2020							December 31, 2019
Weighted Average		Gross						Gross
Amortization Period		Carrying		Accumulated		Net		Carrying		Accumulated		Net
	(Years)	Amount		Amortization		Value		Amount		Amortization		Value
Amortized intangible assets:
Patents	7.1	$	2,703		(1,334)	$	1,369	$	2,804	$	(1,318)	$	1,486
Acquired technology	12.6		105,020		(29,907)		75,113		100,511		(25,430)		75,081
Customer relationships	13.5		279,709		(43,561)		236,148		217,934		(33,924)		184,010
Trademarks and trade names	6.0		44,508		(13,568)		30,940		35,015		(11,003)		24,012
License agreements and other	15.5		22,480		(13,310)		9,170		16,153		(9,658)		6,495
Total intangible assets	12.6	$	454,420	$	(101,680)	$	352,740	$	372,417	$	(81,333)	$	291,084

Aggregate amortization expense for the intangible assets above for the quarters ended June 30, 2020 and 2019 was $12,320 and $6,386, respectively. Aggregate amortization expense for the intangible assets above for the six months ended June 30, 2020 and 2019 was $20,334 and $12,388, respectively.

Future estimated amortization expense for the years ending December 31 is as follows:

2020	$	19,192	(remaining estimated amortization for 2020)
2021		37,723
2022		37,443
2023		37,362
2024 and thereafter		221,020

11

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of June 30, 2020.

NOTE 5 – INCOME TAXES

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items.

The effective tax rate for the three months ended June 30, 2020 and 2019, respectively, was 31.0% and 27.6%. The effective tax rate for the three months ended June 30, 2019 was favorably impacted by net tax benefits of $2.9 million from discrete events. This consisted of a $9.1 million benefit from the excess tax benefits from employee share-based compensation offset by, among other items, a $6.3 million charge to record a valuation allowance to properly reflect the realization of recorded deferred tax assets.

The effective tax rate for the six months ended June 30, 2020 and 2019, respectively, was 30.0% and 28.7%. The effective tax rate for the six months ended June 30, 2020 reflects a favorable impact of net tax benefits of $4.6 million, primarily from the excess tax benefits from employee share-based compensation.  This is offset by the unfavorable impact from the mix of earnings, particularly losses in jurisdictions where we cannot record the tax benefit. The effective tax rate for the six months ended June 30, 2019 was favorably impacted by net tax benefits of $4.1 million from discrete events.  This consisted of a favorable impact of $11.6 million from the excess tax benefits from employee share-based compensation, offset by, among other items, a $7.0 million charge recognized to record a valuation allowance to properly reflect the realization of recorded deferred tax assets.

NOTE 6 – DEBT

Notes Payable, Revolving Credit Facility and Overdrafts

At June 30, 2020 and December 31, 2019, our notes payable, revolving credit facility and overdrafts, consisted of the following:

	June 30,		December 31,
	2020		2019
Notes payable 8.00%	$	831	$	1,436
Revolving credit facility 1.28%		150,000		25,000
Overdrafts 5.68% - 7.82%		—		17,823
	$	150,831	$	44,259

We maintain a multi-currency revolving credit facility with two tranches that matures in July 2022 which provides for unsecured financing of up to $300 million that is available in the U.S. and up to €150 million that is available to our wholly-owned UK subsidiary. $150.0 million was utilized under our U.S. facility and no balance was utilized under our euro-based revolving credit facility as of June 30, 2020. $25.0 million was utilized under our U.S. facility and no balance was utilized on our euro-based revolving credit facility as of December 31, 2019.

There are no compensating balance requirements associated with our revolving credit facility. Each borrowing under the credit facility will bear interest at rates based on LIBOR, prime rates or other similar rates, in each case plus an applicable margin. A facility fee on the total amount of the facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio.

12

Long-Term Obligations

At June 30, 2020, our long-term obligations consisted of the following:

			Unamortized
			Debt Issuance
	Principal		Costs		Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028	$	15,358	$	—	$	15,358
Senior unsecured notes 3.2%, due in 2022		75,000		52		74,948
Senior unsecured debts 2.4% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022		168,000		315		167,685
Senior unsecured notes 3.5%, due in 2023		125,000		126		124,874
Senior unsecured notes 1.0%, due in 2023		112,340		326		112,014
Senior unsecured notes 3.4%, due in 2024		50,000		56		49,944
Senior unsecured notes 3.5%, due in 2024		100,000		126		99,874
Senior unsecured notes 1.2%, due in 2024		224,680		661		224,019
Senior unsecured notes 3.6%, due in 2025		125,000		145		124,855
Senior unsecured notes 3.6%, due in 2026		125,000		145		124,855
Finance Lease Liabilities		30,564		—		30,564
	$	1,150,942	$	1,952	$	1,148,990
Current maturities of long-term obligations		(66,248)		—		(66,248)
Total long-term obligations	$	1,084,694	$	1,952	$	1,082,742

At December 31, 2019, our long-term obligations consisted of the following:

			Unamortized
			Debt Issuance
	Principal		Costs		Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028	$	19,220	$	—	$	19,220
Senior unsecured notes 3.2%, due in 2022		75,000		64		74,936
Senior unsecured debts 3.2% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022		168,000		390		167,610
Senior unsecured notes 3.5%, due in 2023		125,000		144		124,856
Senior unsecured notes 1.0%, due in 2023		112,170		356		111,814
Senior unsecured notes 3.4%, due in 2024		50,000		63		49,937
Senior unsecured notes 3.5%, due in 2024		100,000		144		99,856
Senior unsecured notes 1.2%, due in 2024		224,340		742		223,598
Senior unsecured notes 3.6%, due in 2025		125,000		169		124,831
Senior unsecured notes 3.6%, due in 2026		125,000		169		124,831
Finance Lease Liabilities		29,952		—		29,952
	$	1,153,682	$	2,241	$	1,151,441
Current maturities of long-term obligations		(65,988)		—		(65,988)
Total long-term obligations	$	1,087,694	$	2,241	$	1,085,453

The aggregate long-term maturities, excluding finance lease liabilities, which are disclosed in Note 7, due annually from the current balance sheet date for the next five years are $62,259, $59,990, $133,859, $338,967, $274,900 and $250,404 thereafter.

Covenants

Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

	Requirement	Level at June 30, 2020
Consolidated Leverage Ratio (1)	Maximum of 3.50 to 1.00	1.98 to 1.00
Consolidated Interest Coverage Ratio (1)	Minimum of 3.00 to 1.00	15.50 to 1.00

(1) Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.  

13

NOTE 7 – LEASES

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2034. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.

Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”).

The components of lease expense for the three and six months ended June 30, 2020 and 2019 were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Operating lease cost	$	5,841	$	5,437	$	11,095	$	11,441
Finance lease cost:
Amortization of right-of-use assets	$	906	$	1,004	$	2,105	$	1,876
Interest on lease liabilities		369		325		717		640
Total finance lease cost	$	1,275	$	1,329	$	2,822	$	2,516
Short-term lease and variable lease costs	$	2,430	$	2,328	$	4,878	$	4,270

Supplemental cash flow information related to leases was as follows:

Six Months Ended June 30,	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	11,662	$	10,249
Operating cash flows from finance leases		704		534
Financing cash flows from finance leases		2,545		2,294
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	11,371	$	9,512
Finance leases		3,127		11,622

NOTE 8 – RETIREMENT AND DEFERRED COMPENSATION PLANS

Components of Net Periodic Benefit Cost:

	Domestic Plans				Foreign Plans
Three Months Ended June 30,	2020		2019		2020		2019
Service cost	$	3,562	$	2,775	$	1,767	$	1,445
Interest cost		1,536		1,846		340		495
Expected return on plan assets		(2,702)		(3,095)		(631)		(586)
Amortization of net loss		1,294		489		514		359
Amortization of prior service cost		—		—		95		113
Net periodic benefit cost	$	3,690	$	2,015	$	2,085	$	1,826

	Domestic Plans				Foreign Plans
Six Months Ended June 30,	2020		2019		2020		2019
Service cost	$	7,139	$	5,548	$	3,535	$	2,905
Interest cost		3,523		3,691		680		996
Expected return on plan assets		(6,124)		(6,189)		(1,265)		(1,178)
Amortization of net loss		2,842		978		1,028		722
Amortization of prior service cost		—		—		192		226
Net periodic benefit cost	$	7,380	$	4,028	$	4,170	$	3,671

The components of net periodic benefit cost, other than the service cost component, are included in the line “Miscellaneous, net” in the income statement.

14

EMPLOYER CONTRIBUTIONS

Although we currently have no minimum funding requirements for our domestic and foreign plans, we contributed $204 thousand to our ongoing domestic supplemental employee retirement plan (“SERP”) annuity contracts during the six months ended June 30, 2020. We plan to contribute approximately an additional $200 thousand to pay our ongoing SERP annuity contracts during 2020. We have contributed approximately $1.1 million to our foreign defined benefit plans during the six months ended June 30, 2020 and do not expect additional significant contributions during 2020.

NOTE 9 – ACCUMULATED OTHER COMPREHENSIVE INCOME

Changes in Accumulated Other Comprehensive (Loss) Income by Component:

	Foreign		Defined Benefit
	Currency		Pension Plans		Derivatives		Total
Balance - December 31, 2018	$	(248,401)	$	(60,463)	$	(1,640)	$	(310,504)
Other comprehensive (loss) income before reclassifications		(197)		—		3,727		3,530
Amounts reclassified from accumulated other comprehensive income (loss)		—		1,437		(4,599)		(3,162)
Net current-period other comprehensive (loss) income		(197)		1,437		(872)		368
Balance - June 30, 2019	$	(248,598)	$	(59,026)	$	(2,512)	$	(310,136)
Balance - December 31, 2019	$	(257,124)	$	(83,147)	$	(1,677)	$	(341,948)
Other comprehensive (loss) income before reclassifications		(23,134)		—		1,758		(21,376)
Amounts reclassified from accumulated other comprehensive income (loss)		—		3,076		(1,008)		2,068
Net current-period other comprehensive (loss) income		(23,134)		3,076		750		(19,308)
Balance - June 30, 2020	$	(280,258)	$	(80,071)	$	(927)	$	(361,256)

Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:

	Amount Reclassified from
Details about Accumulated Other	Accumulated Other				Affected Line in the Statement
Comprehensive Income Components	Comprehensive Income				Where Net Income is Presented
Three Months Ended June 30,	2020		2019
Defined Benefit Pension Plans
Amortization of net loss	$	1,808	$	848	(1)
Amortization of prior service cost		95		113	(1)
		1,903		961	Total before tax
		(463)		(245)	Tax benefit
	$	1,440	$	716	Net of tax
Derivatives
Changes in cross currency swap: interest component	$	(525)	$	(1,552)	Interest Expense
Changes in cross currency swap: foreign exchange component		3,060		3,084	Miscellaneous, net
	$	2,535	$	1,532	Net of tax
Total reclassifications for the period	$	3,975	$	2,248

15

	Amount Reclassified from
Details about Accumulated Other	Accumulated Other				Affected Line in the Statement
Comprehensive Income Components	Comprehensive Income				Where Net Income is Presented
Six Months Ended June 30,	2020		2019
Defined Benefit Pension Plans
Amortization of net loss	$	3,870	$	1,700	(1)
Amortization of prior service cost		192		226	(1)
		4,062		1,926	Total before tax
		(986)		(489)	Tax benefit
	$	3,076	$	1,437	Net of tax
Derivatives
Changes in cross currency swap: interest component	$	(1,288)	$	(3,006)	Interest Expense
Changes in cross currency swap: foreign exchange component		280		(1,593)	Miscellaneous, net
	$	(1,008)	$	(4,599)	Net of tax
Total reclassifications for the period	$	2,068	$	(3,162)

(1) These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

NOTE 10 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.

For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets. See Note 11 - Fair Value for additional details.

Cash Flow Hedge

For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows.

During 2017, our wholly-owned UK subsidiary borrowed $280 million in term loan borrowings under a new credit facility. In order to mitigate the currency risk of U.S. dollar debt on a euro functional currency entity and to mitigate the risk of variability in interest rates, we entered into a cross currency swap in the notional amount of $280 million to effectively hedge the foreign exchange and interest rate exposure on the $280 million term loan. This EUR/USD swap agreement fixed our U.S. dollar floating-rate debt to 1.36% euro fixed-rate debt. Related to this hedge, approximately $0.9 million of loss is included in accumulated other comprehensive loss at June 30, 2020. The amount expected to be recognized into earnings during the next 12 months related to the interest component of our cross currency swap based on prevailing foreign exchange and interest rates at June 30, 2020 is $0.3 million. The amount expected to be recognized into earnings during the next 12 months related to the foreign exchange component of our cross currency swap is dependent on fluctuations in currency exchange rates. As of June 30, 2020, the fair values of the cross currency swap were a $3.1 million asset. The swap contract expires on July 20, 2022.

16

Hedge of Net Investments in Foreign Operations

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we maintain debt in these subsidiaries to offset the net asset exposure. We do not otherwise actively manage this risk using derivative financial instruments. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.

Other

As of June 30, 2020, we have recorded the fair value of foreign currency forward exchange contracts of $0.7 million in prepaid and other and $0.1 million in accounts payable and accrued liabilities on the balance sheet. All forward exchange contracts outstanding as of June 30, 2020 had an aggregate notional contract amount of $49.4 million.

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019

		June 30, 2020				December 31, 2019
				Derivatives				Derivatives
		Derivatives		not		Derivatives		not
		Designated		Designated		Designated		Designated
	Balance Sheet	as Hedging		as Hedging		as Hedging		as Hedging
	Location	Instruments		Instruments		Instruments		Instruments
Derivative Assets
Foreign Exchange Contracts	Prepaid and other	$	—	$	747	$	—	$	206
Cross Currency Swap Contract (1)	Prepaid and other		3,052		—		2,552		—
		$	3,052	$	747	$	2,552	$	206
Derivative Liabilities
Foreign Exchange Contracts	Accounts payable, accrued and other liabilities	$	—	$	137	$	—	$	401
		$	—	$	137	$	—	$	401

(1) This cross currency swap contract is composed of both an interest component and a foreign exchange component.

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June 30, 2020 and 2019

						Amount of Gain (Loss)				Total Amount
	Amount of Gain (Loss)				Location of (Loss)	Reclassified from				of Affected
Derivatives in Cash	Recognized in				Gain Recognized	Accumulated				Income
Flow Hedging	Other Comprehensive				in Income on	Other Comprehensive				Statement
Relationships	Income on Derivative				Derivatives	Income on Derivative				Line Item
	2020		2019			2020		2019
Cross currency swap contract:
Interest component	$	(208)	$	1,080	Interest expense	$	525	$	1,552	$	(8,734)
Foreign exchange component		(3,060)		(3,084)	Miscellaneous, net		(3,060)		(3,084)		(923)
	$	(3,268)	$	(2,004)		$	(2,535)	$	(1,532)

17

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Six Months Ended June 30, 2020 and 2019

						Amount of Gain (Loss)				Total Amount
	Amount of Gain (Loss)				Location of (Loss)	Reclassified from				of Affected
Derivatives in Cash	Recognized in				Gain Recognized	Accumulated				Income
Flow Hedging	Other Comprehensive				in Income on	Other Comprehensive				Statement
Relationships	Income on Derivative				Derivatives	Income on Derivative				Line Item
	2020		2019			2020		2019
Cross currency swap contract:
Interest component	$	2,038	$	2,472	Interest expense	$	1,288	$	3,006	$	(17,122)
Foreign exchange component		(280)		1,593	Miscellaneous, net		(280)		1,593		(2,335)
	$	1,758	$	4,065		$	1,008	$	4,599

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2020 and 2019

		Amount of (Loss) Gain
Derivatives Not Designated	Location of (Loss) Gain Recognized	Recognized in Income
as Hedging Instruments	in Income on Derivatives	on Derivatives
		2020		2019
Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	(940)	$	(251)
		$	(940)	$	(251)

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2020 and 2019

		Amount of (Loss) Gain
Derivatives Not Designated	Location of (Loss) Gain Recognized	Recognized in Income
as Hedging Instruments	in Income on Derivatives	on Derivatives
		2020		2019
Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	807	$	(514)
		$	807	$	(514)

						Gross Amounts not Offset
			Gross Amounts	Net Amounts		in the Statement of
			Offset in the	Presented in		Financial Position
	Gross		Statement of	the Statement of		Financial	Cash Collateral	Net
	Amount		Financial Position	Financial Position		Instruments	Received	Amount
Description
June 30, 2020
Derivative Assets	$	3,799	—	$	3,799	—	—	$	3,799
Total Assets	$	3,799	—	$	3,799	—	—	$	3,799
Derivative Liabilities	$	137	—	$	137	—	—	$	137
Total Liabilities	$	137	—	$	137	—	—	$	137
December 31, 2019
Derivative Assets	$	2,758	—	$	2,758	—	—	$	2,758
Total Assets	$	2,758	—	$	2,758	—	—	$	2,758
Derivative Liabilities	$	401	—	$	401	—	—	$	401
Total Liabilities	$	401	—	$	401	—	—	$	401

18

NOTE 11 – FAIR VALUE

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

● Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

● Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

● Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

As of June 30, 2020, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
Assets
Foreign exchange contracts (1)	$	747	$	—	$	747	$	—
Cross currency swap contract (1)		3,052		—		3,052		—
Total assets at fair value	$	3,799	$	—	$	3,799	$	—
Liabilities
Foreign exchange contracts (1)	$	137	$	—	$	137	$	—
Contingent consideration obligation		24,710		—		—		24,710
Total liabilities at fair value	$	24,847	$	—	$	137	$	24,710

As of December 31, 2019, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
Assets
Foreign exchange contracts (1)	$	206	$	—	$	206	$	—
Cross currency swap contract (1)		2,552		—		2,552		—
Total assets at fair value	$	2,758	$	—	$	2,758	$	—
Liabilities
Foreign exchange contracts (1)	$	401	$	—	$	401	$	—
Contingent consideration obligation		5,930		—		—		5,930
Total liabilities at fair value	$	6,331	$	—	$	401	$	5,930

(1) Market approach valuation technique based on observable market transactions of spot and forward rates.

The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instruments. We consider our long-term obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $1.1 billion as of June 30, 2020 and $1.1 billion as of December 31, 2019.

As discussed in Note 17 - Acquisitions, we have a contingent consideration obligation to the selling equity holders of Fusion in connection with the Fusion Acquisition (as defined herein) based on 2022 cumulative performance targets, a contingent consideration obligation to the selling equity holders of Noble in connection with the Noble Acquisition (as defined herein) based on 2024 cumulative performance targets and a contingent consideration obligation to the selling equity holder of Gateway in connection with the Gateway Acquisition (as defined herein) based on 2020 and 2022 performance targets. We consider these obligations Level 3 liabilities and have estimated the aggregate fair value for these contingent consideration arrangements to be $20.3 million, $2.9 million and $1.5 million, respectively, as of June 30, 2020. During the quarter ended June 30, 2020, $1.5 million of the Gateway contingent consideration accrual was paid as a result of the business meeting their first performance target. As of December 31, 2019 the aggregate fair value for these contingent consideration arrangements was $2.9 million and $3.0 million for the Noble Acquisition and the Gateway Acquisition, respectively.

NOTE 12 - COMMITMENTS AND CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur and could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.

19

Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of June 30, 2020 and December 31, 2019.

A fire caused damage to our facility in Annecy, France in June 2016. We are insured for the damages caused by the fire, including business interruption insurance.  For the six months ended June 30, 2020, we did not receive any insurance proceeds, and have no insurance receivable as of June 30, 2020. During the six months ended June 30, 2020 and 2019, profitability was not impacted. The final settlement continues to be negotiated. In many cases, our insurance coverage exceeds the amount of our recognized losses. However, no gain contingencies were recognized during the six months ended June 30, 2020 as our ability to realize those gains remains uncertain.

An environmental investigation, undertaken to assess areas of possible contamination, was completed at our facility in Jundiaí, São Paulo, Brazil. The facility is primarily an internal supplier of anodized aluminum components for certain of our dispensing systems. The testing indicated that soil and groundwater in certain areas of the facility were impacted above acceptable levels established by local regulations. In March 2017, we reported the findings to the relevant environmental authority, the Environmental Company of the State of São Paulo – CETESB. Based upon our best estimate, we recorded a reserve of $1.5 million (operating expense) in the first quarter of 2017 related to this contingency. During 2019, we paid approximately $0.6 million. For the six months ended June 30, 2020, we paid approximately $0.1 million and made adjustments to the accrual based on our future anticipated expenditures.  As of June 30, 2020, our outstanding reserve is $0.4 million. The ultimate loss associated with this environmental contingency is subject to the investigation and ongoing review of the CETESB. We will continue to evaluate the range of likely costs as the investigation proceeds and we have further clarity on the nature and extent of remediation that will be required. We note that the contamination, or any failure to complete any required remediation in a timely manner, could potentially result in fines or penalties.

In March 2017, the Supreme Court of Brazil issued a decision that a certain state value added tax should not be included in the calculation of federal gross receipts taxes. The decision reduces our gross receipts tax in Brazil prospectively and, potentially, retrospectively. During the first quarter of 2019, we received a favorable court decision of $2.7 million for the retrospective right to recover part of our claim. This amount is recorded in cost of sales as a favorable impact of $1.7 million and $1.0 million was recognized as interest income. In June 2020, we received a favorable court decision of $0.7 million for the retrospective right to recover part of our claim. This amount is recorded in cost of sales as a favorable impact of $0.7 million. If the Judicial Court grants full retrospective recovery, we estimate remaining potential recoveries of approximately $1.5 million to $7.5 million, including interest, depending on the future decisions of the Supreme Court of Brazil. Due to uncertainties around our remaining court recovery claims, we have not recorded any further amounts relating to the retrospective nature of this matter.

In December 2019, tax authorities in Brazil notified us of a tax assessment of approximately $6.1 million, including interest and penalties of $2.3 million and $0.8 million, respectively, relating to differences in tax classification codes used for import duties for the period from January 2015 to August 2018. We are vigorously contesting the assessment, including interest and penalties, and have filed an administrative defense appeal in December 2019. On June 4, 2020, an unfavorable decision was issued on the first administrative defense appeal. We are awaiting the formal notification in order to review its content and file our second appeal. We still believe we have a strong defense. Due to uncertainty in the amount of assessment and the timing of our appeal, no liability is recorded as of June 30, 2020.

NOTE 13 – STOCK REPURCHASE PROGRAM

On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

During the three and six months ended June 30, 2020, we did not repurchase any shares. During the three and six months ended June 30, 2019, we repurchased approximately 34 thousand shares and 193 thousand shares for approximately $4.1 million and $19.1 million, respectively. As of June 30, 2020, there was $278.5 million of authorized share repurchases available to us.

20

NOTE 14 – STOCK-BASED COMPENSATION

We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. Performance-based RSUs have one of two vesting conditions: (1) based on our internal financial performance metrics and (2) based on our total shareholder return (“TSR”) relative to total shareholder returns of an industrial peer group. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest over one year.

The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.

Six Months Ended June 30,		2020			2019
Fair value per stock award	$	94.98		$	134.97
Grant date stock price	$	83.93		$	104.51
Assumptions:
Aptar's stock price expected volatility		23.80	%		16.50	%
Expected average volatility of peer companies		48.50	%		31.90	%
Correlation assumption		63.50	%		37.40	%
Risk-free interest rate		0.31	%		2.19	%
Dividend yield assumption		1.72	%		1.30	%

A summary of RSU activity as of June 30, 2020 and changes during the six month period then ended is presented below:

	Time-Based RSUs			Performance-Based RSUs
		Weighted Average			Weighted Average
	Units	Grant-Date Fair Value		Units	Grant-Date Fair Value
Nonvested at January 1, 2020	480,729	$	95.45	181,680	$	117.26
Granted	229,033		85.57	417,313		93.08
Vested	(125,020)		85.55	—		—
Forfeited	(5,692)		99.08	(6,714)		108.10
Nonvested at June 30, 2020	579,050	$	92.14	592,279	$	100.29

Included in the June 30, 2020 time-based RSUs are 12,379 units granted to non-employee directors and 11,490 units vested related to non-employee directors.

Compensation expense recorded attributable to RSUs for the first six months of 2020 and 2019 was approximately $16.3 million and $9.8 million, respectively. The actual tax benefit realized for the tax deduction from RSUs was approximately $3.0 million in the six months ended June 30, 2020. The fair value of units vested during the six months ended June 30, 2020 and 2019 was $10.7 million and $4.1 million, respectively. The intrinsic value of units vested during the six months ended June 30, 2020 and 2019 was $12.8 million and $4.8 million, respectively. As of June 30, 2020, there was $58.8 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 2.2 years.

Historically we issued stock options to our employees and non-employee directors. Beginning in 2019, we no longer issue stock options. Stock options were awarded with the exercise price equal to the market price on the date of grant and generally vest over three years and expire 10 years after grant. Compensation expense attributable to employee stock options for the first six months of 2020 was approximately $1.3 million ($1.0 million after tax). Approximately $1.1 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. Compensation expense attributable to stock options for the first six months of 2019 was approximately $3.2 million ($2.7 million after tax). Approximately $2.7 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. The reduction in stock option expense is due to our move to RSUs as discussed above. For stock option grants, we used historical data to estimate expected life and volatility.

21

A summary of option activity under our stock plans during the six months ended June 30, 2020 is presented below:

	Stock Awards Plans					Director Stock Option Plans
			Weighted Average				Weighted Average
		Options	Exercise Price			Options	Exercise Price
Outstanding, January 1, 2020		5,044,180	$	68.32		135,251	$	58.45
Granted		—		—		—		—
Exercised		(460,243)		58.21		(30,751)		51.22
Forfeited or expired		(14,200)		76.07		—		—
Outstanding at June 30, 2020		4,569,737	$	69.38		104,500	$	60.58
Exercisable at June 30, 2020		4,416,415	$	68.62		104,500	$	60.58
Weighted-Average Remaining Contractual Term (Years):
Outstanding at June 30, 2020		5.0				3.1
Exercisable at June 30, 2020		4.9				3.1
Aggregate Intrinsic Value:
Outstanding at June 30, 2020	$	194,684			$	4,902
Exercisable at June 30, 2020	$	190,936			$	4,902
Intrinsic Value of Options Exercised During the Six Months Ended:
June 30, 2020	$	26,027			$	1,973
June 30, 2019	$	65,944			$	722

The grant date fair value of options vested during the six months ended June 30, 2020 and 2019 was $7.6 million and $12.2 million, respectively. Cash received from option exercises was approximately $30.1 million and the actual tax benefit realized for the tax deduction from option exercises was approximately $6.4 million in the six months ended June 30, 2020. As of June 30, 2020, the remaining valuation of stock option awards to be expensed in future periods was $1.0 million and the related weighted-average period over which it is expected to be recognized is 0.7 years.

NOTE 15 – EARNINGS PER SHARE

Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and six months ended June 30, 2020 and 2019 is as follows:

	Three Months Ended
	June 30, 2020				June 30, 2019
	Diluted		Basic		Diluted		Basic
Consolidated operations
Income available to common stockholders	$	41,839	$	41,839	$	73,915	$	73,915
Average equivalent shares
Shares of common stock		64,262		64,262		63,471		63,471
Effect of dilutive stock-based compensation
Stock options		1,661		—		2,533		—
Restricted stock		461		—		228		—
Total average equivalent shares		66,384		64,262		66,232		63,471
Net income per share	$	0.63	$	0.65	$	1.12	$	1.16

22

	Six Months Ended
	June 30, 2020				June 30, 2019
	Diluted		Basic		Diluted		Basic
Consolidated operations
Income available to common stockholders	$	97,092	$	97,092	$	136,919	$	136,919
Average equivalent shares
Shares of common stock		64,135		64,135		63,219		63,219
Effect of dilutive stock-based compensation
Stock options		1,734		—		2,411		—
Restricted stock		377		—		212		—
Total average equivalent shares		66,246		64,135		65,842		63,219
Net income per share	$	1.47	$	1.51	$	2.08	$	2.17

NOTE 16 – SEGMENT INFORMATION

We are organized into three reporting segments. Our Beauty + Home segment sells to the personal care, beauty and home care markets. Our Pharma segment serves customers in the prescription drug, consumer health care, injectables and active packaging markets. Our Food + Beverage segment sells to the food and beverage markets.

The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2019. We evaluate performance of our business units and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. All internal segment reporting and discussions of results with our Chief Operating Decision Maker (CODM) are based on segment Adjusted EBITDA.

Financial information regarding our reporting segments is shown below:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Total Sales:
Beauty + Home	$	306,469	$	349,253	$	636,935	$	722,756
Pharma		303,885		284,577		603,475		559,071
Food + Beverage		99,023		119,095		199,324		223,822
Total Sales		709,377		752,925	$	1,439,734	$	1,505,649
Less: Intersegment Sales:
Beauty + Home	$	6,683	$	7,173	$	12,589	$	13,017
Pharma		2,626		2,638		5,020		4,431
Food + Beverage		763		453		1,267		1,080
Total Intersegment Sales	$	10,072	$	10,264	$	18,876	$	18,528
Net Sales:
Beauty + Home	$	299,786	$	342,080	$	624,346	$	709,739
Pharma		301,259		281,939		598,455		554,640
Food + Beverage		98,260		118,642		198,057		222,742
Net Sales	$	699,305	$	742,661	$	1,420,858	$	1,487,121
Adjusted EBITDA (1):
Beauty + Home	$	23,974	$	48,745	$	58,221	$	101,936
Pharma		104,099		101,428		212,441		198,785
Food + Beverage		17,785		20,944		33,192		37,635
Corporate & Other, unallocated		(9,279)		(10,630)		(23,107)		(23,385)
Acquisition-related costs (2)		(3,592)		(1,059)		(5,866)		(1,059)
Restructuring Initiatives (3)		(7,331)		(1,737)		(12,170)		(11,267)
Depreciation and amortization		(56,429)		(47,867)		(107,235)		(95,356)
Interest Expense		(8,734)		(8,756)		(17,122)		(17,970)
Interest Income		175		1,033		350		2,781
Income before Income Taxes	$	60,668	$	102,101	$	138,704	$	192,100

(1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs.

23

(2) Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 17 – Acquisitions and Note 18 – Investment in Equity Securities for further details).

(3) Restructuring Initiatives includes expense items for the three and six months ended June 30, 2020 and 2019 as follows (see Note 19 – Restructuring Initiatives for further details):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Restructuring Initiatives by Segment
Beauty + Home	$	7,324	$	1,259	$	12,231	$	9,528
Pharma		(111)		(113)		(142)		213
Food + Beverage		75		112		178		622
Corporate & Other		43		479		(97)		904
Total Restructuring Initiatives	$	7,331	$	1,737	$	12,170	$	11,267

NOTE 17 – ACQUISITIONS

Business Combinations

On April 1, 2020, we completed our acquisition (the “Fusion Acquisition”) of 100% of the equity interests of Fusion Packaging, Inc. (“Fusion”) for a purchase price of approximately $163.8 million (net of $1.0 million of cash acquired), which was funded by a draw on our revolving credit facility and cash on hand. Fusion, based in Dallas, TX, is a global leader in the design, engineering and distribution of luxury packaging for the beauty industry. As part of the Fusion Acquisition, we are also obligated to pay to the selling equity holders of Fusion certain contingent consideration based on 2022 cumulative financial performance metrics as defined in the purchase agreement. Based on a projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $19.1 million utilizing a Black-Scholes valuation model. As of June 30, 2020, $5.7 million was held in restricted cash pending the finalization of a working capital adjustment and indemnity escrow. Subsequent to the end of the quarter, $2.0 million of working capital escrow was released from restriction. Fusion contributed net sales of $13.8 million and pretax loss of $3.3 million for the quarter ended June 30, 2020 which have been included in the Condensed Consolidated Financial Statements within our Beauty + Home segment. Included in pretax loss is $2.7 million of fair value adjustment amortization for inventory sold during 2020. We are in the process of finalizing our purchase accounting.

On October 31, 2019, we completed our acquisition (the “Noble Acquisition”) of 100% of the equity interests of Noble International Holdings, Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as “Noble”). Noble, based in Orlando, FL, is a leading provider in developing patient-centric advanced drug delivery system training devices including autoinjector, prefilled syringe, onbody and respiratory devices for the world’s leading biopharmaceutical companies and original equipment manufacturers. The purchase price was approximately $62.3 million (net of $1.6 million of cash acquired) and was funded by cash on hand. As part of the Noble Acquisition, we are also obligated to pay to the selling equity holders of Noble certain contingent consideration based on 2024 cumulative financial performance metrics defined in the purchase agreement. Based on projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $2.9 million utilizing the Black-Scholes valuation model. As of December 31, 2019, $5 million was held in restricted cash pending the finalization of a working capital adjustment and indemnity escrow. During the first quarter of 2020, $1.0 million related to the working capital escrow was released from restriction, resulting in an additional $463 thousand payment due to the seller and a corresponding increase to our purchase price and associated goodwill balance. The results of Noble’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.

On June 5, 2019, we completed our acquisition (the “Nanopharm Acquisition”) of all of the outstanding capital stock of Nanopharm Ltd. (“Nanopharm”). Nanopharm, located in Newport, UK, is a science-driven, leading provider of orally inhaled and nasal drug product design and development services. The purchase price was approximately $38.1 million (net of $1.8 million of cash acquired) and was funded by cash on hand. The results of Nanopharm’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.

On May 31, 2019, we completed our acquisition (the “Gateway Acquisition”) of all of the outstanding equity interests of Gateway Analytical LLC (“Gateway”). Gateway, located in Gibsonia, PA, provides industry-leading particulate detection and predictive analytical services to customers developing injectable medicines. The purchase price was approximately $7.0 million and was funded by cash on hand. As part of the Gateway Acquisition, we are also obligated to pay to the selling equity holder of Gateway certain contingent consideration based on 2020 and 2022 performance targets defined in the purchase agreement. Based on projections as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $3.0 million. During the quarter ended June 30, 2020, $1.5 million of the contingent consideration accrual was paid as a result of the business meeting their first performance target. Additionally, the remaining $1.5 million accrual was reclassified from long-term to short-term liabilities as the payment is expected to be made within a year. The results of Gateway’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.

24

The following table summarizes the assets acquired and liabilities assumed as of the acquisition date at estimated fair value.

	2020		2019
Assets
Cash and equivalents	$	1,010	$	3,427
Accounts receivable		4,380		3,504
Inventories		386		—
Prepaid and other		1,090		2,478
Property, plant and equipment		2,885		4,267
Goodwill		99,644		59,143
Intangible assets		79,900		52,980
Operating lease right-of-use assets		4,744		—
Other miscellaneous assets		65		430
Liabilities
Accounts payable, accrued and other liabilities		5,641		5,388
Deferred income taxes		—		2,592
Operating lease liabilities		4,207		—
Deferred and other non-current liabilities		322		1,598
Net assets acquired	$	183,934	$	116,651

The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date:

	2020			2019
	Weighted-Average	Estimated		Weighted-Average	Estimated
	Useful Life	Fair Value		Useful Life	Fair Value
	(in years)	of Asset		(in years)	of Asset
Acquired technology	4	$	4,600	8	$	9,160
Customer relationships	13		62,300	11		39,379
Trademarks and trade names	4		10,300	4		2,457
License agreements and other	0.25		2,700	1		1,984
Total		$	79,900		$	52,980

Goodwill in the amount of $99.6 million was recorded related to the Fusion Acquisition which is included in the Beauty + Home segment and $59.1 million was recorded related to the 2019 acquisitions, all of which are included in the Pharma segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill largely consists of unique relationships, brand equity and proprietary technology that has been established creating niches such as turnkey solutions for the beauty market related to the Fusion Acquisition, analytical services for drug developers related to the Nanopharm Acquisition and Gateway Acquisition and patient onboarding related to the Noble Acquisition, as well as the abilities of the acquired companies to maintain their competitive advantage from a technical viewpoint. Goodwill will not be amortized, but will be tested for impairment at least annually. For the Fusion Acquisition, goodwill of $82.3 million will be deductible for tax purposes. For the 2019 acquisitions, goodwill of $31.1 million will be deductible for tax purposes.

The unaudited pro forma results presented below include the effects of the Fusion Acquisition as if it had occurred as of January 1, 2019. The unaudited pro forma results reflect certain adjustments related to the acquisition, such as intangible asset amortization, fair value adjustments for inventory and financing costs related to the change in our debt structure. The pro forma results do not include any synergies or other expected benefits of the acquisition. Accordingly, the unaudited pro forma financial information below is not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been completed on the date indicated.

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Sales	$	699,305	$	762,148	$	1,428,821	$	1,525,826
Net Income Attributable to AptarGroup Inc.		45,989		75,811		96,350		139,003
Net Income per common share — basic		0.72		1.19		1.50		2.20
Net Income per common share — diluted		0.69		1.14		1.45		2.11

25

Asset Acquisition

On August 2, 2019, we completed our asset acquisition (the “Bapco Acquisition”) of the remaining 80% ownership interest in the capital stock of Bapco Closures Holdings Limited (“Bapco”), for $3.8 million (net of $2.9 million of cash acquired). The 20% ownership investment previously held in Bapco is now included within the intangible assets acquired. Bapco, located in Leeds, UK, provides innovative closures sealing technology that provides package integrity and tamper evidence. The results of Bapco’s operations have been included in the Condensed Consolidated Financial Statements within our Food + Beverage segment since the date of acquisition.

NOTE 18 –INVESTMENT IN EQUITY SECURITIES

Our investment in equity securities consisted of the following:

	June 30,		December 31,
	2020		2019
Equity Method Investments:
BTY	$	30,894	$	119
Sonmol		4,969		—
Kali Care		3,691		3,881
Desotec GmbH		845		858
Other Investments		3,794		3,538
	$	44,193	$	8,396

Equity method investments

Sonmol

On April 1, 2020, we invested $5 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”), a pharmaceutical company that provides connected devices for asthma control.

BTY

On October 1, 2019, we entered into a strategic definitive agreement to acquire 49% of the equity interests in 3 related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”), contingent on the settlement date of the transaction. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years subsequent to the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. On January 1, 2020, the transaction closed for an approximate purchase price of $32 million for our 49% share. As of June 30, 2020, we paid approximately $28.8 million, with the remaining amount of $3.2 million included in Accounts payable, accrued and other liabilities. The amount is payable after certain conditions under the definitive agreement are fulfilled and is expected to be paid during the third quarter of 2020.

Kali Care

During 2017, we invested $5 million to acquire 20% of the equity interests in Kali Care, a technology company that provides digital monitoring systems for medical devices.

Desotec GmbH

During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and home and food and beverages markets.

Other investments

During August 2019, we invested an aggregate amount of $3.5 million in two preferred equity investments in sustainability companies Loop and Purecycle Technologies (“Purecycle”) that are accounted for at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.

26

There were no indications of impairment nor were there any changes from observable price changes noted in the six months ended June 30, 2020 related to these investments.

NOTE 19 – RESTRUCTURING INITIATIVES

In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. For the three and six months ended June 30, 2020, we recognized $7.3 million and $12.2 million of restructuring costs related to this plan, respectively. For the three and six months ended June 30, 2019, we recognized $1.7 million and $11.3 million of restructuring costs related to this plan, respectively. Using current exchange rates, we estimate total implementation costs of approximately $125 million for these initiatives, including costs that have been recognized to date. The cumulative expense incurred as of June 30, 2020 was $98.7 million. We also anticipate making capital investments related to the transformation plan of approximately $50 million, of which $43 million has been incurred to date.

As of June 30, 2020 we have recorded the following activity associated with the business transformation:

	Beginning		Net Charges for						Ending
	Reserve at		the Six Months				Interest and		Reserve at
	12/31/2019		Ended 6/30/2020		Cash Paid		FX Impact		6/30/2020
Employee severance	$	7,090	$	8,190	$	(2,324)	$	192	$	13,148
Professional fees and other costs		3,609		3,980		(4,595)		(17)		2,977
Totals	$	10,699	$	12,170	$	(6,919)	$	175	$	16,125

27

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR AS OTHERWISE INDICATED)

RESULTS OF OPERATIONS

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020		2019
Net sales		100.0	%		100.0	%	100.0	%	100.0	%
Cost of sales (exclusive of depreciation and amortization shown below)		63.2			63.2		62.8		63.1
Selling, research & development and administrative		17.6			15.3		17.6		15.8
Depreciation and amortization		8.1			6.5		7.5		6.4
Restructuring initiatives		1.0			0.2		0.9		0.8
Operating income		10.1			14.8		11.2		13.9
Other expense		(1.4)			(1.1)		(1.4)		(1.0)
Income before income taxes		8.7			13.7		9.8		12.9
Net Income		6.0			10.0		6.8		9.2
Effective tax rate		31.0	%		27.6	%	30.0	%	28.7	%
Adjusted EBITDA margin (1)		19.5	%		21.6	%	19.8	%	21.2	%

(1) Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 35.

SIGNIFICANT DEVELOPMENTS

During the second quarter of 2020, financial results and operations continued to be adversely impacted by the novel coronavirus (“COVID-19”) pandemic. The significance of the impacts to our segments during the second quarter and first six months of 2020 are discussed herein and include, but are not limited to, the adverse impact on sales of our beauty products sold via duty free travel and retail stores and a reduction of our products used for on-the-go beverage applications. The extent to which the COVID-19 pandemic impacts our financial results and operations for fiscal year 2020 and going forward for all three of our business segments will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak and the international actions being taken to contain and treat it. No impairments were recorded as of June 30, 2020. While the disruption is currently expected to be temporary, there is uncertainty around the duration. Due to significant uncertainty surrounding the situation, our judgment regarding future results could change and therefore our results could be materially impacted.

As each of our segments produce dispensing systems that have been determined to be essential products by various government agencies around the world, the majority of our facilities remained operational during the second quarter of 2020. We have taken a variety of measures to ensure the availability and functioning of our critical infrastructure, to promote the safety and security of our employees and to support the communities in which we operate. These measures include requiring remote working arrangements for employees where practicable. We are following public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions, the promotion of social distancing and the adoption of work-from-home arrangements, and all of these policies and initiatives have impacted our operations. Due to the speed with which the situation continues to evolve, we are not able at this time to estimate the impact of COVID-19 on our future financial results and operations, but the impact could be material for the remainder of fiscal year 2020 and could be material during any future periods affected either directly or indirectly by this pandemic. See Part II, Item 1A, “Risk Factors,” included in this report for information on material risks associated with COVID-19.

28

NET SALES

We reported net sales of $699.3 million for the quarter ended June 30, 2020, which represents a 6% decrease compared to $742.7 million reported during the second quarter of 2019. Sales were negatively impacted by changes in currency exchange rates, passing through lower resin costs to customers and COVID-19 related effects on certain markets we serve. The average U.S. dollar exchange rate strengthened compared to most major currencies we operate in, resulting in a negative currency translation impact of 3%. The acquisitions of Gateway, Nanopharm, Noble and Fusion positively impacted sales by 3%. Therefore, core sales, which exclude acquisitions and changes in foreign currency rates, decreased by 6% in the second quarter of 2020 compared to the same period in 2019. During the second quarter of 2020, our consolidated core sales were negatively impacted by the COVID-19 pandemic, especially within our Beauty + Home and Food + Beverage segments. For Beauty + Home, beauty sales were significantly impacted by the loss of travel and retail sales during the second quarter of 2020. Our Food + Beverage segment also realized lower core sales due to the negative impact of COVID-19, especially on our single-serving beverage product sales. Food + Beverage sales were also impacted by lower tooling sales the effects of passing through lower resin costs to our customers during the quarter. Conversely, our Pharma segment was less impacted by the COVID-19 pandemic and realized strong core sales growth during the second quarter of 2020 with three of the four divisions reporting increased sales compared to the same prior year period.

Second Quarter 2020	Beauty				Food +
Net Sales Change over Prior Year	+ Home		Pharma		Beverage		Total
Core Sales Growth	(13)	%	6	%	(15)	%	(6)	%
Acquisitions	4	%	2	%	—	%	3	%
Currency Effects (1)	(3)	%	(1)	%	(2)	%	(3)	%
Total Reported Net Sales Growth	(12)	%	7	%	(17)	%	(6)	%

For the first six months of 2020, we reported net sales of $1.42 billion, 4% below the first six months of 2019 reported net sales of $1.49 billion. Sales were negatively impacted by changes in currency exchange rates, passing-through lower resin costs to customers and COVID-19 related effects on certain markets we serve. The average U.S. dollar exchange rate strengthened compared to most major currencies we operate in, resulting in a negative currency translation impact of 2%. The acquisitions of Gateway, Nanopharm, Noble and Fusion positively impacted sales by 2%.  Therefore, core sales, which exclude acquisitions and changes in foreign currency rates, decreased by 4% in the first six months of 2020 compared to the same period in 2019.  As discussed above, the Beauty + Home and Food + Beverage segments have both been significantly impacted by the COVID-19 pandemic, and passing through lower resin costs.

Six Months Ended June 30, 2020	Beauty				Food +
Net Sales Change over Prior Year	+ Home		Pharma		Beverage		Total
Core Sales Growth	(11)	%	6	%	(9)	%	(4)	%
Acquisitions	2	%	3	%	—	%	2	%
Currency Effects (1)	(3)	%	(1)	%	(2)	%	(2)	%
Total Reported Net Sales Growth	(12)	%	8	%	(11)	%	(4)	%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

The following table sets forth, for the periods indicated, net sales by geographic location:

	Three Months Ended June 30,						Six Months Ended June 30,
	2020		% of Total	2019		% of Total	2020		% of Total	2019		% of Total
Domestic	$	229,925	33%	$	215,175	29%	$	460,325	32%	$	429,046	29%
Europe		382,066	55%		425,531	57%		787,915	55%		856,899	57%
Latin America		43,369	6%		57,738	8%		94,163	7%		115,920	8%
Asia		43,945	6%		44,217	6%		78,455	6%		85,256	6%

For further discussion on net sales by reporting segment, please refer to the analysis of segment net sales and segment Adjusted EBITDA on the following pages.

29

COST OF SALES (EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW)

Cost of sales (“COS”) as a percent of net sales remained consistent at 63.2% in the second quarter of 2020 compared to the second quarter of 2019. Our COS percentage was positively impacted by our cost containment efforts and the mix of business as we reported sales growth in our higher margin Pharma segment compared to sales declines in the Beauty + Home and Food + Beverage segments. However, we did experience some additional costs, under-absorbed overhead and temporary disruptions to our manufacturing capacities during the second quarter of 2020 related to the COVID-19 pandemic. For example, we declared a special bonus payment to certain employees who worked to maintain supply to our customers and keep our facilities running, which increased our COS percentage during the second quarter of 2020.  

Cost of sales as a percent of net sales decreased slightly to 62.8% in the first six months of 2020 compared to 63.1% in the same period a year ago. As mentioned above, our COS was favorably impacted by the increased mix in our higher margin Pharma business. We also realized approximately $5.4 million in lower resin costs during the first half of 2020 as prices have declined compared to the prior year. However, we also reported additional costs and temporary inefficiencies in our manufacturing process related to the COVID-19 pandemic as discussed above.

SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE

Selling, research & development and administrative expenses (“SG&A”) increased by approximately $9.6 million to $123.4 million in the second quarter of 2020 compared to $113.8 million during the same period in 2019. Excluding changes in foreign currency rates, SG&A increased by approximately $12.6 million in the quarter. The increase is partly due to $8.0 million of new operational and transaction costs for our acquisitions completed subsequent to June 30, 2019. We also recognized higher personnel costs, including $2.2 million in stock-based compensation, in accordance with our growth strategy. SG&A as a percentage of net sales increased to 17.6% compared to 15.3% in the same period of the prior year due to the cost increases mentioned above.

SG&A increased by $14.6 million to $249.6 million in the first six months of 2020 compared to $235.0 million during the same period a year ago. Excluding changes in foreign currency rates, SG&A increased by approximately $20.2 million in the first six months of 2020 compared to the first six months of 2019. As discussed above, the increase is related to $12.3 million of new SG&A costs from our acquisitions completed subsequent to June 30, 2019, along with higher personnel costs. SG&A as a percentage of net sales increased to 17.6% compared to 15.8% in the same period of the prior year.

DEPRECIATION AND AMORTIZATION

Reported depreciation and amortization expenses increased by approximately $8.5 million to $56.4 million in the second quarter of 2020 compared to $47.9 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $9.8 million in the quarter compared to the same period in 2019. The majority of this increase is due to $6.8 million of incremental depreciation and amortization costs related to our acquired companies. Depreciation and amortization as a percentage of net sales increased to 8.1% in the second quarter of 2020 compared to 6.5% in the same period of the prior year primarily due to a combination of lower sales in the current year and the increase in expenses noted above.

Reported depreciation and amortization expenses increased by approximately $11.9 million to $107.2 million in the first six months of 2020 compared to $95.3 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $14.2 million in the first six months of 2020 compared to the same period a year ago. As discussed above, this increase is mainly due to incremental depreciation and amortization costs associated with our acquisitions Depreciation and amortization as a percentage of net sales increased to 7.5% in the first six months of 2020 compared to 6.4% in the same period of the prior year due to lower sales in the current year and an increase in expenses.

RESTRUCTURING INITIATIVES

In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. Restructuring costs related to this plan for the three and six months ended June 30, 2020 and 2019 are as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Restructuring Initiatives by Segment
Beauty + Home	$	7,324	$	1,259	$	12,231	$	9,528
Pharma		(111)		(113)		(142)		213
Food + Beverage		75		112		178		622
Corporate & Other		43		479		(97)		904
Total Restructuring Initiatives	$	7,331	$	1,737	$	12,170	$	11,267

30

We estimate total implementation costs of approximately $125 million, including costs that have been recognized to date. We also anticipate making capital investments related to the business transformation of approximately $50 million, of which $43 million has been incurred to date. Based on our ongoing restructuring initiatives, we are progressing towards our initial target of $80 million annualized incremental EBITDA by the end of 2020, principally within the Beauty + Home segment. However, in addition to the impacts of COVID-19, ongoing changes in customer and vendor negotiations, material indices, macro-economic trends and other factors represent continuing headwinds to the Beauty + Home segment, and have offset the consolidated net benefits from these initiatives.  

OPERATING INCOME

Operating income decreased approximately $39.4 million to $70.5 million the second quarter of 2020 compared to $109.9 million in the same period a year ago. Excluding changes in foreign currency rates, operating income decreased by approximately $37.5 million in the quarter compared to the same period a year ago. Operating income as a percentage of net sales declined to 10.1% in the second quarter of 2020 compared to 14.8% in the prior year period mainly due to some short-term under-absorption of fixed costs resulting from lower sales related to the COVID-19 pandemic.

For the first six months of 2020, operating income decreased approximately $48.0 million to $158.9 million compared to $207.0 million in the same period of the prior year. Excluding changes in foreign currency rates, operating income decreased by approximately $43.8 million in the first six months of 2020 compared to the same period a year ago. As discussed above, the majority of this decrease occurred during the second quarter of 2020 due to the short-term impact of lower sales related to the COVID-19 pandemic. Operating income as a percentage of net sales decreased to 11.2% in the first six months of 2020 compared to 13.9% for the same period in the prior year.

NET OTHER EXPENSE

Net other expense in the second quarter of 2020 increased $2.0 million to $9.8 million from $7.8 million in the same period of the prior year. Interest income decreased by approximately $0.9 million due to less cash on hand after our acquisition of Fusion at the beginning of the second quarter 2020.  Miscellaneous expenses increased by approximately $0.9 million as a result of higher pension costs due to the decline in discount rates in 2020 compared to 2019.

Net other expense for the six months ended June 30, 2020 increased $5.3 million to $20.2 million from $14.9 million in the same period of the prior year. As discussed above, this increase is mainly due to $2.4 million of lower interest income in 2020 as a result of the Fusion acquisition. Miscellaneous expenses increased by approximately $2.8 million in part due to the high costs to hedge certain Latin American and Asian currencies and the higher pension costs mentioned above.

EFFECTIVE TAX RATE

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items. The effective tax rate for the three months ended June 30, 2020 and 2019, respectively, was 31.0% and 27.6%.  The effective tax rate for the three months ended June 30, 2019 was favorably impacted by net tax benefits of $2.9 million from discrete events. This consisted of a $9.1 million benefit from the excess tax benefits from employee share-based compensation offset by, among other items, a $6.3 million charge to record a valuation allowance to properly reflect the realization of recorded deferred tax assets.  

The effective tax rate for the six months ended June 30, 2020 and 2019, respectively, was 30.0% and 28.7%. The effective tax rate for the six months ended June 30, 2020 reflects a favorable impact of net tax benefits of $4.6 million, primarily from the excess tax benefits from employee share-based compensation.  This is offset by the unfavorable impact from the mix of earnings, particularly losses in jurisdictions where we cannot record the tax benefit.  The effective tax rate for the six months ended June 30, 2019 was favorably impacted by net tax benefits of $4.1 million from discrete events.  This consisted of a favorable impact of $11.6 million from the excess tax benefits from employee share-based compensation, offset by, among other items, a $7.0 million charge recognized to record a valuation allowance to properly reflect the realization of recorded deferred tax assets.  

NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.

We reported net income attributable to AptarGroup of $41.8 million and $97.1 million in the three and six months ended June 30, 2020, compared to $73.9 million and $136.9 million for the same periods in the prior year.

31

BEAUTY + HOME SEGMENT

Operations that sell dispensing systems and sealing solutions to the personal care, beauty and home care markets form the Beauty + Home segment.

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Sales	$	299,786	$	342,080	$	624,346	$	709,739
Adjusted EBITDA (1)		23,974		48,745		58,221		101,936
Adjusted EBITDA margin (1)		8.0%		14.2%		9.3%		14.4%

(1) Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 35.

Reported net sales for the quarter ended June 30, 2020 decreased 12% to $299.8 million compared to $342.1 million in the second quarter of the prior year. Changes in currency rates negatively impacted net sales by 3% while our acquisition of Fusion positively impacted sales by 4% in the second quarter of 2020. Therefore, core sales decreased 13% in the second quarter of 2020 compared to the same quarter of the prior year. The COVID-19 pandemic negatively impacted overall core sales during the second quarter of 2020. Core sales of our products to the beauty market decreased 33% as we experienced a significant reduction in orders from customers providing both prestige and masstige beauty products, mainly in the travel retail and standard retail settings. Many beauty stores remained closed throughout much of the quarter in response to government shelter in place regulations and international travel is down significantly leading to a reduction in duty free sales. Personal care core sales improved 11% on increased sales of our products to our personal cleansing customers, mainly for hand sanitizers and liquid soaps which more than offset continued softness in our deodorant, hair care and sun care applications as consumers continued to shelter in place. Core sales to the home care markets decreased 5% as higher demand for our household cleaner products was not enough to offset declines in sales of our products used on laundry care and automotive products.

Second Quarter 2020	Personal				Home
Net Sales Change over Prior Year	Care		Beauty		Care		Total
Core Sales Growth	11	%	(33)	%	(5)	%	(13)	%
Acquisitions	—	%	8	%	—	%	4	%
Currency Effects (1)	(4)	%	(3)	%	(2)	%	(3)	%
Total Reported Net Sales Growth	7	%	(28)	%	(7)	%	(12)	%

For the first six months of 2020, net sales decreased 12% to $624.3 million compared to $709.7 million in the first six months of the prior year. Core sales decreased by 11% in the first six months of 2020 compared to the same period in the prior year. The COVID-19 pandemic discussed above also impacted the first six months of 2020 as we began to see the effects in our first quarter results. Core sales of our products to the beauty market decreased 23% across all applications, but mainly on lower sales of prestige fragrance products to our customers.  Personal care core sales increased 3%, driven by increases in hand sanitation product sales, while home care core sales decreased 5% mainly on lower sales to our laundry care customers.

Six Months Ended June 30, 2020	Personal				Home
Net Sales Change over Prior Year	Care		Beauty		Care		Total
Core Sales Growth	3	%	(23)	%	(5)	%	(11)	%
Acquisitions	—	%	4	%	—	%	2	%
Currency Effects (1)	(4)	%	(3)	%	(2)	%	(3)	%
Total Reported Net Sales Growth	(1)	%	(22)	%	(7)	%	(12)	%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Adjusted EBITDA in the second quarter of 2020 decreased 51% to $24.0 million compared to $48.7 million in the same period in the prior year. As discussed above, the COVID-19 pandemic affected our profitability due to lower sales volumes. Our profitability was further impacted by special bonus payments to certain employees who worked to maintain supply to our customers and keep our facilities running as well as lower overhead absorption due to fluctuations in demand primarily in our facilities that manufacture beauty products.

32

Adjusted EBITDA in the first six months of 2020 decreased 43% to $58.2 million compared to $101.9 million reported in the same period in the prior year. As discussed above, our profitability during the first half of 2020 was significantly impacted by the COVID-19 pandemic, mainly in our beauty applications.  Our profitability was further impacted by special employee bonus payments and lower overhead absorption as we continue to manage demand fluctuations in our facilities.

PHARMA SEGMENT

Operations that sell drug delivery, sealing and active packaging solutions primarily to the prescription drug, consumer health care, injectables and active packaging markets form the Pharma segment.

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Sales	$	301,259	$	281,939	$	598,455	$	554,640
Adjusted EBITDA (1)		104,099		101,428		212,441		198,785
Adjusted EBITDA margin (1)		34.6%		36.0%		35.5%		35.8%

(1) Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 35.

Net sales for the Pharma segment increased 7% in the second quarter of 2020 to $301.3 million compared to $281.9 million in the second quarter of 2019. Changes in currencies negatively affected net sales by 1% while our acquisitions of Gateway, Nanopharm and Noble positively impacted sales by 2% in the second quarter of 2020. Therefore, core sales increased by 6% in the second quarter of 2020 compared to the second quarter of 2019. Core sales increased in three of our four markets with only the prescription drug market reporting a decline due to difficult prior year comparisons on tooling and central nervous system application sales. Core sales to the consumer health care market increased 10% on strong demand for our products used on nasal decongestant and cough/cold treatments. Injectables core sales grew 26% on increased demand across all components while active packaging core sales improved 21% due to strong growth in our probiotics, diabetes, and ActivFilm products.

Second Quarter 2020	Prescription		Consumer				Active
Net Sales Change over Prior Year	Drug		Health Care		Injectables		Packaging		Total
Core Sales Growth	(6)	%	10	%	26	%	21	%	6	%
Acquisitions	—	%	—	%	15	%	—	%	2	%
Currency Effects (1)	(1)	%	(1)	%	(2)	%	(1)	%	(1)	%
Total Reported Net Sales Growth	(7)	%	9	%	39	%	20	%	7	%

Net sales for the first six months of 2020 increased by 8% to $598.5 million compared to $554.6 million in the first six months of 2019. Changes in currencies negatively affected net sales by 1% while our acquisitions of Noble, Nanopharm and Gateway positively impacted sales by 3% in the first six months of 2020. Therefore, core sales increased by 6% in the first six months of 2020 compared to the same period in the prior year. As discussed above, the prescription drug market core sales decrease of 2% was driven by difficult prior year comparisons on tooling and central nervous system application sales. During 2019, we also benefitted from the realization of $1.8 million of revenue for achieving a development milestone related to a customer project. Core sales to the consumer health care market increased 6% as increased demand for our products used on nasal decongestant and dermal drug delivery treatments more than compensated for some softness in demand for our nasal saline products. Core sales of our products to the injectables and active packaging markets increased 24% and 23% respectively due to strong sales across all applications as discussed above.

Six Months Ended June 30, 2020	Prescription		Consumer				Active
Net Sales Change over Prior Year	Drug		Health Care		Injectables		Packaging		Total
Core Sales Growth	(2)	%	6	%	24	%	23	%	6	%
Acquisitions	1	%	—	%	17	%	—	%	3	%
Currency Effects (1)	(2)	%	(1)	%	(3)	%	(1)	%	(1)	%
Total Reported Net Sales Growth	(3)	%	5	%	38	%	22	%	8	%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

33

Adjusted EBITDA in the second quarter of 2020 increased 3% to $104.1 million compared to $101.4 million reported in the same period of the prior year. The strong product sales growth discussed above along with incremental profit related to our acquisitions led to the increase in reported results for the second quarter of 2020 compared to the second quarter of 2019. While the Pharma segment did not experience a significant sales impact from COVID-19, our margins were negatively impacted by lower sales of our high-margin prescription applications compared to our other product offerings.  We also recognized the special bonus payments discussed above which negatively impacted our Adjusted EBITDA during the second quarter of 2020.

Adjusted EBITDA in the first six months of 2020 increased 7% to $212.4 million compared to $198.8 million reported in the same period of the prior year. The increase in sales along with incremental profit related to our acquisitions was able to compensate for lower prescription sales and special bonus payments made as discussed above.

FOOD + BEVERAGE SEGMENT

Operations that sell dispensing systems and sealing solutions to the food and beverage markets form the Food + Beverage segment.

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Sales	$	98,260	$	118,642	$	198,057	$	222,742
Adjusted EBITDA (1)		17,785		20,944		33,192		37,635
Adjusted EBITDA margin (1)		18.1%		17.7%		16.8%		16.9%

(1) Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 35.

Net sales for the quarter ended June 30, 2020 decreased approximately 17% to $98.3 million compared to $118.6 million in the second quarter of the prior year. Changes in foreign currency rates had an unfavorable impact of 2% on total segment sales. Therefore, core sales decreased by 15% in the second quarter of 2020 compared to the second quarter of 2019. This decrease is due to the passing on of lower resin costs to our customers, lower tooling costs and lower beverage closure sales related to the COVID-19 crisis. For the food market, we realized increased sales of our products used on cooking oils and spreads applications. However, this increase was more than offset by lower tooling sales as we recognized several large tooling projects during the second quarter of 2019.  Core sales to the beverage market decreased 37% as sales of our single-serve bottled water and on-the-go functional drink products were significantly affected by the COVID-19 pandemic.

Second Quarter 2020
Net Sales Change over Prior Year	Food		Beverage		Total
Core Sales Growth	(3)	%	(37)	%	(15)	%
Acquisitions	—	%	—	%	—	%
Currency Effects (1)	(2)	%	(3)	%	(2)	%
Total Reported Net Sales Growth	(5)	%	(40)	%	(17)	%

Net sales for the first six months of 2020 decreased by 11% to $198.1 million compared to $222.7 million in the first six months of 2019. Core sales decreased by 9% in the first six months of 2020 compared to the same period in the prior year. The pass-through of lower resin costs and lower tooling sales negatively impacted the first six months of 2020 by $8.6 million and $6.8 million, respectively. Core sales to the food market were flat while core sales to the beverage market decreased 26% in the first six months of 2020 compared to the same period of the prior year. Sales to the food market increased due to strong sales of our products to our spreads and granular/powder non-beverage dairy customers. These increases were offset by lower tooling sales due to strong activity in the prior year period. As discussed above, core sales to the beverage market decreased as sales of our single-serve bottled water and on-the-go functional drink products and tooling sales were significantly affected by the COVID-19 pandemic.

34

Six Months Ended June 30, 2020
Net Sales Change over Prior Year	Food		Beverage		Total
Core Sales Growth	—	%	(26)	%	(9)	%
Acquisitions	—	%	—	%	—	%
Currency Effects (1)	(2)	%	(3)	%	(2)	%
Total Reported Net Sales Growth	(2)	%	(29)	%	(11)	%

(1) Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Adjusted EBITDA in the second quarter of 2020 decreased 15% to $17.8 million compared to $20.9 million reported in the same period of the prior year. Lower tooling sales and the COVID-19 impacts on product sales discussed above, along with special bonus payments to certain employees who worked to maintain supply to our customers and keep our facilities running, more than offset the benefits we received from cost containment activities and other operational improvements realized during the second quarter of 2020.

Adjusted EBITDA in the first six months of 2020 decreased 12% to $33.2 million compared to $37.6 million reported in the same period of the prior year. The COVID-19 impact on product sales discussed above, along with lower tooling and special bonus payments, more than offset the benefits we received from lower resin input costs and other operational improvements realized during the first half of 2020.

CORPORATE & OTHER

In addition to our three reporting segments, we assign certain costs to “Corporate & Other,” which is presented separately in Note 16 – Segment Information to the Notes to the Condensed Consolidated Financial Statements. For Corporate & Other, Adjusted EBITDA (which excludes net interest, taxes, depreciation, amortization, restructuring and acquisition-related costs) primarily includes certain professional fees, compensation and information system costs which are not allocated directly to our reporting segments. For the quarter ended June 30, 2020, Corporate & Other expenses decreased to $9.3 million from $10.6 million in the second quarter of 2019. This decrease is mainly due to lower variable compensation costs which are tied to company performance, lower travel and entertainment costs due to travel restrictions in place, and lower medical costs as we have experienced lower medical claims during the second quarter of 2020 compared to the prior year second quarter.

Corporate & Other expenses in the first six months of 2020 decreased to $23.1 million compared to $23.4 million reported in the same period of the prior year. As discussed above, this decrease is mainly due to lower variable compensation, travel and entertainment and medical costs which more than offset increased costs in professional fees and other personnel costs as we continue to implement our growth strategy.

NON-U.S. GAAP MEASURES

In addition to the information presented herein that conforms to U.S. GAAP, we also present financial information that does not conform to U.S. GAAP, which are referred to as non-U.S. GAAP financial measures. Management may assess our financial results both on a U.S. GAAP basis and on a non-U.S. GAAP basis. We believe it is useful to present these non-U.S. GAAP financial measures because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect our core operating performance. These non-U.S. GAAP financial measures should not be considered in isolation or as a substitute for U.S. GAAP financial results, but should be read in conjunction with the unaudited Condensed Consolidated Statements of Income and other information presented herein. Investors are cautioned against placing undue reliance on these non-U.S. GAAP measures. Further, investors are urged to review and consider carefully the adjustments made by management to the most directly comparable U.S. GAAP financial measure to arrive at these non-U.S. GAAP financial measures.

In our Management’s Discussion and Analysis, we exclude the impact of foreign currency translation when presenting net sales information, which we define as “constant currency.” Changes in net sales excluding the impact of foreign currency translation is a non-U.S. GAAP financial measure. As a worldwide business, it is important that we take into account the effects of foreign currency translation when we view our results and plan our strategies. Consequently, when our management looks at our financial results to measure the core performance of our business, we may exclude the impact of foreign currency translation by translating our prior period results at current period foreign currency exchange rates. As a result, our management believes that these presentations are useful internally and may be useful to investors. We also exclude the impact of material acquisitions when comparing results to prior periods. Changes in operating results excluding the impact of acquisitions are non-U.S. GAAP financial measures. We believe it is important to exclude the impact of acquisitions on period over period results in order to evaluate performance on a more comparable basis.

35

We present adjusted earnings before net interest and taxes (“Adjusted EBIT”) and consolidated adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”), both of which exclude the business transformation charges (restructuring initiatives), acquisition-related costs and purchase accounting adjustments related to acquisitions and investments. Our “Outlook” discussion below is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates, or reliably predicted because they are not part of our routine activities, such as restructuring and acquisition-related costs.

We provide a reconciliation of Net Debt to Net Capital as a non-U.S. GAAP measure. “Net Debt” is calculated as interest bearing debt less cash and equivalents and short-term investments while “Net Capital” is calculated as stockholders’ equity plus Net Debt. Net Debt to Net Capital measures a company’s financial leverage, which gives users an idea of a company's financial structure, or how it is financing its operations, along with insight into its financial strength. We believe that it is meaningful to take into consideration the balance of our cash and equivalents, and short-term investments when evaluating our leverage. If needed, such assets could be used to reduce our gross debt position.

Finally, we provide a reconciliation of free cash flow as a non-U.S. GAAP measure. Free cash flow is calculated as cash provided by operations less capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives.

	Three Months Ended
	June 30, 2020
	Consolidated		Beauty + Home		Pharma		Food + Beverage		Corporate & Other		Net Interest
Net Sales	$	699,305	$	299,786	$	301,259	$	98,260	$	-	$	-
Reported net income	$	41,860
Reported income taxes		18,808
Reported income before income taxes		60,668		(12,755)		85,467		8,519		(12,004)		(8,559)
Adjustments:
Restructuring initiatives		7,331		7,324		(111)		75		43
Transaction costs related to acquisitions		3,207		3,207
Purchase accounting adjustments related to acquisitions and investments		3,252		2,959		293
Adjusted earnings before income taxes		74,458		735		85,649		8,594		(11,961)		(8,559)
Interest expense		8,734										8,734
Interest income		(175)										(175)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		83,017		735		85,649		8,594		(11,961)		-
Depreciation and amortization		56,429		25,939		18,617		9,191		2,682		-
Purchase accounting adjustments included in Depreciation and amortization above		(2,867)		(2,700)		(167)
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	136,579	$	23,974	$	104,099	$	17,785	$	(9,279)	$	-
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		19.5%		8.0%		34.6%		18.1%

36

	Three Months Ended
	June 30, 2019
	Consolidated		Beauty + Home		Pharma		Food + Beverage		Corporate & Other		Net Interest
Net Sales	$	742,661	$	342,080	$	281,939	$	118,642	$	-	$	-
Reported net income	$	73,921
Reported income taxes		28,180
Reported income before income taxes		102,101		26,813		84,425		12,195		(13,609)		(7,723)
Adjustments:
Restructuring initiatives		1,737		1,259		(113)		112		479
Transaction costs related to acquisitions		1,059				1,059
Purchase accounting adjustments related to acquisitions and investments		222				222
Adjusted earnings before income taxes		105,119		28,072		85,593		12,307		(13,130)		(7,723)
Interest expense		8,756										8,756
Interest income		(1,033)										(1,033)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		112,842		28,072		85,593		12,307		(13,130)		-
Depreciation and amortization		47,867		20,673		16,057		8,637		2,500
Purchase accounting adjustments included in Depreciation and amortization above		(222)				(222)						-
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	160,487	$	48,745	$	101,428	$	20,944	$	(10,630)	$	-
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		21.6%		14.2%		36.0%		17.7%

	Six Months Ended
	June 30, 2020
	Consolidated		Beauty + Home		Pharma		Food + Beverage		Corporate & Other		Net Interest
Net Sales	$	1,420,858	$	624,346	$	598,455	$	198,057	$	-	$	-
Reported net income	$	97,110
Reported income taxes		41,594
Reported income before income taxes		138,704		(5,647)		175,321		14,481		(28,679)		(16,772)
Adjustments:
Restructuring initiatives		12,170		12,231		(142)		178		(97)
Transaction costs related to acquisitions		4,591		4,591
Purchase accounting adjustments related to acquisitions and investments		4,642		3,221		1,421
Adjusted earnings before income taxes		160,107		14,396		176,600		14,659		(28,776)		(16,772)
Interest expense		17,122										17,122
Interest income		(350)										(350)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		176,879		14,396		176,600		14,659		(28,776)		-
Depreciation and amortization		107,235		46,525		36,508		18,533		5,669		-
Purchase accounting adjustments included in Depreciation and amortization above		(3,367)		(2,700)		(667)
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	280,747	$	58,221	$	212,441	$	33,192	$	(23,107)	$	-
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		19.8%		9.3%		35.5%		16.8%

37

	Six Months Ended
	June 30, 2019
	Consolidated		Beauty + Home		Pharma		Food + Beverage		Corporate & Other		Net Interest
Net Sales	$	1,487,121	$	709,739	$	554,640	$	222,742	$	-	$	-
Reported net income	$	136,920
Reported income taxes		55,180
Reported income before income taxes		192,100		50,994		165,683		19,911		(29,299)		(15,189)
Adjustments:
Restructuring initiatives		11,267		9,528		213		622		904
Transaction costs related to acquisitions		1,059				1,059
Purchase accounting adjustments related to acquisitions and investments		222				222
Adjusted earnings before income taxes		204,648		60,522		167,177		20,533		(28,395)		(15,189)
Interest expense		17,970										17,970
Interest income		(2,781)										(2,781)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		219,837		60,522		167,177		20,533		(28,395)		-
Depreciation and amortization		95,356		41,414		31,830		17,102		5,010
Purchase accounting adjustments included in Depreciation and amortization above		(222)				(222)						-
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	314,971	$	101,936	$	198,785	$	37,635	$	(23,385)	$	-
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		21.2%		14.4%		35.8%		16.9%

Net Debt to Net Capital Reconciliation		June 30,		December 31,
		2020		2019
Notes payable, revolving credit facility and overdrafts	$	150,831	$	44,259
Current maturities of long-term obligations, net of unamortized debt issuance costs		66,248		65,988
Long-Term Obligations, net of unamortized debt issuance costs		1,082,742		1,085,453
Total Debt		1,299,821		1,195,700
Less:
Cash and equivalents		247,656		241,970
Net Debt	$	1,052,165	$	953,730
Total Stockholders' Equity	$	1,645,986	$	1,572,252
Net Debt		1,052,165		953,730
Net Capital	$	2,698,151	$	2,525,982
Net Debt to Net Capital		39.0%		37.8%

Free Cash Flow Reconciliation		June 30,		June 30,
		2020		2019
Net Cash Provided by Operations	$	227,686	$	221,140
Less:
Capital Expenditures		122,986		124,774
Free Cash Flow	$	104,700	$	96,366

38

FOREIGN CURRENCY

Because of our international presence, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc and other Asian, European and South American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. We manage our exposures to foreign exchange principally with forward exchange contracts to economically hedge recorded transactions and firm purchase and sales commitments denominated in foreign currencies. Changes in exchange rates on such inter-country sales could materially impact our results of operations. During the second quarter of 2020 the U.S. dollar strengthened compared to the euro and other currencies in Latin America and Asia. This resulted in a dilutive impact on our translated results during the second quarter of 2020 when compared to the second quarter of 2019.

Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. For the six months ended June 30, 2020, our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues.

QUARTERLY TRENDS

Our results of operations in the last quarter of the year typically are negatively impacted by customer plant shutdowns in December. In addition to the significant impact of COVID-19 on our business, our results of operations in a quarterly period could be impacted by factors such as the seasonality of certain products within our segments, changes in foreign currency rates, changes in product mix, changes in material costs, changes in growth rates in the markets to which our products are sold and changes in general economic conditions in any of the countries in which we do business.

LIQUIDITY AND CAPITAL RESOURCES

Given the diversification of our segments, we believe we are in a strong financial position and have the financial resources to meet our business requirements in the foreseeable future. Our Pharma segment provided strong operating cash flows to balance out the temporary softness in some of our Beauty + Home and Food + Beverage markets during the first half of 2020. Our primary uses of liquidity are to invest in equipment and facilities that are necessary to support our growth, cost efficiencies and to make acquisitions that will contribute to the achievement of our strategic objectives. Amid the COVID-19 pandemic, we are focused on preserving our liquidity and therefore we have temporarily suspended repurchasing shares of our common stock and discretionary contributions to our defined benefit plans. However, we intend to continue to pay quarterly dividends to our stockholders, invest in our business and make acquisitions as we consider necessary to achieve our strategic objectives. In the event that customer demand decreases significantly for a prolonged period of time due to the COVID-19 pandemic and adversely impacts our cash flows from operations, we would have the ability to restrict and significantly reduce capital expenditure levels as well as evaluate our acquisition strategy. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.

Cash and equivalents and restricted cash increased to $257.4 million at June 30, 2020 from $247.0 million at December 31, 2019. Total short and long-term interest bearing debt of $1.3 billion at June 30, 2020 increased from $1.2 billion at December 31, 2019 resulting from an increase of $125.0 million in net proceeds from our group credit facility during the first half of 2020 the majority of which was utilized to fund the second quarter Fusion acquisition. The ratio of our Net Debt (interest bearing debt less cash and equivalents) to Net Capital (stockholders’ equity plus Net Debt) increased to 39.0% at June 30, 2020 compared to 37.8% at December 31, 2019. See the reconciliation of non-U.S. GAAP measures starting on page 35.

In the first six months of 2020, our operations provided approximately $227.7 million in net cash flow compared to $221.1 million for the same period a year ago. In both periods, cash flow from operations was primarily derived from earnings before depreciation and amortization. The increase in cash provided by operations during the first six months of 2020 is primarily attributable to better working capital management which offset lower net income.

39

We used $317.1 million in cash for investing activities during the first six months of 2020 compared to $157.2 million during the same period a year ago. During the first six months of 2020, $158.1 million of cash was utilized to fund the Fusion Acquisition. We invested $28.8 million in our 49% equity interest of BTY and $5.0 million in our 30% equity interest of Sonmol, which are accounted for as equity method investments. Additionally, we released $1.0 million relating to the working capital escrow settlement and paid an additional $463 thousand as a working capital payment related to our acquisition of Noble. Our investment in capital projects decreased $1.8 million during the first six months of 2020 compared to the first six months of 2019, as we have reduced our expenditures amid the COVID-19 pandemic. Our 2020 estimated cash outlays for capital expenditures are expected to be in the range of approximately $230 to $250 million but could vary due to changes in exchange rates as well as the timing of capital projects.

Financing activities provided $91.3 million in cash during the first six months of 2020 compared to $31.8 million in cash used by financing activities during the same period a year ago. During the first six months of 2020, we received net proceeds from our U.S. group credit facility of $125.0 million and stock option exercises of $30.1 million. We used cash on hand to pay $46.1 million of dividends and net repayments of $13.3 million related to our notes payable and overdrafts and $2.8 million related to our outstanding long-term debt obligations.

We hold U.S. dollar and euro-denominated debt to align our capital structure with our earnings base. We also maintain a multi-currency revolving credit facility with two tranches, providing for unsecured financing of up to $300 million that is available in the U.S. and up to €150 million that is available to our wholly-owned UK subsidiary. Each borrowing under the credit facility will bear interest at rates based on LIBOR, prime rates or other similar rates, in each case plus an applicable margin. A facility fee on the total amount of the facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. $150.0 million was utilized under our U.S. facility and no balance was utilized under our euro-based revolving credit facility as of June 30, 2020. The $25.0 million balance at December 31, 2019 under our U.S. credit facility was repaid during the first quarter of 2020. Credit facility balances are included in notes payable, including revolving credit facilities on the Condensed Consolidated Balance Sheets.

Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

	Requirement	Level at June 30, 2020
Consolidated Leverage Ratio (1)	Maximum of 3.50 to 1.00	1.98 to 1.00
Consolidated Interest Coverage Ratio (1)	Minimum of 3.00 to 1.00	15.50 to 1.00

(1) Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.

Based upon the above consolidated leverage ratio covenant, we have the ability to borrow approximately an additional $825.8 million before the 3.50 to 1.00 maximum ratio requirement is exceeded.

Our foreign operations have historically met cash requirements with the use of internally generated cash or uncommitted short-term borrowings. We also have committed financing arrangements in both the U.S. and UK as detailed above. We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances.

On July 16, 2020, the Board of Directors declared a quarterly cash dividend of $0.36 per share payable on August 19, 2020 to stockholders of record as of July 29, 2020.

CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. Please refer to Note 12 - Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements for a discussion of contingencies affecting our business.

OFF-BALANCE SHEET ARRANGEMENTS

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating leases. Most of the operating leases contain renewal options and certain equipment leases include options to purchase during or at the end of the lease term. As a result of the adoption of ASU 2016-02 and subsequent amendments, which requires organizations to recognize leases on the balance sheet, we do not have significant off-balance sheet arrangements. Please refer to Note 7 – Leases of the Notes to Condensed Consolidated Financial Statements.

40

RECENTLY ISSUED ACCOUNTING STANDARDS

We have reviewed the recently issued accounting standards updates to the FASB’s Accounting Standards Codification that have future effective dates. Standards that are effective for 2020 are discussed in Note 1 – Summary of Significant Accounting Policies of the Notes to Condensed Consolidated Financial Statements.

In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The new standard is effective upon issuance and can be adopted any time prior to December 31, 2022. We do not anticipate that this new guidance will have a significant impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-14, which amends disclosure requirements for defined benefit pension and other postretirement plans. The amendments in this update remove disclosures that are no longer considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. The new standard is effective for fiscal years ending after December 15, 2020. As this update adds disclosure requirements, we do not expect that this guidance will have a significant impact on our consolidated financial statements.

Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

OUTLOOK

Factors that could impact our third quarter results include among other things, economic uncertainty in some of our markets, driven in part by the recent spike in COVID-19 cases in many regions of the world. We expect to see gradual improvement in the second half of the year although this will be heavily dependent on the pace and breadth of the resumption of travel activity, the reopening of retail stores and general consumer spending confidence.

We expect earnings per share for the third quarter of 2020, excluding any restructuring expenses and acquisition-related costs, to be in the range of $0.80 to $0.88 and this guidance is based on an effective tax rate range of 28% to 30%.

FORWARD-LOOKING STATEMENTS

Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Significant Developments, Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, Contingencies and Outlook sections of this Form 10-Q. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to:

● outbreaks of pandemics, including the impact of COVID-19 on our global supply chain and our global customers and operations, which has elevated and may or will continue to elevate many of the risks and uncertainties discussed below;

● economic conditions worldwide, including potential deflationary or inflationary conditions in regions we rely on for growth;

● political conditions worldwide, including the impact of the UK leaving the European Union (Brexit) on our UK operations;

● significant fluctuations in foreign currency exchange rates or our effective tax rate;

● the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate;

● financial conditions of customers and suppliers;

● consolidations within our customer or supplier bases;

● changes in customer and/or consumer spending levels;

● loss of one or more key accounts;

● the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers;

● fluctuations in the cost of materials, components and other input costs (particularly resin, metal, anodization costs and transportation and energy costs);

41

● our ability to successfully implement facility expansions and new facility projects;

● our ability to offset inflationary impacts with cost containment, productivity initiatives or price increases;

● changes in capital availability or cost, including interest rate fluctuations;

● volatility of global credit markets;

● our ability to identify potential new acquisitions and to successfully acquire and integrate such operations and products, including the successful integration of the businesses we have acquired, including contingent consideration valuation;

● direct or indirect consequences of acts of war, terrorism or social unrest;

● cybersecurity threats that could impact our networks and reporting systems;

● the impact of natural disasters and other weather-related occurrences;

● fiscal and monetary policies and other regulations;

● changes or difficulties in complying with government regulation;

● changing regulations or market conditions regarding environmental sustainability;

● work stoppages due to labor disputes;

● competition, including technological advances;

● our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;

● the outcome of any legal proceeding that has been or may be instituted against us and others;

● our ability to meet future cash flow estimates to support our goodwill impairment testing;

● the demand for existing and new products;

● the success of our customers’ products, particularly in the pharmaceutical industry;

● our ability to manage worldwide customer launches of complex technical products, particularly in developing markets;

● difficulties in product development and uncertainties related to the timing or outcome of product development;

● significant product liability claims;

● the execution of our business transformation plan; and

● other risks associated with our operations.

Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Please refer to Item 1A (Risk Factors) of Part I included in our Annual Report on Form 10-K for the year ended December 31, 2019 and to Item 1A (Risk Factors) of Part II of this report for additional risk factors affecting the Company.

42

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our entities. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso and Swiss franc, among other Asian, European, and South American currencies. A weakening U.S. dollar relative to foreign currencies has an additive translation effect on our financial condition and results of operations. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations.

Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.

We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain firm purchase and sales commitments and intercompany cash transactions denominated in foreign currencies.

The table below provides information as of June 30, 2020 about our forward currency exchange contracts. The majority of the contracts expire before the end of the third quarter of 2020.

			Average	Min / Max
		Contract Amount	Contractual	Notional
Buy/Sell		(in thousands)	Exchange Rate	Volumes
EUR / USD	$	15,273	1.1043	13,329-17,460
EUR / BRL		9,672	5.5705	9,072-9,744
CHF / EUR		7,368	0.9455	205-7,368
EUR / INR		3,774	83.5400	3,767-3,777
CZK / EUR		3,631	0.0373	2,245-3,631
MXN / USD		2,669	0.0426	2,669-3,059
EUR / MXN		2,259	25.5878	2,259-2,863
USD / EUR		2,182	0.9092	1,488-2,593
EUR/THB		1,295	35.3761	1,235-1,295
GBP / EUR		759	1.1334	759-2,824
EUR/GBP		337	0.8901	122-337
CHF / USD		179	1.0317	175-354
CAD/EUR		22	0.6532	20-43
Total	$	49,420

As of June 30, 2020, we have recorded the fair value of foreign currency forward exchange contracts of $0.7 million in prepaid and other and $0.1 million in accounts payable and accrued liabilities on the balance sheet. We also entered into a EUR/USD floating-to-fixed cross currency swap on July 20, 2017 to effectively hedge the foreign exchange and interest rate exposure on the $280 million bank term loan drawn by our wholly-owned UK subsidiary. The fair value of this cash flow hedge is $3.1 million reported in prepaid and other on the balance sheet.

ITEM 4. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

Management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of our disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Exchange Act) as of June 30, 2020. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

During the fiscal quarter ended June 30, 2020, we implemented enterprise resource planning (“ERP”) systems at two operating facilities. Consequently, the control environments have been modified at these locations to incorporate the controls contained within the new ERP systems. Except for the foregoing, no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) occurred during our fiscal quarter ended June 30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Amid the COVID-19 pandemic, we have implemented remote work arrangements and restricted non-essential business travel. These arrangements have not materially affected our ability to maintain our business operations, including the operation of financial reporting systems, internal control over financial reporting and disclosure controls and procedures.

43

PART II - OTHER INFORMATION

ITEM 1A. RISK FACTORS

The following risk factor is in addition to the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under Item 1A, “Risk Factors” filed with the SEC pursuant to the Exchange Act. The effects of the events and circumstances described in the following risk factors have elevated and may or will continue to elevate many of the risks contained in the Company’s Form 10-K, including the risks relating to a deterioration in economic conditions in a particular region or market, our fixed costs structure, reliance on single sourced materials and manufacturing sites and potential asset impairments.

The COVID-19 pandemic is currently adversely affecting our business. Additional factors could exacerbate such negative consequences and/or cause other materially adverse effects. The COVID-19 pandemic adversely affected our sales of products to our travel and retail beauty business and on-the-go beverage customers in the six months ended June 30, 2020 and that adverse impact may continue into the third quarter. Beginning in the first quarter of 2020, economic and health conditions in the United States and across most of the globe have changed rapidly. Customer demand across all segments, particularly our Beauty + Home and Food + Beverage segments, may decrease further from historical levels depending on the duration and severity of the COVID-19 pandemic, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages due to disruptions to our supply chain and distribution channels, delivery delays, increased risk associated with customer payments and reduced sales and operations, any of which could materially affect our stock price, business prospects, financial condition, results of operations and liquidity.

The ability of our employees to work may be significantly impacted by COVID-19. The majority of our office and management personnel are working remotely and the majority of our facilities remained operational during the first half of 2020 as each of our segments produce dispensing systems that have been determined to be essential products by various government agencies around the world. The health and safety of our workforce is of primary concern and we may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the virus. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources across the entire company, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, our ability to manage our business may be impaired, and operational risks, cybersecurity risks and other risks facing us even prior to the pandemic may be elevated.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

RECENT SALES OF UNREGISTERED SECURITIES

Certain French employees are eligible to participate in the FCP Aptar Savings Plan (the “Plan”). An independent agent purchases shares of common stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of common stock under the Plan. The agent under the Plan is Banque Nationale de Paris Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended June 30, 2020, the Plan purchased 19,876 shares of our common stock on behalf of the participants at an average price of $104.89, for an aggregate amount of $2.1 million. The Plan sold 11,571 shares of our common stock on behalf of the participants at an average price of $105.62, for an aggregate amount of $1.2 million during the same period. At June 30, 2020, the Plan owned 96,783 shares of our common stock.

ISSUER PURCHASES OF EQUITY SECURITIES

On April 18, 2019, we announced a share purchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

During the three and six months ended June 30, 2020, we did not repurchase any shares. As of June 30, 2020, there was $278.5 million of authorized share repurchases available to us. Amid the COVID-19 pandemic, we are focused on preserving our liquidity and therefore we have temporarily suspended repurchasing shares of our common stock.

44

ITEM 5. OTHER INFORMATION

On July 30, 2020, the Company’s Board of Directors (the “Board”) amended and restated the Company's by-laws to clarify certain corporate procedures and make certain other enhancements and technical changes. The changes effected by the amendment and restatement of the Company’s by-laws (the “Amended and Restated By-Laws”) include, without limitation, the following:

● updating the advance notice provisions for director nominations and stockholder proposals at stockholder meetings;

● designating the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of litigation;

● clarifying that the Board may postpone, reschedule or cancel a stockholder meeting;

● clarifying when the plurality voting carve-out to the majority vote standard for the election of directors applies;

● clarifying the powers of the chairman of a stockholder meeting to regulate conduct at such meeting;

● allowing emergency special Board meetings to be held with less than 24 hours’ notice; and

● outlining the process for Board action in the event of an emergency.

The Amended and Restated By-Laws are effective July 30, 2020. The preceding summary does not purport to be complete and is qualified in its entirety by reference to the Amended and Restated By-Laws, which are filed as Exhibit 3.1 to this Form 10-Q and incorporated herein by reference.

ITEM 6. EXHIBITS

Exhibit 3.1	Amended and Restated By-Laws of AptarGroup, Inc.
Exhibit 10.1	AptarGroup, Inc. 2018 Equity Incentive Plan (as amended and restated effective May 6, 2020), filed as Exhibit 10.1 to the Company’s current report on Form 8-K filed May 7, 2020, is incorporated herein by reference.
Exhibit 31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.2	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 101	The following information from our Quarterly Report on Form 10-Q for the second quarter of fiscal 2020, filed with the SEC on July 31, 2020, formatted in Inline Extensible Business Reporting Language (XBRL): (i) the Cover Page, (ii) the Condensed Consolidated Statements of Income – Three and Six Months Ended June 30, 2020 and 2019, (iii) the Condensed Consolidated Statements of Comprehensive Income – Three and Six Months Ended June 30, 2020 and 2019, (iv) the Condensed Consolidated Balance Sheets – June 30, 2020 and December 31, 2019, (v) the Condensed Consolidated Statements of Changes in Equity – Three and Six Months Ended June 30, 2020 and 2019, (vi) the Condensed Consolidated Statements of Cash Flows - Six Months Ended June 30, 2020 and 2019 and (vii) the Notes to Condensed Consolidated Financial Statements.
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

45

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AptarGroup, Inc.
	(Registrant)
By	/s/ ROBERT W. KUHN
	Robert W. Kuhn
	Executive Vice President,
	Chief Financial Officer and Secretary
	(Duly Authorized Officer and
	Principal Accounting and Financial Officer)
	Date: July 31, 2020

46

EX-3.1

Exhibit 3.1

APTARGROUP, INC.

a Delaware Corporation

________________________________________

AMENDED AND RESTATED

BY-LAWS

Effective July 30, 2020

________________________________________

ARTICLE I
MEETINGS OF STOCKHOLDERS

Section 1.1 Place of Meeting. All meetings of the stockholders shall be held at such place, within or without the State of Delaware, as is fixed in the notice of the meeting. The Board of Directors may postpone, reschedule or cancel any meeting of the stockholders for any reason.

Section 1.2 Annual Meeting. An annual meeting of the stockholders of the Corporation for the election of directors and the transaction of such other business as may properly come before the meeting shall be held on a date specified by the Board of Directors and at the time and place specified by the Board of Directors. If for any reason any annual meeting shall not be held during any year, the business thereof may be transacted at any special meeting of the stockholders.

Section 1.3 Special Meetings. Special meetings of stockholders may be called only in the manner provided in the Certificate of Incorporation.

Section 1.4 Notice of Meetings; Remote Meetings. Notice of the date, time and place of each annual and each special meeting of the stockholders shall be given to each of the stockholders entitled to vote at such meeting by mailing the same in a postage prepaid wrapper addressed to each such stockholder at his address as it appears on the books of the Corporation, or by delivering the same personally to any such stockholder, in lieu of such mailing, at least ten (10) days prior to, and not more than sixty (60) days before, such meeting, and meetings may be held without notice if all of the stockholders entitled to vote thereat are present in person or by proxy, or if notice thereof is waived by all such stockholders not present in person or by proxy, before or after the meeting. The notice of each special meeting of the stockholders shall set forth the purposes thereof and the business transacted at all special meetings of stockholders shall be confined to the purposes stated in the notice thereof.

The Board of Directors, acting in its sole discretion, may determine that any meeting of the stockholders will not be held at any place but will be held solely by means of remote communication, and may establish guidelines and procedures in accordance with applicable provisions of the Delaware General Corporation Law (the “DGCL”) and any other applicable law or regulation for participation in a stockholder meeting by means of remote communication. Subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxyholders not physically present at a stockholder meeting held by means of remote communication may be deemed present in person, may participate in the meeting and may vote, whether such meeting is to be held at a designated place or solely by means of remote communication; provided, however, that (i) the Corporation shall implement measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or proxyholder, (ii) the Corporation shall implement measures to provide such stockholders and proxyholders an opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (iii) if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a record of such vote or other action shall be maintained by the Corporation or a delegate thereof.

Section 1.5 Setting of Record Date. The Board of Directors shall have the power to fix a record date which (i) in the case of any meeting of stockholders, shall be not more than sixty (60) nor less than ten (10) days before the date of such meeting, (ii) in the case of the payment of any dividend, the allotment of rights, the exercise of any rights in respect of any change or conversion or exchange of capital stock, shall be not more than sixty (60) days before such action or (iii) (in the event the Certificate of Incorporation is amended to permit action to be taken by stockholders by consent) in the case of obtaining the consent of stockholders for any purpose, shall be not more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. The record date shall be used by the Corporation for the determination of the stockholders entitled (a) to notice of and to vote at any meeting of stockholders, (b) to receive payment of any dividend or allotment of rights, (c) to exercise the right in respect of any change, conversion or exchange of capital stock or (d) to give any consent of stockholders, and in such case only such stockholders as shall be stockholders of record on the date so fixed shall be entitled to such notice of and to vote at such meeting or to receive payment of such dividend or to receive such allotment of rights or to exercise such rights or to give such consent, as the case may be, notwithstanding any transfer of any stock on the books of the Corporation after any such record date fixed as aforesaid.

Section 1.6 Organization. At each meeting of the stockholders, the Chief Executive Officer, or in the case of vacancy in office or absence of the Chief Executive Officer, the Chairman of the Board, or in the case of vacancy in office or absence of the Chairman of the Board, one of the following officers present in the order stated: the Vice-Chairman of the Board, the President, the Chief Operating Officer, the Vice-Presidents in their order of rank and seniority or a chairman chosen by the stockholders entitled to cast a majority of the votes which all stockholders present in person or by proxy are entitled to cast on such matter, shall act as chairman, and the Secretary, or, in the absence of the Secretary, an Assistant Secretary, or in the absence of both the Secretary and Assistant Secretaries, a person appointed by the chairman, shall act as secretary.

Section 1.7 Voting at Stockholders’ Meetings. At each meeting of the stockholders, every stockholder having the right to vote thereat shall be entitled to vote in person, or by proxy. Stockholders shall have the voting rights specified in the Certificate of Incorporation. The vote for directors, and, upon the demand of any stockholder, the vote upon any question before the meeting, shall be by written ballot.

2

Section 1.8 Quorum and Adjournment. Except as otherwise provided by law or by the Certificate of Incorporation, at any meeting of the stockholders the presence, in person or by proxy, of the holders of shares of stock of the Corporation entitled to cast at least a majority of the votes which the outstanding stock entitled to vote thereat is entitled to cast on a particular matter shall be requisite and shall constitute a quorum entitled to take action with respect to that vote on that matter. If at any meeting of stockholders there shall be less than a quorum so present, the stockholders present in person or by proxy and entitled to vote thereat on such matter may without further notice, except as required by law, adjourn the meeting from time to time until a quorum shall be present, but no business shall be transacted at any such adjourned meeting except such as might have been lawfully transacted had the meeting not been adjourned. Regardless of whether a quorum is present, the chairman of a meeting of the stockholders or the Board of Directors may adjourn the meeting for any reason. At an adjourned meeting of the stockholders at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed. If the adjournment is for more than thirty (30) days or if after the adjournment, a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder entitled to vote at the meeting.

Section 1.9 List of Stockholders. The Secretary shall prepare, at least ten (10) days before every meeting of the stockholders, a complete list of the stockholders entitled to vote at such meeting arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder, and such list shall be open to examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, at the principal place of business of the Corporation. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.

3

Section 1.10 Advance Notice of Stockholder Nominations. Nominations of persons for election to the Board of Directors and the proposal of business to be transacted by the stockholders may be made at an annual or special meeting of the stockholders only (x) pursuant to the Corporation’s notice with respect to such meeting, (y) by or at the direction of the Board of Directors or (z) by any stockholder of the Corporation who was a stockholder of record on the record date set with respect to such meeting as provided for in Section 1.5, who is entitled to vote at the meeting and who has complied with the notice procedures set forth in this Section 1.10. For nominations or other business to be properly brought before an annual or special meeting by a stockholder pursuant to clause (z) above, the stockholder must give timely notice thereof in writing to the Secretary of the Corporation and such business must be a proper matter for stockholder action under the DGCL and a proper matter for consideration at such meeting under the Certificate of Incorporation and these By-Laws. To be timely, (1) in the case of special meetings of the stockholders, a stockholder’s notice must be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the ninetieth (90th) day prior to such meeting and not later than the close of business on the later of the sixtieth (60th) day prior to such meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made and (2) in the case of all annual meetings of stockholders, a stockholder’s notice must be delivered to the Secretary at the principal executive offices of the Corporation not less than sixty (60) days nor more than ninety (90) days prior to the first anniversary of the preceding year’s annual meeting of stockholders; provided, however, that in the event that the date of the annual meeting is more than thirty (30) days prior to or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the ninetieth (90th) day prior to such annual meeting and not later than the close of business on the later of the sixtieth (60th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made. The number of individuals a stockholder may nominate for election at a meeting of the stockholders (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such meeting. Persons nominated by stockholders to serve as directors of the Corporation who have not been nominated in accordance with this Section 1.10 shall not be eligible to serve as directors. Only such business shall be conducted at an annual or special meeting of stockholders as shall have been brought before the meeting in accordance with this Section 1.10. The chairman of the meeting shall determine whether a nomination or any business proposed to be transacted by the stockholders has been properly brought before the meeting and, if any proposed nomination or business has not been properly brought before the meeting, the chairman shall declare that such proposed business or nomination shall not be presented for stockholder action at the meeting. Nothing in this Section 1.10 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

(i)A stockholder’s notice shall set forth:

(a)as to each individual whom the stockholder proposes to nominate for election or reelection as a director (each, a “Proposed Nominee”), if any:

(1)the name, age, business address and residence address of such Proposed Nominee;

(2)the principal occupation and employment of such Proposed Nominee;

4

(3)a written questionnaire with respect to the background and qualification of such Proposed Nominee completed by the Proposed Nominee in the form required by the Corporation (which form the stockholder shall request in writing from the Secretary and which the Secretary shall provide to such stockholder within ten (10) days of receiving such request);

(4)such Proposed Nominee’s executed written consent to being named in the proxy statement for the meeting of the stockholders as a nominee;

(5)such Proposed Nominee’s written representation and agreement, in the form required by the Corporation (which form the stockholder shall request in writing from the Secretary and which the Secretary shall provide to such stockholder within ten (10) days of receiving such request), that such Proposed Nominee: (I) is not and will not become party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law; (II) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Corporation; (III) would, if elected as a director, comply with applicable law of the exchanges upon which the Corporation’s shares of common stock trade, all of the Corporation’s corporate governance, ethics, conflict of interest, confidentiality and stock ownership and trading policies and guidelines applicable generally to the Corporation’s directors and applicable fiduciary duties under state law and, if elected as a director of the Corporation, currently would be in compliance with any such policies and guidelines that have been publicly disclosed; (IV) intends to serve a full term if elected as a director of the Corporation; and (V) will provide facts, statements and other information in all communications with the Corporation and its stockholders that are or will be true and correct in all material respects, and that do not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they are made, not misleading;

(6)all information relating to such Proposed Nominee that would be required to be disclosed in a proxy statement or other filings required to be made in connection with the solicitation of proxies for a director election where the number of nominees for election exceeds the number of directors to be elected, or may otherwise be required, pursuant to Section 14 of the Exchange Act (or pursuant to any law or statute replacing such section) and the rules and regulations promulgated thereunder; and

(7)a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among the Proposed Nominee, on the one hand, and the stockholder giving notice and any Stockholder Associated Person (as defined below), on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 promulgated under Regulation S-K if the stockholder giving notice and any Stockholder Associated Person were the “registrant” for purposes of such rule and the person being nominated were a director or executive officer of such registrant;

5

(b)as to any other business that the stockholder proposes to bring before the meeting of the stockholders:

(1)a brief description of the business desired to be brought before the meeting;

(2)the reasons for conducting such business at the meeting;

(3)the text of the proposal (including the complete text of any resolutions proposed for consideration and, in the event that such business includes a proposal to amend these By-Laws, the language of the proposed amendment); and

(4)a complete and accurate description of any material interest in such business of the stockholder giving notice and any Stockholder Associated Person, individually or in the aggregate, including any anticipated benefit to the stockholder and any Stockholder Associated Person therefrom, and all other information related to such proposed business that would be required to be disclosed in a proxy statement or other filing required to be made by the stockholder or any Stockholder Associated Person in connection with the solicitation of proxies or consents in support of such proposed business by such stockholder or any Stockholder Associated Person pursuant to Regulation 14A under the Exchange Act;

(c)as to the stockholder giving notice, any Proposed Nominee and any Stockholder Associated Person:

(1)the name and address of such stockholder, as they appear on the Corporation’s books and records, and the name and address of any Stockholder Associated Person;

(2)the number of shares of capital stock of the Corporation which are, directly or indirectly, owned beneficially and/or of record by such stockholder, Proposed Nominee and Stockholder Associated Person, and the date or dates such shares were acquired and the investment intent of such acquisition;

(3)the nominee holder for, and number of, any Corporation securities owned beneficially but not of record by such stockholder, Proposed Nominee or Stockholder Associated Person;

(4)short interest of such stockholder, Proposed Nominee or Stockholder Associated Person in any security of the Corporation (for purposes of these By-Laws, a person shall be deemed to have a short interest in a security if such person, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value of the subject security);

6

(5)a complete and accurate description of all agreements, arrangements or understandings (whether written or oral) (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights with an exercise or conversion privilege or a settlement payment or mechanism at a price related to the capital stock of the Corporation or with a value derived in whole or in part from the value of the capital stock of the Corporation, hedging transactions, and borrowed or loaned shares) (each, a “Derivative Instrument”), that have been entered into as of the date of the stockholder’s notice or any supplement thereto by, or on behalf of, such stockholder, Proposed Nominee or Stockholder Associated Person, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation;

(6)any rights to dividends on the shares of the Corporation owned beneficially by such stockholder, Proposed Nominee or Stockholder Associated Person;

(7)any proportionate interest in shares of capital stock of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership or similar entity in which such stockholder, Proposed Nominee or Stockholder Associated Person (I) is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, or (II) is the manager, managing member or, directly or indirectly, beneficially owns an interest in the manager or managing member of a limited liability company or similar entity;

(8)any substantial interest, direct or indirect (including, without limitation, any existing or prospective commercial, business or contractual relationship with the Corporation), by security holdings or otherwise, of such stockholder, Proposed Nominee or Stockholder Associated Person, in the Corporation or any affiliate (as defined below) thereof, other than an interest arising from the ownership of the Corporation’s securities where such stockholder, Proposed Nominee or Stockholder Associated Person receives no extra or special benefit not shared on a pro rata basis by all other holders;

(9)a complete and accurate description of all agreements, arrangements or understandings, written or oral, and formal or informal, (I) between or among the stockholder giving notice and any Stockholder Associated Person or (II) between or among the stockholder giving notice or any Stockholder Associated Person and any other person or entity (naming each such person or entity) in connection with or related to the foregoing or any Proposed Nominee, including, without limitation, (x) any proxy, contract, arrangement, understanding or relationship pursuant to which such stockholder or Stockholder Associated Person has the right to vote any shares of any security of the Corporation, (y) any understanding, formal or informal, written or oral, that such stockholder or any Stockholder Associated Person may have reached with any stockholder of the Corporation (including their names) with respect to how such stockholder will vote its shares in the Corporation at any meeting of the Corporation’s stockholders or take other action in support of any Proposed Nominee, or other action to be taken, by the proposing stockholder or any Stockholder Associated Person and (z) any other agreements that would be required to be disclosed by such stockholder or any Stockholder Associated Person or any other person or entity pursuant to Item 5 or Item 6 of a Schedule 13D that would be filed pursuant to the Exchange Act and the rules and regulations promulgated thereunder (regardless of whether the requirement to file a Schedule 13D is applicable to the stockholder giving notice, or any Proposed Nominee or any Stockholder Associated Person or other person or entity);

7

(10)a complete and accurate description of any performance-related fees (other than an asset-based fee) to which any such stockholder, Proposed Nominee or Stockholder Associated Person may be entitled as a result of any increase or decrease in the value of shares of the Corporation or any Derivative Instruments; and

(11)a complete and accurate description of any pending or threatened legal proceeding in which such stockholder, Proposed Nominee or Stockholder Associated Person is a party or participant involving the Corporation or any officer, affiliate or associate (as defined below) of the Corporation;

(d)as to the stockholder giving notice and any Stockholder Associated Person:

(1)whether such stockholder or Stockholder Associated Person intends or is part of a group which intends (I) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding capital stock required to elect the Proposed Nominee(s) and/or approve or adopt the proposal(s) and/or (II) otherwise to solicit proxies in support of such Proposed Nominee(s) or proposal(s);

(2)whether and the extent to which any agreement, arrangement or understanding has been made, the effect or intent of which is to increase or decrease the voting power of such stockholder or Stockholder Associated Person with respect to any shares of the capital stock of the Corporation, without regard to whether such transaction is required to be reported on a Schedule 13D in accordance with the Exchange Act; and

(3)the investment strategy or objective, if any, of such stockholder and Stockholder Associated Person who is not an individual and a copy of the prospectus, offering memorandum or similar document, if any, provided to investors or potential investors in such stockholder or Stockholder Associated Person;

(e)a representation from the stockholder giving notice that (1) such stockholder (I) is a holder of record of stock of the Corporation entitled to vote at the meeting, (II) intends to vote such stock at the meeting and (III) intends to appear in person or by proxy at the meeting to nominate any Proposed Nominees or bring such business before the meeting; and (2) if such stockholder does not appear to present such Proposed Nominee or business at the meeting, the Corporation need not present such Proposed Nominee or business for a vote at such meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation; and

(f)such other information regarding each matter of business to be proposed by the stockholder giving notice, regarding the stockholder in his or her capacity as a proponent of a stockholder proposal or regarding any Stockholder Associated Person, that would be required to be disclosed in a proxy statement or other filings required to be made in connection with the solicitations of proxies for such business or the election of any Proposed Nominee, or is otherwise required, pursuant to Section 14 of the Exchange Act (or pursuant to any law or statute amending, restating or replacing such section) and the rules and regulations promulgated thereunder.

8

(ii)In addition to the information required in Section 1.10(i) above, the Corporation may require any Proposed Nominee to furnish such other information as may reasonably be required by the Corporation to determine the eligibility of such Proposed Nominee to serve as an independent director of the Corporation or that could be material to a reasonable stockholder’s understanding of the independence, or lack thereof, of such Proposed Nominee, under the listing standards of each principal securities exchange upon which the shares of the Corporation are listed, any applicable rules of the Securities and Exchange Commission and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the Corporation’s directors, including those applicable to a director’s service on any of the committees of the Board of Directors.

(iii)Notwithstanding the foregoing provisions of this Section 1.10, if the stockholder (or a qualified representative of the stockholder) proposing a nominee for director or business to be conducted at a meeting of stockholders does not appear at the meeting to present such nomination or business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation.

(iv)A stockholder providing notice under this Section 1.10 shall update such notice, if necessary, so that the information provided or required to be provided in such notice shall continue to be true and correct (a) as of the record date for the meeting and (b) as of the date that is ten (10) business days prior to the meeting (or any postponement, adjournment or recess thereof), and such update shall be delivered to, or mailed and received by, the Secretary at the principal executive office of the Corporation not later than five (5) business days after the record date for the meeting (in the case of an update required to be made as of the record date) and not later than seven (7) business days prior to the date for the meeting, if practicable or, if not practicable, on the first practicable date prior to the meeting or any adjournment, recess or postponement thereof (in the case of an update required to be made as of ten (10) business days prior to the meeting or any adjournment, recess or postponement thereof).

(v)If any information submitted pursuant to this Section 1.10 by any stockholder proposing business for consideration or individuals to nominate for election or reelection as a director at a meeting of stockholders shall be inaccurate in any respect, such information may be deemed not to have been provided in accordance with these By-Laws. Any such stockholder shall notify the Corporation of any inaccuracy or change in any such information within two (2) business days of becoming aware of such inaccuracy or change. Upon written request by the Secretary of the Corporation, the Board of Directors or any committee thereof, any such stockholder shall provide, within seven (7) business days of delivery of such request (or such other period as may be specified in such request), (a) written verification, reasonably satisfactory to the Board of Directors, any committee thereof or any authorized officer of the Corporation, to demonstrate the accuracy of any information submitted by the stockholder pursuant to this Section 1.10, and (b) a written update of any information (including written confirmation by such stockholder that it continues to intend to bring such nomination or other business proposal before the meeting) submitted by the stockholder pursuant to this Section 1.10 as of an earlier date. If a stockholder fails to provide such written verification within such period, the information as to which written verification was requested may be deemed not to have been provided in accordance with this Section 1.10.

9

(vi)Notwithstanding the foregoing provisions of this Section 1.10, a stockholder shall also comply with all applicable requirements of state law and all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to matters set forth herein, provided, however, that any references in these By-Laws to the Exchange Act or the rules promulgated thereunder are not intended to and shall not limit the requirements applicable to stockholder proposals to be considered pursuant to this Section 1.10. Nothing in this Section 1.10 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act. Subject to Rule 14a-8 under the Exchange Act, nothing in these By-Laws shall be construed to permit any stockholder, or give any stockholder the right, to include or have disseminated or described in the Corporation’s proxy statement any nomination of a director or directors or any other business proposal.

(vii)As used in these By-Laws, (a) an “affiliate” and “associate” each have the respective meanings set forth in Rule 12b-2 under the Exchange Act; (b) “Stockholder Associated Person” shall mean (1) any person who is a member of a “group” (as such term is used in Rule 13d‑5 of the Exchange Act) with or otherwise acting in concert with such stockholder, (2) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such stockholder (other than a stockholder that is a depositary), (3) any person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such stockholder or such Stockholder Associated Person and beneficially owns, directly or indirectly, shares of stock of the Corporation, (4) any person that directly, or indirectly through one or more intermediaries, controls such stockholder or any Stockholder Associated Person and (5) any participant (as defined in paragraphs (a)(ii)(vi) of Instruction 3 to Item 4 of Schedule 14A, or any successor instructions) with such stockholder or other Stockholder Associated Person in respect of any proposals or nominations, as applicable; and (c) “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service, in a document filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act or in a notice pursuant to the applicable rules of an exchange on which the securities of the Corporation are listed.

Section 1.11 Required Vote for Directors. Except as otherwise required by law or by the Certificate of Incorporation, each director shall be elected by the vote of the majority of the votes cast in person or represented by proxy and entitled to vote on the election of directors with respect to the director at any meeting for the election of directors at which a quorum is present; provided, however, that each director shall be elected by a plurality of the votes cast in person or represented by proxy at the meeting and entitled to vote on the election of directors for any meeting for the election of directors for which (i) the Secretary receives a notice that a stockholder has nominated one or more candidates for election to the Board of Directors in compliance with the requirements set forth in these By-Laws and (ii) such nomination has not yet been withdrawn by such stockholder on or prior to the tenth (10th) day preceding the date that the Corporation first mails its notice of meeting for such election. For purposes of this Section 1.11, “majority of the votes cast” means that the number of shares voted “for” a director exceeds the number of shares voted “against” that director (with “abstentions” and “broker nonvotes” not counted as a vote cast either “for” or “against” that director’s election).

10

Section 1.12 Conduct of Meetings. The Board of Directors may adopt rules and regulations for the conduct of any meeting of the stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations, the chairman of any meeting of the stockholders shall have the right and authority to prescribe rules, regulations and procedures and to take all acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting, may include or address, without limitation, the following: (i) the establishment of an agenda or order of business for the meeting; (ii) the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (iii) maintenance of order at the meeting and the safety of those present; (iv) compliance with state and local laws and regulations concerning safety and security; (v) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the chairman of the meeting shall determine; (vi) restrictions on entry to the meeting after the time fixed for the commencement thereof; (vii) limitations on the time allotted to questions or comments by participants; (viii) removal of any stockholder or any other individual who refuses to comply with meeting procedures, rules or guidelines; (ix) conclusion, recess or adjournment of the meeting, whether or not a quorum is present, to a later date and time and at a place announced at the meeting; and (x) restrictions on the use of audio and video recording devices and cell phones. Unless and to the extent determined by the Board of Directors or the chairman of the stockholder meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure.

ARTICLE II
DIRECTORS

Section 2.1 Number of Directors. Subject to any rights of the holders of the Preferred Stock or any series thereof to elect additional directors under specified circumstances, the number of directors which shall constitute the whole Board of Directors of the Corporation shall be such number as shall from time to time be fixed by resolution adopted by directors constituting not less than seventy percent (70%) of the whole Board of Directors.

Section 2.2 Chairman of the Board. At each regular annual meeting of the Board of Directors, a majority of the members of the Board of Directors shall select one of its members as Chairman of the Board. The Chairman of the Board shall hold such position until the first regular annual meeting of the Board of Directors following such selection or until the Chairman’s successor is selected and qualifies, provided that the Chairman may be removed at any time as Chairman of the Board, with or without cause, by the affirmative vote therefor of a majority of the whole Board of Directors.

11

Section 2.3 Vacancies and Newly Created Directorships. Subject to any rights of the holders of the Preferred Stock or any series thereof to fill such newly created directorships or vacancies, any newly created directorships resulting from any increase in the authorized number of directors and any vacancies in the Board of Directors resulting from death, resignation, disqualification, removal or other cause shall, unless otherwise provided by law or by resolution of directors constituting not less than seventy percent (70%) of the whole Board of Directors, be filled only by a resolution of directors constituting not less than seventy percent (70%) of the whole Board of Directors, and any director so chosen shall hold office until the next election of the class for which such director shall have been chosen, and until his successor shall have been duly elected and qualified, unless he shall resign, die, become disqualified or be removed. Notwithstanding the foregoing, in the event that at the time of the existence of an unfilled newly created directorship or any such vacancy there are unfilled newly created directorships and/or vacancies constituting more than thirty percent (30%) of the whole Board of Directors, a majority of the directors then serving on the Board of Directors shall have the authority to fill enough of such unfilled newly created directorships and/or vacancies so that, after giving effect thereto, there will be the minimum number of directors serving on the Board of Directors necessary to constitute seventy percent (70%) of the whole Board of Directors.

Section 2.4 Powers, Qualifications and Removal. The business of the Corporation shall be managed by or under the direction of the Board of Directors. Any director may tender his resignation at any time. Subject to any rights of the holders of the Preferred Stock or any series thereof, any director or the entire Board of Directors may be removed at any time, but only for cause.

Section 2.5 Regular and Special Meetings of the Board. The Board of Directors may hold its meetings, whether organizational, regular or special, either within or without the State of Delaware. Regular meetings of the Board may be held with or without notice at such time and place as shall from time to time be determined by resolution of the Board. Whenever the time or place of regular meetings of the Board shall have been determined by resolution of the Board, no regular meetings shall be held pursuant to any resolution of the Board altering or modifying its previous resolution relating to the time or place of the holding of regular meetings, without first giving three (3) days’ notice to each director, either personally or by facsimile telecommunication, or five (5) days’ written notice to each director by mail, of the substance and effect of such new resolution relating to the time and place at which regular meetings of the Board may thereafter be held without notice. Special meetings of the Board shall be held whenever called in writing by the Chairman of the Board, Chief Executive Officer, the Vice-Chairman of the Board, the President, the Chief Operating Officer or any three (3) directors. Notice of each special meeting of the Board shall be delivered personally to each director or sent by telegraph to his residence or usual place of business at least three (3) days before the meeting, or mailed to him to his residence or usual place of business at least five (5) days before the meeting; provided, however, that less than twenty-four (24) hours’ notice may be provided if the person or persons calling such special meeting deem it necessary or appropriate under the circumstances. Meetings of the Board, whether regular or special, may be held at any time and place, and for any purpose, without notice, when all the directors are present or when all directors not present shall, in writing, waive notice of and consent to the holding of such meeting, which waiver and consent may be given after the holding of such meeting.

Section 2.6 Organization. At every meeting of the Board, the Chairman of the Board or, in the case of vacancy in such position or absence of the Chairman of the Board, one of the following officers present in the order stated: the Chief Executive Officer, the Vice-Chairman of the Board, the President, the Chief Operating Officer, the Vice Presidents in their order of rank and seniority, or a chairman chosen by a majority of the directors present, shall preside, and the Secretary, or, in the absence of the Secretary, an Assistant Secretary, or in the absence of the Secretary and the Assistant Secretaries, any person appointed by the chairman of the meeting, shall act as secretary.

12

Section 2.7 Quorum and Adjournment. At all meetings of the Board a majority of the whole Board of Directors shall be necessary and sufficient to constitute a quorum for the transaction of business except as may otherwise be specifically provided in the Certificate of Incorporation or in these By-Laws; provided, that if a quorum of directors shall not be present at any duly called or regular meeting thereof, the directors present may adjourn said meeting from time to time for a period of not exceeding two (2) weeks in the aggregate and notice of any such adjourned meeting shall not be necessary unless an adjournment was taken sine die.

Section 2.8 Executive Committee. There shall be a committee of the Board of Directors designated as the Executive Committee, to consist of three (3) or more of the directors, as shall from time to time be appointed by resolution of directors constituting not less than seventy percent (70%) of the whole Board of Directors. Except as otherwise limited by resolution of directors constituting not less than seventy percent (70%) of the whole Board of Directors or by law, the Certificate of Incorporation or these By-Laws, the Executive Committee shall have and may exercise, when the Board is not in session, all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it; but the Executive Committee shall not, except to the extent both permitted by law and expressly so authorized in a resolution of directors constituting not less than seventy percent (70%) of the whole Board of Directors, have power (i) to fill vacancies in the Board, (ii) to change the membership of or to fill vacancies in the Executive Committee, (iii) to remove or replace the chairman of the Executive Committee, (iv) to authorize the Corporation to sell, lease or otherwise dispose of assets of the Corporation, (v) to authorize the Corporation to liquidate, dissolve or effect a recapitalization or reorganization in any form of transaction, (vi) to authorize the Corporation to acquire any interest in any business (whether by a purchase of assets, purchase of stock, merger or otherwise) or enter into any joint venture, (vii) to adopt a bonus or other compensation plan in which directors or officers of the Corporation are eligible to participate, (viii) to authorize the Corporation to create, incur, assume or suffer to exist any indebtedness or (ix) to amend these By-Laws. An affirmative vote of directors constituting at least seventy percent (70%) of the whole Board of Directors shall be required to change the size, membership or powers of the Executive Committee, to fill vacancies in it, or to dissolve it. The Executive Committee may make rules for the conduct of its business and may appoint such assistants as it shall from time to time deem necessary. A majority of the members of the Executive Committee shall constitute a quorum. A member of the Executive Committee shall be appointed chairman of the Executive Committee by resolution of directors constituting at least seventy percent (70%) of the whole Board of Directors and shall preside at all meetings of the Executive Committee; provided that in the case of vacancy in such position or absence of the chairman of the Executive Committee at the time of any such meeting, a member of the Executive Committee selected by a majority of the members of the Executive Committee shall preside at such meeting.

Section 2.9 Audit Committee. There shall be a committee of the Board of Directors designated as the Audit Committee, to consist of not fewer than three members of the Board as shall from time to time be appointed by resolution of the Board. No member of the Board who is an officer or an employee of the Corporation or any subsidiary of the Corporation shall be eligible to serve on the Audit Committee. The Audit Committee shall review and, as it shall deem appropriate, approve internal accounting and financial controls for the Corporation and accounting principles and auditing practices and procedures to be employed in the preparation and review of financial statements of the Corporation. The Audit Committee shall engage independent public accountants to audit the annual financial statements of the Corporation and its subsidiaries and shall arrange with such accountants the scope of the audit to be undertaken by such accountants. The Board shall have the power at any time to change the membership of the Audit Committee, to fill vacancies in it, or to dissolve it. The Audit Committee may make rules for the conduct of its business and may appoint such assistants as it shall from time to time deem necessary. A majority of the members of the Audit Committee shall constitute a quorum.

13

Section 2.10 Compensation Committee. There shall be a committee of the Board of Directors designated as the Compensation Committee, to consist of not fewer than two members of the Board as shall from time to time be appointed by resolution of directors constituting at least seventy percent (70%) of the whole Board of Directors. No member of the Board who is an officer or an employee of the Corporation or any subsidiary of the Corporation shall be eligible to serve on the Compensation Committee. The Compensation Committee shall make such determinations and perform such other duties as are expressly delegated to it from time to time pursuant to the terms of any stock option, equity bonus or other employee benefit plan of the Corporation, and make such recommendations to the Board regarding other compensation of officers and employees of the Corporation as it deems appropriate. The Board shall have the power at any time to change the size, membership or powers of the Compensation Committee, to fill vacancies in it, or to dissolve it; provided, however, that an affirmative vote of directors constituting at least seventy percent (70%) of the whole Board of Directors shall be required to take any such action. The Compensation Committee may make rules for the conduct of its business and may appoint such assistants as it shall from time to time deem necessary. A majority of the members of the Compensation Committee shall constitute a quorum.

Section 2.11 Corporate Governance Committee. There shall be a committee of the Board of Directors designated as the Corporate Governance Committee, to consist of not fewer than two members of the Board as shall from time to time be appointed by resolution of directors constituting at least seventy percent (70%) of the whole Board of Directors. The Corporate Governance Committee shall (i) identify, evaluate and recommend individuals qualified to be directors of the Corporation to the Board for either appointment to the Board or to stand for election at a meeting of the stockholders, (ii) review and recommend to the Board appropriate compensation for the Corporation’s directors and (iii) develop and recommend to the Board corporate governance principles for the Corporation. The Board shall have the power at any time to change the membership or powers of the Corporate Governance Committee, to fill vacancies in it, or to dissolve it; provided, however, that an affirmative vote of directors constituting at least seventy percent (70%) of the whole Board of Directors shall be required to take any such action. The Corporate Governance Committee may make rules for the conduct of its business (including, without limitation, rules as to whether and on what basis, if any, it will consider suggestions regarding candidates for election submitted by stockholders) and may appoint such assistants as it shall from time to time deem necessary. A majority of the members of the Corporate Governance Committee shall constitute a quorum.

14

Section 2.12 Other Committees; Designation of Replacement Members of Committees. The Board of Directors may also, by resolution or resolutions passed by the affirmative vote therefor of directors constituting at least seventy percent (70%) of the whole Board of Directors, designate one or more other committees, which, to the extent provided in said resolution or resolutions, shall have and may exercise, when the Board is not in session, the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it. Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board of Directors. A majority of the members of any such committee may determine its action and fix the time and place of its meetings unless directors constituting at least seventy percent (70%) of the whole Board of Directors shall otherwise provide. The Board of Directors shall have power, through the affirmative vote of directors constituting at least seventy percent (70%) of the whole Board of Directors, at any time to fill vacancies in, to change the size membership or powers of, or to dissolve any such committee. The Board of Directors may designate in advance a person to replace a specified director as a member of any committee of the Board of Directors in the event that such director shall for any reason cease to be a member of such committee. The vote of the Board of Directors required to designate in advance a person for such purpose shall be the same as that which is required under these By-Laws to appoint a member of such committee. In the event that any member of any committee of the Board of Directors shall for any reason cease to be a member of such committee, the person designated in advance to replace such member, if any, shall, without any further action on the part of the Board of Directors and so long as such person is at that time a member of the Board of Directors, become a member of such committee. Such person shall also assume the chairmanship of such committee if held by the member such person is replacing immediately prior to such member ceasing to be a member of such committee.

Section 2.13 Compensation of Directors. By resolution of the Board of Directors, the directors shall be paid their reasonable expenses, if any, for attendance at each regular or special meeting of the Board or of any committee designated in these By-Laws or by the Board pursuant to these By-Laws and, by resolution of directors constituting at least seventy percent (70%) of the whole Board of Directors, may be paid a fixed sum for attendance at such meeting, or a stated salary as director, or both, or may be paid other compensation (in cash, stock or other form) for acting as directors. Nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity and receiving compensation therefor; provided however that directors who are also salaried officers of the Corporation or any subsidiary of the Corporation shall not receive fees or salaries as directors.

Section 2.14 Communications Equipment. Members of the Board of Directors or any committee thereof may participate in and act at any meeting of the Board or such committee through the use of a conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in the meeting pursuant to this Section 2.14 shall constitute presence in person at the meeting.

Section 2.15 Waiver of Notice and Presumption of Assent. Any member of the Board of Directors or any committee thereof who is present at a meeting shall be conclusively presumed to have waived notice of such meeting except when such member attends for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Such member shall be conclusively presumed to have assented to any action taken unless his or her dissent shall be entered in the minutes of the meeting or unless his or her written dissent to such action shall be filed with the person acting as the secretary of the meeting before the adjournment thereof or shall be forwarded by registered mail to the secretary of the corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to any member who voted in favor of such action.

15

Section 2.16 Action by Written Consent. Unless otherwise restricted by the Certificate of Incorporation, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee.

ARTICLE III
OFFICERS

Section 3.1 Designation, Term, Vacancies. The officers of the Corporation shall be a Chief Executive Officer, a Vice-Chairman of the Board, a President, a Chief Operating Officer, one or more Vice-Presidents, a Secretary, one or more Assistant Secretaries, a Treasurer, one or more Assistant Treasurers and such other officers as the Board of Directors may from time to time deem necessary. Such officers may have and perform the powers and duties usually pertaining to their respective offices, the powers and duties respectively prescribed by law and by these By-Laws, and such additional powers and duties as may from time to time be prescribed by the Board. The same person may hold any two (2) or more offices.

At each regular annual meeting of the Board of Directors, the Board shall, at its discretion, elect the Chief Executive Officer, the Vice-Chairman of the Board, the President, the Chief Operating Officer, the Secretary, the Treasurer and, at their discretion, such Vice-Presidents as the Board shall determine, all of whom shall hold office until the first regular annual meeting of the Board of Directors following their appointment or until their successors are appointed and qualify, provided that they, or any of them, may be removed at any time, with or without cause, by the affirmative vote therefor of a majority of the whole Board of Directors. All other agents and employees of the Corporation shall hold office during the pleasure of the Board of Directors. Vacancies occurring among the officers of the Corporation shall be filled by the Board of Directors. The salaries of all officers of the Corporation shall be fixed by the Board of Directors.

Section 3.2 Chief Executive Officer. The Chief Executive Officer shall be the chief executive officer of the Corporation and shall exercise such other powers as may from time to time be delegated to the Chief Executive Officer by these By-Laws or by resolution of the Board of Directors. Subject to the Board of Directors, the Chief Executive Officer shall have general charge of the entire business of the Corporation. The Chief Executive Officer may sign certificates of stock and may sign and seal bonds, debentures, contracts or other obligations authorized by the Board, and may, without previous authority of the Board, make such contracts as the ordinary conduct of the Corporation’s business requires. The Chief Executive Officer shall have the usual powers and duties vested in a chief executive officer of a corporation. He shall have power to select and appoint all necessary officers and employees of the Corporation, except those selected by the Board of Directors, and to remove all such officers and employees, except those selected by the Board of Directors, and make new appointments to fill vacancies. The Chief Executive Officer may delegate any of his or her powers to the Vice-Chairman of the Board, the President, the Chief Operating Officer or a Vice-President of the Corporation. The Chief Executive Officer shall at all times be subject to the direction of the Board of Directors.

16

Section 3.3 Vice-Chairman of the Board. The Vice-Chairman of the Board shall have such of the Chief Executive Officer’s powers and duties as the Chief Executive Officer may from time to time delegate to him and shall exercise such other powers as may from time to time be delegated to the Vice-Chairman of the Board by these By-Laws or by resolution of the Board of Directors. The Vice-Chairman of the Board may sign certificates of stock and may sign and seal bonds, debentures, contracts or other obligations authorized by the Board, and may, without previous specific authority of the Board, make such contracts as the ordinary conduct of the Corporation’s business requires.

Section 3.4 President. The President shall have such powers as may from time to time be delegated to the President by these By-Laws or by resolution of the Board of Directors. The President may sign certificates of stock and may sign and seal bonds, debentures, contracts or other obligations authorized by the Board, and may, without previous specific authority of the Board, make such contracts as the ordinary conduct of the Corporation’s business requires.

Section 3.5 Chief Operating Officer. The Chief Operating Officer shall have such powers as may from time to time be delegated to the Chief Operating Officer by these By-Laws or by resolutions of the Board of Directors. The Chief Operating Officer may sign certificates of stock and may sign and seal bonds, debentures, contracts or other obligations authorized by the Board, and may, without previous specific authority of the Board, make such contracts as the ordinary conduct of the Corporation’s business requires.

Section 3.6 Vice-Presidents. Each Vice-President shall have such of the Chief Executive Officer’s, the Vice-Chairman of the Board’s, the President’s and the Chief Operating Officer’s powers and duties as the Chief Operating Officer, the Vice Chairman of the Board, the President and the Chief Operating Officer, respectively, may from time to time delegate to such Vice-President and each Vice-President shall have such other powers and perform such other duties as may be assigned to such Vice-President by these By-Laws or by resolution of the Board of Directors.

Section 3.7 Treasurer. The Treasurer shall have custody of such funds and securities of the Corporation as may come to the Treasurer’s hands or be committed to the Treasurer’s care by the Board of Directors. Whenever necessary or proper, the Treasurer shall endorse on behalf of the Corporation, for collection, checks, notes, or other obligations, and shall deposit the same to the credit of the Corporation in such bank or banks or depositories, approved by the Board of Directors, as the Board of Directors, Chief Executive Officer, Vice-Chairman of the Board, President or Chief Operating Officer may designate. The Treasurer may sign receipts or vouchers for payments made to the Corporation, and the Board of Directors may require that such receipts or vouchers shall also be signed by some other officer to be designated by them. Whenever required by the Board of Directors, the Treasurer shall render a statement of the Corporation’s cash accounts and such other statements respecting the affairs of the Corporation as may be required. The Treasurer shall keep proper and accurate books of account. The Treasurer shall perform all acts incident to the office of Treasurer, subject to the direction of the Board of Directors.

17

Section 3.8 Secretary. The Secretary shall have custody of the seal of the Corporation and when required by the Board of Directors, or when any instrument signed by another officer of the Corporation duly authorized to sign the same so requires, or when necessary to attest any proceedings of the stockholders or directors, shall affix it to any instrument requiring the same and shall attest the same with his or her signature, provided that the seal may be affixed by the Chief Executive Officer, the Vice Chairman of the Board, the President, the Chief Operating Officer or a Vice-President or other officer of the Corporation to any document executed by any of them respectively on behalf of the Corporation which does not require the attestation of the Secretary. The Secretary shall attend to the giving and serving of notices of meetings. The Secretary shall have charge of such books and papers as properly belong to such office or as may be committed to his or her care by the Board of Directors. The Secretary shall perform such other duties as appertain to such office or as may be required by the Board of Directors.

Section 3.9 Assistant Secretary. Each Assistant Secretary shall be vested with such powers and duties as may be delegated to him or her by the President, the Chief Operating Officer or the Secretary and any act may be done or duty performed by an Assistant Secretary with like effect as though done or performed by the Secretary; and shall have such other powers and perform such other duties as may be assigned to him or her by the Board of Directors.

Section 3.10 Assistant Treasurer. Each Assistant Treasurer shall be vested with such powers and duties as may be delegated to him or her by the Chief Executive Officer, the Vice-Chairman of the Board, the President, the Chief Operating Officer or the Treasurer, and any act may be performed by an Assistant Treasurer with like effect as though done or performed by the Treasurer; and shall have such other powers and perform such other duties as may be assigned to him or her by the Board of Directors.

Section 3.11 Delegation. In case of the absence of any officer of the Corporation, or for any other reason that the Board of Directors may deem sufficient, the Board may delegate, for the time being, the powers or duties, or any of them, of such officer to any other officer or to any director.

Section 3.12 Compensation. The compensation of any officer of the Corporation for serving in such capacity, other than compensation under any plan which has received stockholder approval, shall require the approval of directors constituting at least a majority of the directors serving on the Board of Directors who are not salaried officers of the Corporation or any subsidiary of the Corporation.

ARTICLE IV
STOCK

Section 4.1 Certificates of Stock. All certificates of shares of the capital stock of the Corporation shall be in such form not inconsistent with the Certificate of Incorporation, these By-Laws and the laws of the State of Delaware, as shall be approved by the Board of Directors, and shall be signed by the Chief Executive Officer, the Vice-Chairman of the Board, the President, the Chief Operating Officer or a Vice-President and by the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer and shall bear the seal of the Corporation and shall not be valid unless so signed and sealed. Certificates countersigned by a duly appointed transfer agent and/or registered by a duly appointed registrar shall be deemed to be so signed and sealed whether the signatures be manual or facsimile signatures and whether the seal be a facsimile seal or any other form of seal. All certificates for each class of stock shall be consecutively numbered and the name of the person owning the shares represented thereby, his address, with the number of such shares and the date of issue, shall be entered on the Corporation’s books. All certificates surrendered shall be canceled and no new certificates shall be issued until the former certificates for the same number of shares shall have been surrendered and canceled, except in cases provided for herein.

18

In case any officer or officers who shall have signed, or whose facsimile signature or signatures shall have been affixed to, any such certificate or certificates shall cease to be such officer or officers of the Corporation before such certificate or certificates shall have been delivered by the Corporation, such certificate or certificates may nevertheless be adopted by the Corporation, and may be issued and delivered as though the person or persons who signed such certificates, or whose facsimile signature or signatures shall have been affixed thereto, had not ceased to be such officer or officers of the Corporation.

Section 4.2 Uncertificated Shares; Transfers of Shares. The Board of Directors of the Corporation may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Notwithstanding the adoption of such a resolution by the Board of Directors, every holder of stock represented by certificates and upon request every holder of uncertificated shares shall be entitled to have a certificate signed by, or in the name of, the Corporation as provided for in these By-Laws and the laws of the State of Delaware. Transfers of certificated shares of stock shall be made upon the books of the Corporation by the holder in person or by attorney, upon the surrender and cancellation of the certificate or certificates for such shares. But the Board of Directors may appoint one or more suitable banks and/or trust companies as transfer agents and/or registrars of transfers, for facilitating transfers of any class or series of stock of the Corporation by the holders thereof under such regulations as the Board of Directors may from time to time prescribe. Upon such appointment being made all certificates of such class or series thereafter issued shall be countersigned by one of such transfer agents and/or one of such registrars or transfers, and shall not be valid unless so countersigned. Uncertificated shares of the stock of the Corporation shall be transferred on the books of the Corporation only by the person then registered in the stock records of the Corporation as the owner of such shares or by such person’s representative as determined in accordance with generally accepted securities industry practices.

Section 4.3 Stolen, Lost, Mutilated and Destroyed Certificates. The Board of Directors may in its sole discretion direct that a new certificate or certificates of stock may be issued in place of any certificate or certificates of stock theretofore issued by the Corporation, alleged to have been stolen, lost, mutilated or destroyed, and the Board of Directors when authorizing the issuance of such new certificate or certificates may, in its discretion, and as a condition precedent thereto, require the owner of such mutilated certificate to surrender the same and the owner of such stolen, lost, mutilated or destroyed certificate or certificates or his legal representatives to give to the Corporation, and to such registrar or registrars and/or transfer agent or transfer agents as may be authorized or required to countersign such new certificate or certificates, a bond in such sum as the Corporation may direct not exceeding double the value of the stock represented by the certificate alleged to have been stolen, lost, mutilated or destroyed, as indemnity against any claim that may be made against them or any of them for or in respect of the shares of stock represented by the certificate alleged to have been stolen, lost, mutilated or destroyed.

Section 4.4 Registered Stockholders. The Corporation shall be entitled to treat the holder of record of any share or shares of stock as the owner in fact thereof and accordingly shall not be bound to recognize any equitable or other claim to or interest in such share on the part of any other person, whether or not it shall have express or other notice thereof, save as expressly provided by the laws of Delaware.

19

ARTICLE V
CONTRACTS, CHECKS, DRAFTS, BANK ACCOUNTS

Section 5.1 Contracts. Subject to the provisions of the Certificate of Incorporation, the Board of Directors or the Executive Committee (subject to Section 2.8) may authorize any officer or officers, fiscal agent or other agent or employee of the Corporation to enter into any contract or execute or deliver any instrument in the name of or on behalf of the Corporation and such authority may be general or confined to specific instances; and unless so authorized by the Board of Directors or by these By-Laws, no officer, fiscal or other agent or employee of the Corporation shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose.

Section 5.2 Loans. The Chairman of the Board or any officer or agent of the Corporation when authorized by the Board of Directors or the Executive Committee may negotiate loans and advances for the Corporation from any bank, trust company or other institution or from any firm, corporation or individual, and for such loans and advances, when authorized by the Board of Directors or the Executive Committee (subject to Section 2.8), may make, execute and deliver promissory notes or other evidences of indebtedness of the Corporation, and pledge, hypothecate or transfer as security for the payment thereof securities or other property at any time held by the Corporation. No loans shall be contracted on behalf of the Corporation and no notes or other evidences of indebtedness shall be issued in its behalf unless and except as authorized by the Board of Directors or the Executive Committee (if authorized pursuant to Section 2.8).

Section 5.3 Deposits. All funds of the Corporation shall be deposited from time to time to the credit of the Corporation in such banks or trust companies or with such bankers or other depositories in the United States or elsewhere as the Board of Directors, the Executive Committee, the Chief Executive Officer, the Vice-Chairman of the Board, the President or the Chief Operating Officer may approve.

Section 5.4 Checks, Drafts, Etc. All notes, drafts, acceptances, checks, endorsements or other evidences of indebtedness shall be signed by the Chairman of the Board, Chief Executive Officer, the Vice-Chairman of the Board, the President, the Chief Operating Officer or a Vice-president and shall be countersigned by the Treasurer or an Assistant Treasurer of the Corporation, or by such officers as may, from time to time, be designated by resolution of the Board of Directors or the Executive Committee for that purpose. Endorsements for deposit to the credit of the Corporation in any of its duly authorized depositories may be made by the Treasurer or an Assistant Treasurer or by any other officer or agent who may be designated by resolution of the Board of Directors or the Executive Committee.

Section 5.5 Safe Deposit Vaults. To the extent permitted by law, securities of the Corporation may be deposited in such safe deposit vaults in the United States or elsewhere as the Board of Directors or the Executive Committee may approve, and access to such vaults shall be only by such officer together with such additional officer or officers and/or responsible employee or employees as may from time to time be designated for the purpose by resolution of the Board of Directors.

Section 5.6 Deposit of Securities for Safekeeping. From time to time, to the extent permitted by law, the Board of Directors or the Executive Committee may deposit for safekeeping with one or more banks, trust companies or other financial institutions to be selected by them in the United States or elsewhere, any securities owned by the Corporation and not otherwise deposited or pledged as security. Any and all securities so deposited may be withdrawn from time to time only by such officer of the Corporation together with such additional officer or officers and/or responsible employee or employees as may from time to time, to the extent permitted by law, be designated for the purpose by resolution of the Board of Directors or the Executive Committee.

20

ARTICLE VI
GENERAL

Section 6.1 Seal. The corporate seal shall have inscribed thereon the name of the Corporation, and shall be in such form as may be approved from time to time by the Board of Directors. One or more duplicate dies for impressing such seal may be kept and used.

Section 6.2 Books and Records. Subject to the provisions of the statute under which the Corporation is organized, the Corporation may keep its books outside the State of Delaware.

The Board of Directors shall have power, from time to time, to determine whether and to what extent and at what times and places and under what conditions and regulations the accounts and books of the Corporation (except such as may by statute be specifically open to inspection), or any of them shall be open to the inspection of the stockholders and no stockholder shall have any right to inspect any account or book or document of the Corporation except as conferred by statute or authorized by the Board of Directors.

Section 6.3 Fiscal Year. The fiscal year shall begin the first day of January in each year.

Section 6.4 Notices. Whenever under the provisions of these By-Laws notice is required to be given to any director, officer or stockholder, it shall not be construed to mean personal notice, but such notice may be given in writing, by mail, by depositing the same in the post office or letter-box, in a post-paid sealed wrapper, addressed to such stockholder, officer or director at such address as appears on the books of the Corporation, or, in default of other address, to such director, officer or stockholder at his last known post office address and such notice shall be deemed to be given at the time when the same shall be thus mailed.

Any stockholder, director or officer may waive any notice required to be given under these By-Laws by instrument in writing signed (either before or after the holding of any meeting in respect of which the notice is required) by such stockholder, director or officer and filed with the Corporation.

Section 6.5 Stock of Other Corporations. The Chairman of the Board, Chief Executive Officer, the Vice-Chairman of the Board, the President, the Chief Operating Officer and each Vice-President are each individually authorized on behalf of the Corporation, in person or by proxy, to attend, act and vote at meetings of the stockholders of any corporation in which the Corporation shall hold stock, and to exercise thereat any and all rights and powers incident to the ownership of such stock, and to execute waivers of notice of such meetings and calls therefor, and to take or participate in the taking of action by the stockholders of such corporation by consent in lieu of a meeting. The Board of Directors or the Executive Committee may also authorize any other director, officer or other person on behalf of the Corporation to take any and all of such actions, and authority may be given to exercise such authority either on one or more designated occasions, or generally on all occasions until revoked by the Board of Directors or the Executive Committee.

Section 6.6 Registration of Securities. Any stocks or securities owned by the Corporation may, if so determined by the Board of Directors or the Executive Committee, be registered either in the name of the Corporation or in the name of any nominee or nominees appointed for that purpose by the Board of Directors or the Executive Committee.

21

Section 6.7 Amendments. These By-Laws may be altered or amended by the holders of shares of stock of the Corporation entitled to vote with respect thereto, present in person or by proxy at any regular or special meeting of the stockholders, if notice of the proposed alteration or amendment be contained in the notice of the meeting, or by the affirmative vote therefor of directors constituting at least seventy percent (70%) of the whole Board of Directors, provided, however, that these By-Laws may not be altered or amended either by action of the stockholders or by action of the Board of Directors to make provisions contrary to or in conflict with or in any way modifying any provision of the Certificate of Incorporation and provided, further, that the vote of stockholders necessary to alter or amend these By-Laws shall be as provided for in the Certificate of Incorporation. For purposes of these By-Laws, “whole Board of Directors” means the total number of directors which the Corporation would have on the Board of Directors if there were no vacancies.

ARTICLE VII
FORUM FOR ADJUDICATION OF DISPUTES

Section 7.1 Forum for Adjudication of Disputes. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the Certificate of Incorporation or these By-Laws and (iv) any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 7.1.

ARTICLE VIII
EMERGENCY BY-LAWS

Section 8.1 Emergency By-Laws. Notwithstanding anything to the contrary in the Certificate of Incorporation or these By-Laws, in the event there is any emergency, disaster or catastrophe, as referred to in Section 110 of the DGCL, or other similar emergency condition (each, an “emergency”) and irrespective of whether a quorum of the Board of Directors or a standing committee thereof can readily be convened for action, this ARTICLE VIIIshall apply.

(i)Any director or senior executive officer of the Corporation may call a meeting of the Board of Directors or any committee thereof by any feasible means and with such advance notice as circumstances permit in the judgment of the person calling the meeting. Neither the business to be transacted nor the purpose of any such meeting need be specified in the notice thereof.

(ii)At any meeting called in accordance with Section 8.1(i), the director or directors in attendance shall constitute a quorum. In the event that no directors are able to attend the meeting, the Designated Officers in attendance shall be deemed directors for such meeting. For purposes of this Section 8.1(ii), a “Designated Officer” means an officer who is included on a list of officers of the Corporation who shall be deemed to be directors of the Corporation for purposes of obtaining a quorum during an emergency if a quorum of directors cannot otherwise be obtained, which officers have been designated by the Board of Directors prior to such time as an emergency may have occurred.

(iii)Directors may take action to appoint one or more of the directors to membership on any standing or temporary committees of the Board of Directors as they deem advisable. Directors may also take action to designate one or more of the officers of the Corporation to serve as directors of the Corporation while this ARTICLE VIII applies.

22

(iv)To the extent that it considers it practical to do so, the Board of Directors shall manage the business of the Corporation during an emergency in a manner that is consistent with the Certificate of Incorporation and these By-Laws. It is recognized, however, that in an emergency, it may not always be practical to act in this manner and this ARTICLE VIII is intended to, and does hereby, empower the Board of Directors with the maximum authority possible under the DGCL and all other applicable law to conduct the interim management of the affairs of the Corporation in an emergency in what it considers to be in the best interests of the Corporation, including, without limitation, taking any action that it determines to be practical and necessary to address the circumstances of the emergency.

(v)No director, officer or employee acting in accordance with this ARTICLE VIII or otherwise pursuant to Section 110 of the DGCL (or any successor section) shall be liable except for willful misconduct.

(vi)This ARTICLE VIII shall continue to apply until such time following the emergency when it is feasible for at least a majority of the Board of Directors immediately prior to the emergency to resume management of the business of the Corporation.

(vii)At any meeting called in accordance with Section 8.1(i), the Board of Directors may modify, amend or add to the provisions of this ARTICLE VIII in order to make any provision that may be practical or necessary given the circumstances of the emergency.

(viii)The provisions of this ARTICLE VIII shall be subject to repeal or change by further action of the Board of Directors or by action of the stockholders, but no such repeal or change shall modify the provisions of Section 8.1(v) with regard to action taken prior to the time of such repeal or change.

(ix)Nothing contained in this ARTICLE VIII shall be deemed exclusive of any other provisions for emergency powers consistent with other sections of the DGCL that have been or may be adopted by corporations created under the DGCL.

ARTICLE IX
MISCELLANEOUS

Section 9.1 Section Headings. Section headings in these By-Laws are for convenience of reference only and shall not be given any substantive effect in limiting or otherwise construing any provision herein.

Section 9.2 Inconsistent Provisions. In the event that any provision of these By-Laws is or becomes inconsistent with any provision of the Certificate of Incorporation, the DGCL or any other applicable law, the provision of these By-Laws shall not be given any effect to the extent of such inconsistency but shall otherwise be given full force and effect.

23

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Stephan B. Tanda, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AptarGroup, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a--15(e) and 15d--15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a--15(f) and 15d--15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	July 31, 2020
By:	/s/ STEPHAN B. TANDA
	Stephan B. Tanda
	President and Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Robert W. Kuhn, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AptarGroup, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a--15(e) and 15d--15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a--15(f) and 15d--15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	July 31, 2020
By:	/s/ ROBERT W. KUHN
	Robert W. Kuhn
	Executive Vice President,
	Chief Financial Officer and Secretary

EX-32.1

Exhibit 32.1

Certificate Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

I, Stephan B. Tanda, president and chief executive officer of AptarGroup, Inc., certify that (i) the Quarterly Report on Form 10-Q of AptarGroup, Inc. for the quarter ended June 30, 2020 (the “Form 10-Q”) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of AptarGroup, Inc.

By:	/s/ STEPHAN B. TANDA
	Stephan B. Tanda
	President and Chief Executive Officer
	July 31, 2020

EX-32.2

Exhibit 32.2

Certificate Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

I, Robert W. Kuhn, executive vice president and chief financial officer and secretary of AptarGroup, Inc., certify that (i) the Quarterly Report on Form 10-Q of AptarGroup, Inc. for the quarter ended June 30, 2020 (the “Form 10-Q”) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of AptarGroup, Inc.

By:	/s/ ROBERT W. KUHN
	Robert W. Kuhn
	Executive Vice President,
	Chief Financial Officer and Secretary
	July 31, 2020

XML

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 24, 2020
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2020
Entity File Number	1-11846
Entity Registrant Name	APTARGROUP INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3853103
Entity Address, Address Line One	265 EXCHANGE DRIVE
Entity Address, Address Line Two	SUITE 100
Entity Address, City or Town	CRYSTAL LAKE
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		64,473,805
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000896622
Amendment Flag	false

XML

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Net sales	$ 699,305	$ 742,661	$ 1,420,858	$ 1,487,121
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	441,702	469,441	892,958	938,573
Selling, research & development and administrative	123,365	113,752	249,557	234,967
Depreciation and amortization	56,429	47,867	107,235	95,356
Restructuring initiatives	7,331	1,737	12,170	11,267
Total Operating Expenses	628,827	632,797	1,261,920	1,280,163
Operating Income	70,478	109,864	158,938	206,958
Other (Expense) Income:
Interest expense	(8,734)	(8,756)	(17,122)	(17,970)
Interest income	175	1,033	350	2,781
Equity in results of affiliates	(328)	9	(1,127)	(86)
Miscellaneous, net	(923)	(49)	(2,335)	417
Total Other Income (Expense)	(9,810)	(7,763)	(20,234)	(14,858)
Income before Income Taxes	60,668	102,101	138,704	192,100
Provision for Income Taxes	18,808	28,180	41,594	55,180
Net Income	41,860	73,921	97,110	136,920
Net (Income) Loss Attributable to Noncontrolling Interests	(21)	(6)	(18)	(1)
Net Income Attributable to AptarGroup, Inc.	$ 41,839	$ 73,915	$ 97,092	$ 136,919
Net Income Attributable to AptarGroup, Inc. Per Common Share:
Basic (in dollars per share)	$ 0.65	$ 1.16	$ 1.51	$ 2.17
Diluted (in dollars per share)	$ 0.63	$ 1.12	$ 1.47	$ 2.08
Average number of shares outstanding:
Basic (in shares)	64,262	63,471	64,135	63,219
Diluted (in shares)	66,384	66,232	66,246	65,842
Dividends per Common Share (in dollars per share)	$ 0.36	$ 0.36	$ 0.72	$ 0.70

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net Income	$ 41,860	$ 73,921	$ 97,110	$ 136,920
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	19,096	9,414	(23,133)	(197)
Changes in derivative (losses) gains, net of tax	(733)	(479)	750	(872)
Defined benefit pension plan, net of tax
Amortization of prior service cost included in net income, net of tax	72	83	143	167
Amortization of net loss included in net income, net of tax	1,368	633	2,933	1,270
Total defined benefit pension plan, net of tax	1,440	716	3,076	1,437
Total other comprehensive income (loss)	19,803	9,651	(19,307)	368
Comprehensive Income	61,663	83,572	77,803	137,288
Comprehensive (Income) Loss Attributable to Noncontrolling Interests	(22)	2	(19)	(1)
Comprehensive Income Attributable to AptarGroup, Inc.	$ 61,641	$ 83,574	$ 77,784	$ 137,287

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and equivalents	$ 247,656	$ 241,970
Accounts and notes receivable, less current expected credit loss ("CECL") of $6,080 in 2020 and $3,626 in 2019	575,655	558,428
Inventories	381,939	375,795
Prepaid and other	138,321	115,048
Total Current Assets	1,343,571	1,291,241
Property, Plant and Equipment:
Buildings and improvements	521,312	504,328
Machinery and equipment	2,578,354	2,521,737
Property, Plant and Equipment, Gross	3,099,666	3,026,065
Less: Accumulated depreciation	(2,028,101)	(1,963,520)
Property, Plant and Equipment, Net	1,071,565	1,062,545
Land	26,355	25,133
Total Property, Plant and Equipment	1,097,920	1,087,678
Other Assets:
Investments in equity securities	44,193	8,396
Goodwill	861,928	763,461
Intangible assets	352,740	291,084
Operating lease right-of-use assets	68,665	72,377
Miscellaneous	44,999	47,882
Total Other Assets	1,372,525	1,183,200
Total Assets	3,814,016	3,562,119
Current Liabilities:
Notes payable, revolving credit facility and overdrafts	150,831	44,259
Current maturities of long-term obligations, net of unamortized debt issuance costs	66,248	65,988
Accounts payable, accrued and other liabilities	612,688	573,028
Total Current Liabilities	829,767	683,275
Long-term obligations, net of unamortized debt issuance costs	1,082,742	1,085,453
Deferred Liabilities and Other:
Deferred income taxes	39,414	41,388
Retirement and deferred compensation plans	108,896	101,225
Operating lease liabilities	52,036	55,276
Deferred and other non-current liabilities	55,175	23,250
Commitments and contingencies
Total Deferred Liabilities and Other	255,521	221,139
AptarGroup, Inc. stockholders' equity
Common stock, $.01 par value, 199 million shares authorized, 69.0 and 68.6 million shares issued as of June 30, 2020 and December 31, 2019, respectively	690	686
Capital in excess of par value	803,511	770,596
Retained earnings	1,573,392	1,523,820
Accumulated other comprehensive (loss)	(361,256)	(341,948)
Less treasury stock at cost, 4.7 and 4.8 million shares as of June 30, 2020 and December 31, 2019, respectively	(370,706)	(381,238)
Total AptarGroup, Inc. Stockholders' Equity	1,645,631	1,571,916
Noncontrolling interests in subsidiaries	355	336
Total Stockholders' Equity	1,645,986	1,572,252
Total Liabilities and Stockholders' Equity	$ 3,814,016	$ 3,562,119

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands, shares in Millions	Jun. 30, 2020	Dec. 31, 2019
CONDENSED CONSOLIDATED BALANCE SHEETS
Accounts and notes receivable, allowance for doubtful accounts (in dollars)	$ 6,080	$ 3,626
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	199.0	199.0
Common stock, shares issued	69.0	68.6
Treasury stock, shares	4.7	4.8

XML

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Retained Earnings	Accumulated Other Comprehensive Income/(Loss)	Common Stock Par Value	Treasury Stock	Capital in Excess of Par Value	Non-Controlling Interest	Total
Balance at Dec. 31, 2018	$ 1,371,826	$ (310,504)	$ 673	$ (318,208)	$ 678,769	$ 315	$ 1,422,871
Increase (Decrease) in Stockholders' Equity
Net Income	136,919					1	136,920
Foreign currency translation adjustments		(197)					(197)
Changes in unrecognized pension gains (losses) and related amortization, net of tax		1,437					1,437
Changes in derivative gains (losses), net of tax		(872)					(872)
Stock awards and option exercises			10	19,924	64,563		84,497
Cash dividends declared on common stock	(44,138)						(44,138)
Treasury stock purchased				(19,096)			(19,096)
Balance at Jun. 30, 2019	1,464,607	(310,136)	683	(317,380)	743,332	316	1,581,422
Balance at Mar. 31, 2019	1,413,453	(319,795)	676	(327,871)	700,933	318	1,467,714
Increase (Decrease) in Stockholders' Equity
Net Income	73,915					6	73,921
Foreign currency translation adjustments		9,422				(8)	9,414
Changes in unrecognized pension gains (losses) and related amortization, net of tax		716					716
Changes in derivative gains (losses), net of tax		(479)					(479)
Stock awards and option exercises			7	14,587	42,399		56,993
Cash dividends declared on common stock	(22,761)						(22,761)
Treasury stock purchased				(4,096)			(4,096)
Balance at Jun. 30, 2019	1,464,607	(310,136)	683	(317,380)	743,332	316	1,581,422
Balance at Dec. 31, 2019	1,523,820	(341,948)	686	(381,238)	770,596	336	1,572,252
Increase (Decrease) in Stockholders' Equity
Net Income	97,092					18	97,110
Adoption of accounting standards | Accounting Standards Update 2016-13	(1,377)						(1,377)
Foreign currency translation adjustments		(23,134)				1	(23,133)
Changes in unrecognized pension gains (losses) and related amortization, net of tax		3,076					3,076
Changes in derivative gains (losses), net of tax		750					750
Stock awards and option exercises			4	10,532	32,915		43,451
Cash dividends declared on common stock	(46,143)						(46,143)
Balance at Jun. 30, 2020	1,573,392	(361,256)	690	(370,706)	803,511	355	1,645,986
Balance at Mar. 31, 2020	1,554,665	(381,058)	689	(372,573)	785,567	333	1,587,623
Increase (Decrease) in Stockholders' Equity
Net Income	41,839					21	41,860
Foreign currency translation adjustments		19,095				1	19,096
Changes in unrecognized pension gains (losses) and related amortization, net of tax		1,440					1,440
Changes in derivative gains (losses), net of tax		(733)					(733)
Stock awards and option exercises			1	1,867	17,944		19,812
Cash dividends declared on common stock	(23,112)						(23,112)
Balance at Jun. 30, 2020	$ 1,573,392	$ (361,256)	$ 690	$ (370,706)	$ 803,511	$ 355	$ 1,645,986

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities:
Net income	$ 97,110	$ 136,920
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	86,901	82,968
Amortization	20,334	12,388
Stock based compensation	17,603	12,978
Provision for CECL	1,089	312
(Gain) loss on disposition of fixed assets	(46)	368
Deferred income taxes	9	679
Defined benefit plan expense	11,550	7,699
Equity in results of affiliates	1,127	86
Changes in balance sheet items, excluding effects from acquisitions and foreign currency adjustments:
Accounts and other receivables	(25,625)	(28,772)
Inventories	(13,241)	(18,503)
Prepaid and other current assets	(16,936)	546
Accounts payable, accrued and other liabilities	63,256	14,590
Income taxes payable	(8,446)	1,840
Retirement and deferred compensation plan liabilities	(5,916)	(4,652)
Other changes, net	(1,083)	1,693
Net Cash Provided by Operations	227,686	221,140
Cash Flows from Investing Activities:
Capital expenditures	(122,986)	(124,774)
Proceeds from sale of property, plant and equipment	4,130	1,082
Acquisition of business, net of cash acquired	(159,570)	(49,131)
Acquisition of intangible assets	(3,612)	(602)
Investment in equity securities	(34,044)
Proceeds from sale of investment in equity securities		16,487
Notes receivable, net	(1,045)	(220)
Net Cash Used by Investing Activities	(317,127)	(157,158)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts	14,464	31,022
Repayments of notes payable and overdrafts	(27,788)	(35,490)
Proceeds and repayments of short term credit facility, net	125,000	(38,685)
Proceeds from long-term obligations	1,316	10,446
Repayments of long-term obligations	(4,067)	(6,546)
Payment of contingent consideration obligations	(1,500)
Dividends paid	(46,143)	(44,138)
Proceeds from stock option exercises	30,058	70,712
Purchase of treasury stock		(19,096)
Net Cash Provided (Used) by Financing Activities	91,340	(31,775)
Effect of Exchange Rate Changes on Cash	8,522	3,920
Net Increase (Decrease) in Cash and Equivalents and Restricted Cash	10,421	36,127
Cash and Equivalents and Restricted Cash at Beginning of Period	246,973	266,823
Cash and Equivalents and Restricted Cash at End of Period	$ 257,394	$ 302,950

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow.
Cash and equivalents	$ 247,656	$ 241,970	$ 302,950
Restricted cash included in prepaid and other	9,738
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$ 257,394	$ 246,973	$ 302,950	$ 266,823

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.

In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.

Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. For the six months ended June 30, 2020, our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues.

There are many uncertainties regarding the current COVID-19 pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic and the extent of local and worldwide social, political and economic disruption it may cause. The pandemic has impacted our business, operations and financial results during the six months ended June 30, 2020 including an overall reduction to net sales. No impairments were recorded as of June 30, 2020. While the disruption is currently expected to be temporary, there is uncertainty around the duration. Due to significant uncertainty surrounding the situation, our judgment regarding future results could change and therefore our results could be materially impacted.

ADOPTION OF RECENT ACCOUNTING STANDARDS

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.

Effective January 1, 2020, we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, issued by the FASB in June 2016, as well as the clarifying amendments subsequently issued. We applied the guidance using a modified retrospective approach and accordingly recognized an amount of $1.4 million as the cumulative adjustment to opening retained earnings in the first quarter of 2020. This is based on management's best estimates of specific losses on individual exposures particularly on current trade receivables, as well as the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. On an ongoing basis, we will contemplate forward-looking economic conditions in recording lifetime expected credit losses for our financial assets measured at cost, such as our trade receivables and certain other assets.

In January 2017, the FASB issued ASU 2017-04, which provides guidance to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As a result, impairment charges are required for the amount by which a reporting unit’s carrying amount exceeds its fair value up to the amount of its allocated goodwill. We adopted the standard on January 1, 2020 and did not record any impairment charges.

In August 2018, the FASB issued ASU 2018-15 to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted the standard on January 1, 2020 and no material impacts were noted.

In August 2018, the FASB issued ASU 2018-13, which amends disclosure requirements for fair value measurements. The new standard modifies disclosure requirements including removing requirements to disclose the valuation process for Level 3 measurements and adding requirements to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements and the range and weighted average of significant unobservable inputs used to develop Level 3 measurements. We adopted the standard on January 1, 2020 and no material impacts were noted.

Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.

INCOME TAXES

We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested.  Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and the global cash management goals of the Company.

We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition.

The Company is subject to taxation and files income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. The Company believes that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in the Company’s tax audits are resolved in a manner inconsistent with its expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.

XML

REVENUE

6 Months Ended

Jun. 30, 2020

REVENUE.

REVENUE

NOTE 2 – REVENUE

At contract inception, we assess the goods and services promised in our contracts with customers and identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product and tooling sales; however, we also receive revenues from service, license, exclusivity and royalty arrangements, which collectively are not material to the quarterly and year-to-date results. Revenue by segment and geography for the three and six months ended June 30, 2020 and 2019 is as follows:

	For the Three Months Ended June 30, 2020
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	152,412	$	94,349	$	29,893	$	23,132	$	299,786
Pharma		201,813		81,098		6,987		11,361		301,259
Food + Beverage		27,841		54,478		6,489		9,452		98,260
Total	$	382,066	$	229,925	$	43,369	$	43,945	$	699,305

	For the Three Months Ended June 30, 2019
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	202,541	$	73,973	$	41,449	$	24,117	$	342,080
Pharma		190,654		76,042		7,078		8,165		281,939
Food + Beverage		32,336		65,160		9,211		11,935		118,642
Total	$	425,531	$	215,175	$	57,738	$	44,217	$	742,661

	For the Six Months Ended June 30, 2020
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	339,362	$	176,194	$	66,074	$	42,716	$	624,346
Pharma		391,943		172,063		13,566		20,883		598,455
Food + Beverage		56,610		112,068		14,523		14,856		198,057
Total	$	787,915	$	460,325	$	94,163	$	78,455	$	1,420,858

	For the Six Months Ended June 30, 2019
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	418,774	$	160,952	$	84,091	$	45,922	$	709,739
Pharma		374,828		147,814		14,734		17,264		554,640
Food + Beverage		63,297		120,280		17,095		22,070		222,742
Total	$	856,899	$	429,046	$	115,920	$	85,256	$	1,487,121

We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the receipt of the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance.

The opening and closing balances of our contract asset and contract liabilities are as follows:

	Balance as of		Balance as of		Increase/
	December 31, 2019		June 30, 2020		(Decrease)
Contract asset (current)	$	16,245	$	15,113	$	(1,132)
Contract asset (long-term)	$	—	$	—	$	—
Contract liability (current)	$	79,305	$	70,708	$	(8,597)
Contract liability (long-term)	$	9,779	$	20,662	$	10,883

The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the customer’s payment. The total amount of revenue recognized during the current year against contract liabilities is $27.3 million, including $21.6 million relating to contract liabilities at the beginning of the year.

Determining the Transaction Price

In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled.

Product Sales

We primarily manufacture and sell dispensing, sealing and active packaging solutions. The amount of consideration is typically fixed for such customers. At the time of delivery, the customer is invoiced the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer.

To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. A majority of product sales are sold free on board (“FOB”) shipping point. For FOB shipping point shipments, control of the goods transfers to the customer at the time of shipment of the goods. Therefore, our performance obligation is satisfied at the time of shipment. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale.

There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the Output Method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks.

As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties.

Tooling Sales

We also build, or contract to build molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the Input Method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any material significant payment terms as payment is typically either received during the mold-build process or shortly after completion.

In certain instances, we offer extended warranties on tools sold to our customers above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. At December 31, 2019, $515 thousand of unearned revenue associated with outstanding contracts was reported in Accounts Payable, Accrued and Other Liabilities. At June 30, 2020, the unearned amount was $410 thousand. We expect to recognize approximately $111 thousand of the unearned amount during the remainder of 2020, $125 thousand in 2021, and $174 thousand thereafter.

Credit Risk

We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review.

We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.

At June 30, 2020, we reported $576 million of accounts receivable, net of CECL of $6.1 million. Changes in the allowance were not material for the six months ended June 30, 2020. Current uncertainty in credit and market conditions due to the COVID-19 pandemic may slow our collection efforts if customers experience significant difficulty accessing credit and paying their obligations, which may lead to higher than normal accounts receivable and increased CECL charges.

XML

INVENTORIES

6 Months Ended

Jun. 30, 2020

INVENTORIES

INVENTORIES

NOTE 3 - INVENTORIES

Inventories, by component, consisted of:

	June 30,		December 31,
	2020		2019
Raw materials	$	112,287	$	111,653
Work in process		123,710		123,750
Finished goods		145,942		140,392
Total	$	381,939	$	375,795

XML

GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2020

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

NOTE 4 – GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by reporting segment since December 31, 2019 are as follows:

	Beauty +				Food +		Corporate
	Home		Pharma		Beverage		& Other		Total
Goodwill	$	221,658	$	413,650	$	128,153	$	1,615	$	765,076
Accumulated impairment losses		—		—		—		(1,615)		(1,615)
Balance as of December 31, 2019	$	221,658	$	413,650	$	128,153	$	—	$	763,461
Acquisition		99,644		463		—		—		100,107
Foreign currency exchange effects		(473)		(1,175)		8		—		(1,640)
Goodwill	$	320,829	$	412,938	$	128,161	$	1,615	$	863,543
Accumulated impairment losses		—		—		—		(1,615)		(1,615)
Balance as of June 30, 2020	$	320,829	$	412,938	$	128,161	$	—	$	861,928

The table below shows a summary of intangible assets as of June 30, 2020 and December 31, 2019.

		June 30, 2020							December 31, 2019
Weighted Average		Gross						Gross
Amortization Period		Carrying		Accumulated		Net		Carrying		Accumulated		Net
	(Years)	Amount		Amortization		Value		Amount		Amortization		Value
Amortized intangible assets:
Patents	7.1	$	2,703		(1,334)	$	1,369	$	2,804	$	(1,318)	$	1,486
Acquired technology	12.6		105,020		(29,907)		75,113		100,511		(25,430)		75,081
Customer relationships	13.5		279,709		(43,561)		236,148		217,934		(33,924)		184,010
Trademarks and trade names	6.0		44,508		(13,568)		30,940		35,015		(11,003)		24,012
License agreements and other	15.5		22,480		(13,310)		9,170		16,153		(9,658)		6,495
Total intangible assets	12.6	$	454,420	$	(101,680)	$	352,740	$	372,417	$	(81,333)	$	291,084

Aggregate amortization expense for the intangible assets above for the quarters ended June 30, 2020 and 2019 was $12,320 and $6,386, respectively. Aggregate amortization expense for the intangible assets above for the six months ended June 30, 2020 and 2019 was $20,334 and $12,388, respectively.

Future estimated amortization expense for the years ending December 31 is as follows:

2020	$	19,192	(remaining estimated amortization for 2020)
2021		37,723
2022		37,443
2023		37,362
2024 and thereafter		221,020

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of June 30, 2020.

XML

INCOME TAXES

6 Months Ended

Jun. 30, 2020

INCOME TAXES

INCOME TAXES

NOTE 5 – INCOME TAXES

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items.

The effective tax rate for the three months ended June 30, 2020 and 2019, respectively, was 31.0% and 27.6%. The effective tax rate for the three months ended June 30, 2019 was favorably impacted by net tax benefits of $2.9 million from discrete events. This consisted of a $9.1 million benefit from the excess tax benefits from employee share-based compensation offset by, among other items, a $6.3 million charge to record a valuation allowance to properly reflect the realization of recorded deferred tax assets.

The effective tax rate for the six months ended June 30, 2020 and 2019, respectively, was 30.0% and 28.7%. The effective tax rate for the six months ended June 30, 2020 reflects a favorable impact of net tax benefits of $4.6 million, primarily from the excess tax benefits from employee share-based compensation.  This is offset by the unfavorable impact from the mix of earnings, particularly losses in jurisdictions where we cannot record the tax benefit. The effective tax rate for the six months ended June 30, 2019 was favorably impacted by net tax benefits of $4.1 million from discrete events.  This consisted of a favorable impact of $11.6 million from the excess tax benefits from employee share-based compensation, offset by, among other items, a $7.0 million charge recognized to record a valuation allowance to properly reflect the realization of recorded deferred tax assets.

XML

DEBT

6 Months Ended

Jun. 30, 2020

DEBT

DEBT

NOTE 6 – DEBT

Notes Payable, Revolving Credit Facility and Overdrafts

At June 30, 2020 and December 31, 2019, our notes payable, revolving credit facility and overdrafts, consisted of the following:

	June 30,		December 31,
	2020		2019
Notes payable 8.00%	$	831	$	1,436
Revolving credit facility 1.28%		150,000		25,000
Overdrafts 5.68% - 7.82%		—		17,823
	$	150,831	$	44,259

We maintain a multi-currency revolving credit facility with two tranches that matures in July 2022 which provides for unsecured financing of up to $300 million that is available in the U.S. and up to €150 million that is available to our wholly-owned UK subsidiary. $150.0 million was utilized under our U.S. facility and no balance was utilized under our euro-based revolving credit facility as of June 30, 2020. $25.0 million was utilized under our U.S. facility and no balance was utilized on our euro-based revolving credit facility as of December 31, 2019.

There are no compensating balance requirements associated with our revolving credit facility. Each borrowing under the credit facility will bear interest at rates based on LIBOR, prime rates or other similar rates, in each case plus an applicable margin. A facility fee on the total amount of the facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio.

Long-Term Obligations

At June 30, 2020, our long-term obligations consisted of the following:

			Unamortized
			Debt Issuance
	Principal		Costs		Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028	$	15,358	$	—	$	15,358
Senior unsecured notes 3.2%, due in 2022		75,000		52		74,948
Senior unsecured debts 2.4% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022		168,000		315		167,685
Senior unsecured notes 3.5%, due in 2023		125,000		126		124,874
Senior unsecured notes 1.0%, due in 2023		112,340		326		112,014
Senior unsecured notes 3.4%, due in 2024		50,000		56		49,944
Senior unsecured notes 3.5%, due in 2024		100,000		126		99,874
Senior unsecured notes 1.2%, due in 2024		224,680		661		224,019
Senior unsecured notes 3.6%, due in 2025		125,000		145		124,855
Senior unsecured notes 3.6%, due in 2026		125,000		145		124,855
Finance Lease Liabilities		30,564		—		30,564
	$	1,150,942	$	1,952	$	1,148,990
Current maturities of long-term obligations		(66,248)		—		(66,248)
Total long-term obligations	$	1,084,694	$	1,952	$	1,082,742

At December 31, 2019, our long-term obligations consisted of the following:

			Unamortized
			Debt Issuance
	Principal		Costs		Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028	$	19,220	$	—	$	19,220
Senior unsecured notes 3.2%, due in 2022		75,000		64		74,936
Senior unsecured debts 3.2% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022		168,000		390		167,610
Senior unsecured notes 3.5%, due in 2023		125,000		144		124,856
Senior unsecured notes 1.0%, due in 2023		112,170		356		111,814
Senior unsecured notes 3.4%, due in 2024		50,000		63		49,937
Senior unsecured notes 3.5%, due in 2024		100,000		144		99,856
Senior unsecured notes 1.2%, due in 2024		224,340		742		223,598
Senior unsecured notes 3.6%, due in 2025		125,000		169		124,831
Senior unsecured notes 3.6%, due in 2026		125,000		169		124,831
Finance Lease Liabilities		29,952		—		29,952
	$	1,153,682	$	2,241	$	1,151,441
Current maturities of long-term obligations		(65,988)		—		(65,988)
Total long-term obligations	$	1,087,694	$	2,241	$	1,085,453

The aggregate long-term maturities, excluding finance lease liabilities, which are disclosed in Note 7, due annually from the current balance sheet date for the next five years are $62,259, $59,990, $133,859, $338,967, $274,900 and $250,404 thereafter.

Covenants

Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

	Requirement	Level at June 30, 2020
Consolidated Leverage Ratio (1)	Maximum of 3.50 to 1.00	1.98 to 1.00
Consolidated Interest Coverage Ratio (1)	Minimum of 3.00 to 1.00	15.50 to 1.00

(1) Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.  

XML

LEASE COMMITMENTS

6 Months Ended

Jun. 30, 2020

LEASE COMMITMENTS

LEASE COMMITMENTS

NOTE 7 – LEASES

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2034. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.

Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”).

The components of lease expense for the three and six months ended June 30, 2020 and 2019 were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Operating lease cost	$	5,841	$	5,437	$	11,095	$	11,441
Finance lease cost:
Amortization of right-of-use assets	$	906	$	1,004	$	2,105	$	1,876
Interest on lease liabilities		369		325		717		640
Total finance lease cost	$	1,275	$	1,329	$	2,822	$	2,516
Short-term lease and variable lease costs	$	2,430	$	2,328	$	4,878	$	4,270

Supplemental cash flow information related to leases was as follows:

Six Months Ended June 30,	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	11,662	$	10,249
Operating cash flows from finance leases		704		534
Financing cash flows from finance leases		2,545		2,294
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	11,371	$	9,512
Finance leases		3,127		11,622

XML

RETIREMENT AND DEFERRED COMPENSATION PLANS

6 Months Ended

Jun. 30, 2020

RETIREMENT AND DEFERRED COMPENSATION PLANS

RETIREMENT AND DEFERRED COMPENSATION PLANS

NOTE 8 – RETIREMENT AND DEFERRED COMPENSATION PLANS

Components of Net Periodic Benefit Cost:

	Domestic Plans				Foreign Plans
Three Months Ended June 30,	2020		2019		2020		2019
Service cost	$	3,562	$	2,775	$	1,767	$	1,445
Interest cost		1,536		1,846		340		495
Expected return on plan assets		(2,702)		(3,095)		(631)		(586)
Amortization of net loss		1,294		489		514		359
Amortization of prior service cost		—		—		95		113
Net periodic benefit cost	$	3,690	$	2,015	$	2,085	$	1,826

	Domestic Plans				Foreign Plans
Six Months Ended June 30,	2020		2019		2020		2019
Service cost	$	7,139	$	5,548	$	3,535	$	2,905
Interest cost		3,523		3,691		680		996
Expected return on plan assets		(6,124)		(6,189)		(1,265)		(1,178)
Amortization of net loss		2,842		978		1,028		722
Amortization of prior service cost		—		—		192		226
Net periodic benefit cost	$	7,380	$	4,028	$	4,170	$	3,671

The components of net periodic benefit cost, other than the service cost component, are included in the line “Miscellaneous, net” in the income statement.

EMPLOYER CONTRIBUTIONS

Although we currently have no minimum funding requirements for our domestic and foreign plans, we contributed $204 thousand to our ongoing domestic supplemental employee retirement plan (“SERP”) annuity contracts during the six months ended June 30, 2020. We plan to contribute approximately an additional $200 thousand to pay our ongoing SERP annuity contracts during 2020. We have contributed approximately $1.1 million to our foreign defined benefit plans during the six months ended June 30, 2020 and do not expect additional significant contributions during 2020.

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME

6 Months Ended

Jun. 30, 2020

ACCUMULATED OTHER COMPREHENSIVE INCOME

ACCUMULATED OTHER COMPREHENSIVE INCOME

NOTE 9 – ACCUMULATED OTHER COMPREHENSIVE INCOME

Changes in Accumulated Other Comprehensive (Loss) Income by Component:

	Foreign		Defined Benefit
	Currency		Pension Plans		Derivatives		Total
Balance - December 31, 2018	$	(248,401)	$	(60,463)	$	(1,640)	$	(310,504)
Other comprehensive (loss) income before reclassifications		(197)		—		3,727		3,530
Amounts reclassified from accumulated other comprehensive income (loss)		—		1,437		(4,599)		(3,162)
Net current-period other comprehensive (loss) income		(197)		1,437		(872)		368
Balance - June 30, 2019	$	(248,598)	$	(59,026)	$	(2,512)	$	(310,136)
Balance - December 31, 2019	$	(257,124)	$	(83,147)	$	(1,677)	$	(341,948)
Other comprehensive (loss) income before reclassifications		(23,134)		—		1,758		(21,376)
Amounts reclassified from accumulated other comprehensive income (loss)		—		3,076		(1,008)		2,068
Net current-period other comprehensive (loss) income		(23,134)		3,076		750		(19,308)
Balance - June 30, 2020	$	(280,258)	$	(80,071)	$	(927)	$	(361,256)

Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:

	Amount Reclassified from
Details about Accumulated Other	Accumulated Other				Affected Line in the Statement
Comprehensive Income Components	Comprehensive Income				Where Net Income is Presented
Three Months Ended June 30,	2020		2019
Defined Benefit Pension Plans
Amortization of net loss	$	1,808	$	848	(1)
Amortization of prior service cost		95		113	(1)
		1,903		961	Total before tax
		(463)		(245)	Tax benefit
	$	1,440	$	716	Net of tax
Derivatives
Changes in cross currency swap: interest component	$	(525)	$	(1,552)	Interest Expense
Changes in cross currency swap: foreign exchange component		3,060		3,084	Miscellaneous, net
	$	2,535	$	1,532	Net of tax
Total reclassifications for the period	$	3,975	$	2,248

	Amount Reclassified from
Details about Accumulated Other	Accumulated Other				Affected Line in the Statement
Comprehensive Income Components	Comprehensive Income				Where Net Income is Presented
Six Months Ended June 30,	2020		2019
Defined Benefit Pension Plans
Amortization of net loss	$	3,870	$	1,700	(1)
Amortization of prior service cost		192		226	(1)
		4,062		1,926	Total before tax
		(986)		(489)	Tax benefit
	$	3,076	$	1,437	Net of tax
Derivatives
Changes in cross currency swap: interest component	$	(1,288)	$	(3,006)	Interest Expense
Changes in cross currency swap: foreign exchange component		280		(1,593)	Miscellaneous, net
	$	(1,008)	$	(4,599)	Net of tax
Total reclassifications for the period	$	2,068	$	(3,162)

(1) These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

6 Months Ended

Jun. 30, 2020

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

NOTE 10 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.

For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets. See Note 11 - Fair Value for additional details.

Cash Flow Hedge

For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows.

During 2017, our wholly-owned UK subsidiary borrowed $280 million in term loan borrowings under a new credit facility. In order to mitigate the currency risk of U.S. dollar debt on a euro functional currency entity and to mitigate the risk of variability in interest rates, we entered into a cross currency swap in the notional amount of $280 million to effectively hedge the foreign exchange and interest rate exposure on the $280 million term loan. This EUR/USD swap agreement fixed our U.S. dollar floating-rate debt to 1.36% euro fixed-rate debt. Related to this hedge, approximately $0.9 million of loss is included in accumulated other comprehensive loss at June 30, 2020. The amount expected to be recognized into earnings during the next 12 months related to the interest component of our cross currency swap based on prevailing foreign exchange and interest rates at June 30, 2020 is $0.3 million. The amount expected to be recognized into earnings during the next 12 months related to the foreign exchange component of our cross currency swap is dependent on fluctuations in currency exchange rates. As of June 30, 2020, the fair values of the cross currency swap were a $3.1 million asset. The swap contract expires on July 20, 2022.

Hedge of Net Investments in Foreign Operations

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we maintain debt in these subsidiaries to offset the net asset exposure. We do not otherwise actively manage this risk using derivative financial instruments. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.

Other

As of June 30, 2020, we have recorded the fair value of foreign currency forward exchange contracts of $0.7 million in prepaid and other and $0.1 million in accounts payable and accrued liabilities on the balance sheet. All forward exchange contracts outstanding as of June 30, 2020 had an aggregate notional contract amount of $49.4 million.

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019

		June 30, 2020				December 31, 2019
				Derivatives				Derivatives
		Derivatives		not		Derivatives		not
		Designated		Designated		Designated		Designated
	Balance Sheet	as Hedging		as Hedging		as Hedging		as Hedging
	Location	Instruments		Instruments		Instruments		Instruments
Derivative Assets
Foreign Exchange Contracts	Prepaid and other	$	—	$	747	$	—	$	206
Cross Currency Swap Contract (1)	Prepaid and other		3,052		—		2,552		—
		$	3,052	$	747	$	2,552	$	206
Derivative Liabilities
Foreign Exchange Contracts	Accounts payable, accrued and other liabilities	$	—	$	137	$	—	$	401
		$	—	$	137	$	—	$	401

(1) This cross currency swap contract is composed of both an interest component and a foreign exchange component.

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June 30, 2020 and 2019

						Amount of Gain (Loss)				Total Amount
	Amount of Gain (Loss)				Location of (Loss)	Reclassified from				of Affected
Derivatives in Cash	Recognized in				Gain Recognized	Accumulated				Income
Flow Hedging	Other Comprehensive				in Income on	Other Comprehensive				Statement
Relationships	Income on Derivative				Derivatives	Income on Derivative				Line Item
	2020		2019			2020		2019
Cross currency swap contract:
Interest component	$	(208)	$	1,080	Interest expense	$	525	$	1,552	$	(8,734)
Foreign exchange component		(3,060)		(3,084)	Miscellaneous, net		(3,060)		(3,084)		(923)
	$	(3,268)	$	(2,004)		$	(2,535)	$	(1,532)

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Six Months Ended June 30, 2020 and 2019

						Amount of Gain (Loss)				Total Amount
	Amount of Gain (Loss)				Location of (Loss)	Reclassified from				of Affected
Derivatives in Cash	Recognized in				Gain Recognized	Accumulated				Income
Flow Hedging	Other Comprehensive				in Income on	Other Comprehensive				Statement
Relationships	Income on Derivative				Derivatives	Income on Derivative				Line Item
	2020		2019			2020		2019
Cross currency swap contract:
Interest component	$	2,038	$	2,472	Interest expense	$	1,288	$	3,006	$	(17,122)
Foreign exchange component		(280)		1,593	Miscellaneous, net		(280)		1,593		(2,335)
	$	1,758	$	4,065		$	1,008	$	4,599

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2020 and 2019

		Amount of (Loss) Gain
Derivatives Not Designated	Location of (Loss) Gain Recognized	Recognized in Income
as Hedging Instruments	in Income on Derivatives	on Derivatives
		2020		2019
Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	(940)	$	(251)
		$	(940)	$	(251)

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2020 and 2019

		Amount of (Loss) Gain
Derivatives Not Designated	Location of (Loss) Gain Recognized	Recognized in Income
as Hedging Instruments	in Income on Derivatives	on Derivatives
		2020		2019
Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	807	$	(514)
		$	807	$	(514)

						Gross Amounts not Offset
			Gross Amounts	Net Amounts		in the Statement of
			Offset in the	Presented in		Financial Position
	Gross		Statement of	the Statement of		Financial	Cash Collateral	Net
	Amount		Financial Position	Financial Position		Instruments	Received	Amount
Description
June 30, 2020
Derivative Assets	$	3,799	—	$	3,799	—	—	$	3,799
Total Assets	$	3,799	—	$	3,799	—	—	$	3,799
Derivative Liabilities	$	137	—	$	137	—	—	$	137
Total Liabilities	$	137	—	$	137	—	—	$	137
December 31, 2019
Derivative Assets	$	2,758	—	$	2,758	—	—	$	2,758
Total Assets	$	2,758	—	$	2,758	—	—	$	2,758
Derivative Liabilities	$	401	—	$	401	—	—	$	401
Total Liabilities	$	401	—	$	401	—	—	$	401

XML

FAIR VALUE

6 Months Ended

Jun. 30, 2020

FAIR VALUE

FAIR VALUE

NOTE 11 – FAIR VALUE

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

● Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

● Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

● Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

As of June 30, 2020, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
Assets
Foreign exchange contracts (1)	$	747	$	—	$	747	$	—
Cross currency swap contract (1)		3,052		—		3,052		—
Total assets at fair value	$	3,799	$	—	$	3,799	$	—
Liabilities
Foreign exchange contracts (1)	$	137	$	—	$	137	$	—
Contingent consideration obligation		24,710		—		—		24,710
Total liabilities at fair value	$	24,847	$	—	$	137	$	24,710

As of December 31, 2019, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
Assets
Foreign exchange contracts (1)	$	206	$	—	$	206	$	—
Cross currency swap contract (1)		2,552		—		2,552		—
Total assets at fair value	$	2,758	$	—	$	2,758	$	—
Liabilities
Foreign exchange contracts (1)	$	401	$	—	$	401	$	—
Contingent consideration obligation		5,930		—		—		5,930
Total liabilities at fair value	$	6,331	$	—	$	401	$	5,930

(1) Market approach valuation technique based on observable market transactions of spot and forward rates.

The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instruments. We consider our long-term obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $1.1 billion as of June 30, 2020 and $1.1 billion as of December 31, 2019.

As discussed in Note 17 - Acquisitions, we have a contingent consideration obligation to the selling equity holders of Fusion in connection with the Fusion Acquisition (as defined herein) based on 2022 cumulative performance targets, a contingent consideration obligation to the selling equity holders of Noble in connection with the Noble Acquisition (as defined herein) based on 2024 cumulative performance targets and a contingent consideration obligation to the selling equity holder of Gateway in connection with the Gateway Acquisition (as defined herein) based on 2020 and 2022 performance targets. We consider these obligations Level 3 liabilities and have estimated the aggregate fair value for these contingent consideration arrangements to be $20.3 million, $2.9 million and $1.5 million, respectively, as of June 30, 2020. During the quarter ended June 30, 2020, $1.5 million of the Gateway contingent consideration accrual was paid as a result of the business meeting their first performance target. As of December 31, 2019 the aggregate fair value for these contingent consideration arrangements was $2.9 million and $3.0 million for the Noble Acquisition and the Gateway Acquisition, respectively.

XML

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2020

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

NOTE 12 - COMMITMENTS AND CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur and could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.

Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of June 30, 2020 and December 31, 2019.

A fire caused damage to our facility in Annecy, France in June 2016. We are insured for the damages caused by the fire, including business interruption insurance.  For the six months ended June 30, 2020, we did not receive any insurance proceeds, and have no insurance receivable as of June 30, 2020. During the six months ended June 30, 2020 and 2019, profitability was not impacted. The final settlement continues to be negotiated. In many cases, our insurance coverage exceeds the amount of our recognized losses. However, no gain contingencies were recognized during the six months ended June 30, 2020 as our ability to realize those gains remains uncertain.

An environmental investigation, undertaken to assess areas of possible contamination, was completed at our facility in Jundiaí, São Paulo, Brazil. The facility is primarily an internal supplier of anodized aluminum components for certain of our dispensing systems. The testing indicated that soil and groundwater in certain areas of the facility were impacted above acceptable levels established by local regulations. In March 2017, we reported the findings to the relevant environmental authority, the Environmental Company of the State of São Paulo – CETESB. Based upon our best estimate, we recorded a reserve of $1.5 million (operating expense) in the first quarter of 2017 related to this contingency. During 2019, we paid approximately $0.6 million. For the six months ended June 30, 2020, we paid approximately $0.1 million and made adjustments to the accrual based on our future anticipated expenditures.  As of June 30, 2020, our outstanding reserve is $0.4 million. The ultimate loss associated with this environmental contingency is subject to the investigation and ongoing review of the CETESB. We will continue to evaluate the range of likely costs as the investigation proceeds and we have further clarity on the nature and extent of remediation that will be required. We note that the contamination, or any failure to complete any required remediation in a timely manner, could potentially result in fines or penalties.

In March 2017, the Supreme Court of Brazil issued a decision that a certain state value added tax should not be included in the calculation of federal gross receipts taxes. The decision reduces our gross receipts tax in Brazil prospectively and, potentially, retrospectively. During the first quarter of 2019, we received a favorable court decision of $2.7 million for the retrospective right to recover part of our claim. This amount is recorded in cost of sales as a favorable impact of $1.7 million and $1.0 million was recognized as interest income. In June 2020, we received a favorable court decision of $0.7 million for the retrospective right to recover part of our claim. This amount is recorded in cost of sales as a favorable impact of $0.7 million. If the Judicial Court grants full retrospective recovery, we estimate remaining potential recoveries of approximately $1.5 million to $7.5 million, including interest, depending on the future decisions of the Supreme Court of Brazil. Due to uncertainties around our remaining court recovery claims, we have not recorded any further amounts relating to the retrospective nature of this matter.

In December 2019, tax authorities in Brazil notified us of a tax assessment of approximately $6.1 million, including interest and penalties of $2.3 million and $0.8 million, respectively, relating to differences in tax classification codes used for import duties for the period from January 2015 to August 2018. We are vigorously contesting the assessment, including interest and penalties, and have filed an administrative defense appeal in December 2019. On June 4, 2020, an unfavorable decision was issued on the first administrative defense appeal. We are awaiting the formal notification in order to review its content and file our second appeal. We still believe we have a strong defense. Due to uncertainty in the amount of assessment and the timing of our appeal, no liability is recorded as of June 30, 2020.

XML

STOCK REPURCHASE PROGRAM

6 Months Ended

Jun. 30, 2020

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM

NOTE 13 – STOCK REPURCHASE PROGRAM

On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

During the three and six months ended June 30, 2020, we did not repurchase any shares. During the three and six months ended June 30, 2019, we repurchased approximately 34 thousand shares and 193 thousand shares for approximately $4.1 million and $19.1 million, respectively. As of June 30, 2020, there was $278.5 million of authorized share repurchases available to us.

XML

STOCK-BASED COMPENSATION

6 Months Ended

Jun. 30, 2020

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

NOTE 14 – STOCK-BASED COMPENSATION

We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. Performance-based RSUs have one of two vesting conditions: (1) based on our internal financial performance metrics and (2) based on our total shareholder return (“TSR”) relative to total shareholder returns of an industrial peer group. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest over one year.

The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.

Six Months Ended June 30,		2020			2019
Fair value per stock award	$	94.98		$	134.97
Grant date stock price	$	83.93		$	104.51
Assumptions:
Aptar's stock price expected volatility		23.80	%		16.50	%
Expected average volatility of peer companies		48.50	%		31.90	%
Correlation assumption		63.50	%		37.40	%
Risk-free interest rate		0.31	%		2.19	%
Dividend yield assumption		1.72	%		1.30	%

A summary of RSU activity as of June 30, 2020 and changes during the six month period then ended is presented below:

	Time-Based RSUs			Performance-Based RSUs
		Weighted Average			Weighted Average
	Units	Grant-Date Fair Value		Units	Grant-Date Fair Value
Nonvested at January 1, 2020	480,729	$	95.45	181,680	$	117.26
Granted	229,033		85.57	417,313		93.08
Vested	(125,020)		85.55	—		—
Forfeited	(5,692)		99.08	(6,714)		108.10
Nonvested at June 30, 2020	579,050	$	92.14	592,279	$	100.29

Included in the June 30, 2020 time-based RSUs are 12,379 units granted to non-employee directors and 11,490 units vested related to non-employee directors.

Compensation expense recorded attributable to RSUs for the first six months of 2020 and 2019 was approximately $16.3 million and $9.8 million, respectively. The actual tax benefit realized for the tax deduction from RSUs was approximately $3.0 million in the six months ended June 30, 2020. The fair value of units vested during the six months ended June 30, 2020 and 2019 was $10.7 million and $4.1 million, respectively. The intrinsic value of units vested during the six months ended June 30, 2020 and 2019 was $12.8 million and $4.8 million, respectively. As of June 30, 2020, there was $58.8 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 2.2 years.

Historically we issued stock options to our employees and non-employee directors. Beginning in 2019, we no longer issue stock options. Stock options were awarded with the exercise price equal to the market price on the date of grant and generally vest over three years and expire 10 years after grant. Compensation expense attributable to employee stock options for the first six months of 2020 was approximately $1.3 million ($1.0 million after tax). Approximately $1.1 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. Compensation expense attributable to stock options for the first six months of 2019 was approximately $3.2 million ($2.7 million after tax). Approximately $2.7 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. The reduction in stock option expense is due to our move to RSUs as discussed above. For stock option grants, we used historical data to estimate expected life and volatility.

A summary of option activity under our stock plans during the six months ended June 30, 2020 is presented below:

	Stock Awards Plans					Director Stock Option Plans
			Weighted Average				Weighted Average
		Options	Exercise Price			Options	Exercise Price
Outstanding, January 1, 2020		5,044,180	$	68.32		135,251	$	58.45
Granted		—		—		—		—
Exercised		(460,243)		58.21		(30,751)		51.22
Forfeited or expired		(14,200)		76.07		—		—
Outstanding at June 30, 2020		4,569,737	$	69.38		104,500	$	60.58
Exercisable at June 30, 2020		4,416,415	$	68.62		104,500	$	60.58
Weighted-Average Remaining Contractual Term (Years):
Outstanding at June 30, 2020		5.0				3.1
Exercisable at June 30, 2020		4.9				3.1
Aggregate Intrinsic Value:
Outstanding at June 30, 2020	$	194,684			$	4,902
Exercisable at June 30, 2020	$	190,936			$	4,902
Intrinsic Value of Options Exercised During the Six Months Ended:
June 30, 2020	$	26,027			$	1,973
June 30, 2019	$	65,944			$	722

The grant date fair value of options vested during the six months ended June 30, 2020 and 2019 was $7.6 million and $12.2 million, respectively. Cash received from option exercises was approximately $30.1 million and the actual tax benefit realized for the tax deduction from option exercises was approximately $6.4 million in the six months ended June 30, 2020. As of June 30, 2020, the remaining valuation of stock option awards to be expensed in future periods was $1.0 million and the related weighted-average period over which it is expected to be recognized is 0.7 years.

XML

EARNINGS PER SHARE

6 Months Ended

Jun. 30, 2020

EARNINGS PER SHARE

EARNINGS PER SHARE

NOTE 15 – EARNINGS PER SHARE

Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and six months ended June 30, 2020 and 2019 is as follows:

	Three Months Ended
	June 30, 2020				June 30, 2019
	Diluted		Basic		Diluted		Basic
Consolidated operations
Income available to common stockholders	$	41,839	$	41,839	$	73,915	$	73,915
Average equivalent shares
Shares of common stock		64,262		64,262		63,471		63,471
Effect of dilutive stock-based compensation
Stock options		1,661		—		2,533		—
Restricted stock		461		—		228		—
Total average equivalent shares		66,384		64,262		66,232		63,471
Net income per share	$	0.63	$	0.65	$	1.12	$	1.16

	Six Months Ended
	June 30, 2020				June 30, 2019
	Diluted		Basic		Diluted		Basic
Consolidated operations
Income available to common stockholders	$	97,092	$	97,092	$	136,919	$	136,919
Average equivalent shares
Shares of common stock		64,135		64,135		63,219		63,219
Effect of dilutive stock-based compensation
Stock options		1,734		—		2,411		—
Restricted stock		377		—		212		—
Total average equivalent shares		66,246		64,135		65,842		63,219
Net income per share	$	1.47	$	1.51	$	2.08	$	2.17

XML

SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2020

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE 16 – SEGMENT INFORMATION

We are organized into three reporting segments. Our Beauty + Home segment sells to the personal care, beauty and home care markets. Our Pharma segment serves customers in the prescription drug, consumer health care, injectables and active packaging markets. Our Food + Beverage segment sells to the food and beverage markets.

The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2019. We evaluate performance of our business units and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. All internal segment reporting and discussions of results with our Chief Operating Decision Maker (CODM) are based on segment Adjusted EBITDA.

Financial information regarding our reporting segments is shown below:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Total Sales:
Beauty + Home	$	306,469	$	349,253	$	636,935	$	722,756
Pharma		303,885		284,577		603,475		559,071
Food + Beverage		99,023		119,095		199,324		223,822
Total Sales		709,377		752,925	$	1,439,734	$	1,505,649
Less: Intersegment Sales:
Beauty + Home	$	6,683	$	7,173	$	12,589	$	13,017
Pharma		2,626		2,638		5,020		4,431
Food + Beverage		763		453		1,267		1,080
Total Intersegment Sales	$	10,072	$	10,264	$	18,876	$	18,528
Net Sales:
Beauty + Home	$	299,786	$	342,080	$	624,346	$	709,739
Pharma		301,259		281,939		598,455		554,640
Food + Beverage		98,260		118,642		198,057		222,742
Net Sales	$	699,305	$	742,661	$	1,420,858	$	1,487,121
Adjusted EBITDA (1):
Beauty + Home	$	23,974	$	48,745	$	58,221	$	101,936
Pharma		104,099		101,428		212,441		198,785
Food + Beverage		17,785		20,944		33,192		37,635
Corporate & Other, unallocated		(9,279)		(10,630)		(23,107)		(23,385)
Acquisition-related costs (2)		(3,592)		(1,059)		(5,866)		(1,059)
Restructuring Initiatives (3)		(7,331)		(1,737)		(12,170)		(11,267)
Depreciation and amortization		(56,429)		(47,867)		(107,235)		(95,356)
Interest Expense		(8,734)		(8,756)		(17,122)		(17,970)
Interest Income		175		1,033		350		2,781
Income before Income Taxes	$	60,668	$	102,101	$	138,704	$	192,100

(1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs.

(2) Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 17 – Acquisitions and Note 18 – Investment in Equity Securities for further details).

(3) Restructuring Initiatives includes expense items for the three and six months ended June 30, 2020 and 2019 as follows (see Note 19 – Restructuring Initiatives for further details):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Restructuring Initiatives by Segment
Beauty + Home	$	7,324	$	1,259	$	12,231	$	9,528
Pharma		(111)		(113)		(142)		213
Food + Beverage		75		112		178		622
Corporate & Other		43		479		(97)		904
Total Restructuring Initiatives	$	7,331	$	1,737	$	12,170	$	11,267

XML

ACQUISITIONS

6 Months Ended

Jun. 30, 2020

ACQUISITIONS

ACQUISITIONS

NOTE 17 – ACQUISITIONS

Business Combinations

On April 1, 2020, we completed our acquisition (the “Fusion Acquisition”) of 100% of the equity interests of Fusion Packaging, Inc. (“Fusion”) for a purchase price of approximately $163.8 million (net of $1.0 million of cash acquired), which was funded by a draw on our revolving credit facility and cash on hand. Fusion, based in Dallas, TX, is a global leader in the design, engineering and distribution of luxury packaging for the beauty industry. As part of the Fusion Acquisition, we are also obligated to pay to the selling equity holders of Fusion certain contingent consideration based on 2022 cumulative financial performance metrics as defined in the purchase agreement. Based on a projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $19.1 million utilizing a Black-Scholes valuation model. As of June 30, 2020, $5.7 million was held in restricted cash pending the finalization of a working capital adjustment and indemnity escrow. Subsequent to the end of the quarter, $2.0 million of working capital escrow was released from restriction. Fusion contributed net sales of $13.8 million and pretax loss of $3.3 million for the quarter ended June 30, 2020 which have been included in the Condensed Consolidated Financial Statements within our Beauty + Home segment. Included in pretax loss is $2.7 million of fair value adjustment amortization for inventory sold during 2020. We are in the process of finalizing our purchase accounting.

On October 31, 2019, we completed our acquisition (the “Noble Acquisition”) of 100% of the equity interests of Noble International Holdings, Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as “Noble”). Noble, based in Orlando, FL, is a leading provider in developing patient-centric advanced drug delivery system training devices including autoinjector, prefilled syringe, onbody and respiratory devices for the world’s leading biopharmaceutical companies and original equipment manufacturers. The purchase price was approximately $62.3 million (net of $1.6 million of cash acquired) and was funded by cash on hand. As part of the Noble Acquisition, we are also obligated to pay to the selling equity holders of Noble certain contingent consideration based on 2024 cumulative financial performance metrics defined in the purchase agreement. Based on projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $2.9 million utilizing the Black-Scholes valuation model. As of December 31, 2019, $5 million was held in restricted cash pending the finalization of a working capital adjustment and indemnity escrow. During the first quarter of 2020, $1.0 million related to the working capital escrow was released from restriction, resulting in an additional $463 thousand payment due to the seller and a corresponding increase to our purchase price and associated goodwill balance. The results of Noble’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.

On June 5, 2019, we completed our acquisition (the “Nanopharm Acquisition”) of all of the outstanding capital stock of Nanopharm Ltd. (“Nanopharm”). Nanopharm, located in Newport, UK, is a science-driven, leading provider of orally inhaled and nasal drug product design and development services. The purchase price was approximately $38.1 million (net of $1.8 million of cash acquired) and was funded by cash on hand. The results of Nanopharm’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.

On May 31, 2019, we completed our acquisition (the “Gateway Acquisition”) of all of the outstanding equity interests of Gateway Analytical LLC (“Gateway”). Gateway, located in Gibsonia, PA, provides industry-leading particulate detection and predictive analytical services to customers developing injectable medicines. The purchase price was approximately $7.0 million and was funded by cash on hand. As part of the Gateway Acquisition, we are also obligated to pay to the selling equity holder of Gateway certain contingent consideration based on 2020 and 2022 performance targets defined in the purchase agreement. Based on projections as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $3.0 million. During the quarter ended June 30, 2020, $1.5 million of the contingent consideration accrual was paid as a result of the business meeting their first performance target. Additionally, the remaining $1.5 million accrual was reclassified from long-term to short-term liabilities as the payment is expected to be made within a year. The results of Gateway’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.

The following table summarizes the assets acquired and liabilities assumed as of the acquisition date at estimated fair value.

	2020		2019
Assets
Cash and equivalents	$	1,010	$	3,427
Accounts receivable		4,380		3,504
Inventories		386		—
Prepaid and other		1,090		2,478
Property, plant and equipment		2,885		4,267
Goodwill		99,644		59,143
Intangible assets		79,900		52,980
Operating lease right-of-use assets		4,744		—
Other miscellaneous assets		65		430
Liabilities
Accounts payable, accrued and other liabilities		5,641		5,388
Deferred income taxes		—		2,592
Operating lease liabilities		4,207		—
Deferred and other non-current liabilities		322		1,598
Net assets acquired	$	183,934	$	116,651

The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date:

	2020			2019
	Weighted-Average	Estimated		Weighted-Average	Estimated
	Useful Life	Fair Value		Useful Life	Fair Value
	(in years)	of Asset		(in years)	of Asset
Acquired technology	4	$	4,600	8	$	9,160
Customer relationships	13		62,300	11		39,379
Trademarks and trade names	4		10,300	4		2,457
License agreements and other	0.25		2,700	1		1,984
Total		$	79,900		$	52,980

Goodwill in the amount of $99.6 million was recorded related to the Fusion Acquisition which is included in the Beauty + Home segment and $59.1 million was recorded related to the 2019 acquisitions, all of which are included in the Pharma segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill largely consists of unique relationships, brand equity and proprietary technology that has been established creating niches such as turnkey solutions for the beauty market related to the Fusion Acquisition, analytical services for drug developers related to the Nanopharm Acquisition and Gateway Acquisition and patient onboarding related to the Noble Acquisition, as well as the abilities of the acquired companies to maintain their competitive advantage from a technical viewpoint. Goodwill will not be amortized, but will be tested for impairment at least annually. For the Fusion Acquisition, goodwill of $82.3 million will be deductible for tax purposes. For the 2019 acquisitions, goodwill of $31.1 million will be deductible for tax purposes.

The unaudited pro forma results presented below include the effects of the Fusion Acquisition as if it had occurred as of January 1, 2019. The unaudited pro forma results reflect certain adjustments related to the acquisition, such as intangible asset amortization, fair value adjustments for inventory and financing costs related to the change in our debt structure. The pro forma results do not include any synergies or other expected benefits of the acquisition. Accordingly, the unaudited pro forma financial information below is not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been completed on the date indicated.

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Sales	$	699,305	$	762,148	$	1,428,821	$	1,525,826
Net Income Attributable to AptarGroup Inc.		45,989		75,811		96,350		139,003
Net Income per common share — basic		0.72		1.19		1.50		2.20
Net Income per common share — diluted		0.69		1.14		1.45		2.11

Asset Acquisition

On August 2, 2019, we completed our asset acquisition (the “Bapco Acquisition”) of the remaining 80% ownership interest in the capital stock of Bapco Closures Holdings Limited (“Bapco”), for $3.8 million (net of $2.9 million of cash acquired). The 20% ownership investment previously held in Bapco is now included within the intangible assets acquired. Bapco, located in Leeds, UK, provides innovative closures sealing technology that provides package integrity and tamper evidence. The results of Bapco’s operations have been included in the Condensed Consolidated Financial Statements within our Food + Beverage segment since the date of acquisition.

XML

INVESTMENT IN EQUITY SECURITIES

6 Months Ended

Jun. 30, 2020

Equity Method and Other Investments [Abstract]

INVESTMENT IN EQUITY SECURITIES

NOTE 18 –INVESTMENT IN EQUITY SECURITIES

Our investment in equity securities consisted of the following:

	June 30,		December 31,
	2020		2019
Equity Method Investments:
BTY	$	30,894	$	119
Sonmol		4,969		—
Kali Care		3,691		3,881
Desotec GmbH		845		858
Other Investments		3,794		3,538
	$	44,193	$	8,396

Equity method investments

Sonmol

On April 1, 2020, we invested $5 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”), a pharmaceutical company that provides connected devices for asthma control.

BTY

On October 1, 2019, we entered into a strategic definitive agreement to acquire 49% of the equity interests in 3 related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”), contingent on the settlement date of the transaction. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years subsequent to the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. On January 1, 2020, the transaction closed for an approximate purchase price of $32 million for our 49% share. As of June 30, 2020, we paid approximately $28.8 million, with the remaining amount of $3.2 million included in Accounts payable, accrued and other liabilities. The amount is payable after certain conditions under the definitive agreement are fulfilled and is expected to be paid during the third quarter of 2020.

Kali Care

During 2017, we invested $5 million to acquire 20% of the equity interests in Kali Care, a technology company that provides digital monitoring systems for medical devices.

Desotec GmbH

During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and home and food and beverages markets.

Other investments

During August 2019, we invested an aggregate amount of $3.5 million in two preferred equity investments in sustainability companies Loop and Purecycle Technologies (“Purecycle”) that are accounted for at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.

There were no indications of impairment nor were there any changes from observable price changes noted in the six months ended June 30, 2020 related to these investments.

XML

RESTRUCTURING INITIATIVES

6 Months Ended

Jun. 30, 2020

RESTRUCTURING INITIATIVES.

RESTRUCTURING INITIATIVES

NOTE 19 – RESTRUCTURING INITIATIVES

In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. For the three and six months ended June 30, 2020, we recognized $7.3 million and $12.2 million of restructuring costs related to this plan, respectively. For the three and six months ended June 30, 2019, we recognized $1.7 million and $11.3 million of restructuring costs related to this plan, respectively. Using current exchange rates, we estimate total implementation costs of approximately $125 million for these initiatives, including costs that have been recognized to date. The cumulative expense incurred as of June 30, 2020 was $98.7 million. We also anticipate making capital investments related to the transformation plan of approximately $50 million, of which $43 million has been incurred to date.

As of June 30, 2020 we have recorded the following activity associated with the business transformation:

	Beginning		Net Charges for						Ending
	Reserve at		the Six Months				Interest and		Reserve at
	12/31/2019		Ended 6/30/2020		Cash Paid		FX Impact		6/30/2020
Employee severance	$	7,090	$	8,190	$	(2,324)	$	192	$	13,148
Professional fees and other costs		3,609		3,980		(4,595)		(17)		2,977
Totals	$	10,699	$	12,170	$	(6,919)	$	175	$	16,125

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.

In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.

Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. For the six months ended June 30, 2020, our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues.

There are many uncertainties regarding the current COVID-19 pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic and the extent of local and worldwide social, political and economic disruption it may cause. The pandemic has impacted our business, operations and financial results during the six months ended June 30, 2020 including an overall reduction to net sales. No impairments were recorded as of June 30, 2020. While the disruption is currently expected to be temporary, there is uncertainty around the duration. Due to significant uncertainty surrounding the situation, our judgment regarding future results could change and therefore our results could be materially impacted.

INCOME TAXES

INCOME TAXES

We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested.  Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and the global cash management goals of the Company.

We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition.

The Company is subject to taxation and files income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. The Company believes that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in the Company’s tax audits are resolved in a manner inconsistent with its expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.

ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS

ADOPTION OF RECENT ACCOUNTING STANDARDS

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.

Effective January 1, 2020, we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, issued by the FASB in June 2016, as well as the clarifying amendments subsequently issued. We applied the guidance using a modified retrospective approach and accordingly recognized an amount of $1.4 million as the cumulative adjustment to opening retained earnings in the first quarter of 2020. This is based on management's best estimates of specific losses on individual exposures particularly on current trade receivables, as well as the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. On an ongoing basis, we will contemplate forward-looking economic conditions in recording lifetime expected credit losses for our financial assets measured at cost, such as our trade receivables and certain other assets.

In January 2017, the FASB issued ASU 2017-04, which provides guidance to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As a result, impairment charges are required for the amount by which a reporting unit’s carrying amount exceeds its fair value up to the amount of its allocated goodwill. We adopted the standard on January 1, 2020 and did not record any impairment charges.

In August 2018, the FASB issued ASU 2018-15 to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted the standard on January 1, 2020 and no material impacts were noted.

In August 2018, the FASB issued ASU 2018-13, which amends disclosure requirements for fair value measurements. The new standard modifies disclosure requirements including removing requirements to disclose the valuation process for Level 3 measurements and adding requirements to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements and the range and weighted average of significant unobservable inputs used to develop Level 3 measurements. We adopted the standard on January 1, 2020 and no material impacts were noted.

Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.

XML

REVENUE (Tables)

6 Months Ended

Jun. 30, 2020

REVENUE.

Schedule of revenue by segment by geographic area

	For the Three Months Ended June 30, 2020
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	152,412	$	94,349	$	29,893	$	23,132	$	299,786
Pharma		201,813		81,098		6,987		11,361		301,259
Food + Beverage		27,841		54,478		6,489		9,452		98,260
Total	$	382,066	$	229,925	$	43,369	$	43,945	$	699,305

	For the Three Months Ended June 30, 2019
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	202,541	$	73,973	$	41,449	$	24,117	$	342,080
Pharma		190,654		76,042		7,078		8,165		281,939
Food + Beverage		32,336		65,160		9,211		11,935		118,642
Total	$	425,531	$	215,175	$	57,738	$	44,217	$	742,661

	For the Six Months Ended June 30, 2020
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	339,362	$	176,194	$	66,074	$	42,716	$	624,346
Pharma		391,943		172,063		13,566		20,883		598,455
Food + Beverage		56,610		112,068		14,523		14,856		198,057
Total	$	787,915	$	460,325	$	94,163	$	78,455	$	1,420,858

	For the Six Months Ended June 30, 2019
					Latin
Segment	Europe		Domestic		America		Asia		Total
Beauty + Home	$	418,774	$	160,952	$	84,091	$	45,922	$	709,739
Pharma		374,828		147,814		14,734		17,264		554,640
Food + Beverage		63,297		120,280		17,095		22,070		222,742
Total	$	856,899	$	429,046	$	115,920	$	85,256	$	1,487,121

Schedule of opening and closing balances of contract assets and contract liabilities

	Balance as of		Balance as of		Increase/
	December 31, 2019		June 30, 2020		(Decrease)
Contract asset (current)	$	16,245	$	15,113	$	(1,132)
Contract asset (long-term)	$	—	$	—	$	—
Contract liability (current)	$	79,305	$	70,708	$	(8,597)
Contract liability (long-term)	$	9,779	$	20,662	$	10,883

XML

INVENTORIES (Tables)

6 Months Ended

Jun. 30, 2020

INVENTORIES

Schedule of inventories, by component

	June 30,		December 31,
	2020		2019
Raw materials	$	112,287	$	111,653
Work in process		123,710		123,750
Finished goods		145,942		140,392
Total	$	381,939	$	375,795

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2020

GOODWILL AND OTHER INTANGIBLE ASSETS

Schedule of changes in the carrying amount of goodwill

	Beauty +				Food +		Corporate
	Home		Pharma		Beverage		& Other		Total
Goodwill	$	221,658	$	413,650	$	128,153	$	1,615	$	765,076
Accumulated impairment losses		—		—		—		(1,615)		(1,615)
Balance as of December 31, 2019	$	221,658	$	413,650	$	128,153	$	—	$	763,461
Acquisition		99,644		463		—		—		100,107
Foreign currency exchange effects		(473)		(1,175)		8		—		(1,640)
Goodwill	$	320,829	$	412,938	$	128,161	$	1,615	$	863,543
Accumulated impairment losses		—		—		—		(1,615)		(1,615)
Balance as of June 30, 2020	$	320,829	$	412,938	$	128,161	$	—	$	861,928

Summary of amortized intangible assets

		June 30, 2020							December 31, 2019
Weighted Average		Gross						Gross
Amortization Period		Carrying		Accumulated		Net		Carrying		Accumulated		Net
	(Years)	Amount		Amortization		Value		Amount		Amortization		Value
Amortized intangible assets:
Patents	7.1	$	2,703		(1,334)	$	1,369	$	2,804	$	(1,318)	$	1,486
Acquired technology	12.6		105,020		(29,907)		75,113		100,511		(25,430)		75,081
Customer relationships	13.5		279,709		(43,561)		236,148		217,934		(33,924)		184,010
Trademarks and trade names	6.0		44,508		(13,568)		30,940		35,015		(11,003)		24,012
License agreements and other	15.5		22,480		(13,310)		9,170		16,153		(9,658)		6,495
Total intangible assets	12.6	$	454,420	$	(101,680)	$	352,740	$	372,417	$	(81,333)	$	291,084

Schedule of future estimated amortization expense

Future estimated amortization expense for the years ending December 31 is as follows:

2020	$	19,192	(remaining estimated amortization for 2020)
2021		37,723
2022		37,443
2023		37,362
2024 and thereafter		221,020

XML

DEBT (Tables)

6 Months Ended

Jun. 30, 2020

DEBT

Schedule of short-term debt

	June 30,		December 31,
	2020		2019
Notes payable 8.00%	$	831	$	1,436
Revolving credit facility 1.28%		150,000		25,000
Overdrafts 5.68% - 7.82%		—		17,823
	$	150,831	$	44,259

Schedule of long-term obligations

At June 30, 2020, our long-term obligations consisted of the following:

			Unamortized
			Debt Issuance
	Principal		Costs		Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028	$	15,358	$	—	$	15,358
Senior unsecured notes 3.2%, due in 2022		75,000		52		74,948
Senior unsecured debts 2.4% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022		168,000		315		167,685
Senior unsecured notes 3.5%, due in 2023		125,000		126		124,874
Senior unsecured notes 1.0%, due in 2023		112,340		326		112,014
Senior unsecured notes 3.4%, due in 2024		50,000		56		49,944
Senior unsecured notes 3.5%, due in 2024		100,000		126		99,874
Senior unsecured notes 1.2%, due in 2024		224,680		661		224,019
Senior unsecured notes 3.6%, due in 2025		125,000		145		124,855
Senior unsecured notes 3.6%, due in 2026		125,000		145		124,855
Finance Lease Liabilities		30,564		—		30,564
	$	1,150,942	$	1,952	$	1,148,990
Current maturities of long-term obligations		(66,248)		—		(66,248)
Total long-term obligations	$	1,084,694	$	1,952	$	1,082,742

At December 31, 2019, our long-term obligations consisted of the following:

			Unamortized
			Debt Issuance
	Principal		Costs		Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028	$	19,220	$	—	$	19,220
Senior unsecured notes 3.2%, due in 2022		75,000		64		74,936
Senior unsecured debts 3.2% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022		168,000		390		167,610
Senior unsecured notes 3.5%, due in 2023		125,000		144		124,856
Senior unsecured notes 1.0%, due in 2023		112,170		356		111,814
Senior unsecured notes 3.4%, due in 2024		50,000		63		49,937
Senior unsecured notes 3.5%, due in 2024		100,000		144		99,856
Senior unsecured notes 1.2%, due in 2024		224,340		742		223,598
Senior unsecured notes 3.6%, due in 2025		125,000		169		124,831
Senior unsecured notes 3.6%, due in 2026		125,000		169		124,831
Finance Lease Liabilities		29,952		—		29,952
	$	1,153,682	$	2,241	$	1,151,441
Current maturities of long-term obligations		(65,988)		—		(65,988)
Total long-term obligations	$	1,087,694	$	2,241	$	1,085,453

Schedule of covenants on revolving credit facility and corporate long-term obligations

	Requirement	Level at June 30, 2020
Consolidated Leverage Ratio (1)	Maximum of 3.50 to 1.00	1.98 to 1.00
Consolidated Interest Coverage Ratio (1)	Minimum of 3.00 to 1.00	15.50 to 1.00

(1) Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.  

XML

LEASE COMMITMENTS (Tables)

6 Months Ended

Jun. 30, 2020

LEASE COMMITMENTS

Schedule of components of lease expense

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Operating lease cost	$	5,841	$	5,437	$	11,095	$	11,441
Finance lease cost:
Amortization of right-of-use assets	$	906	$	1,004	$	2,105	$	1,876
Interest on lease liabilities		369		325		717		640
Total finance lease cost	$	1,275	$	1,329	$	2,822	$	2,516
Short-term lease and variable lease costs	$	2,430	$	2,328	$	4,878	$	4,270

Schedule of supplemental cash flow information related to leases

Six Months Ended June 30,	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	11,662	$	10,249
Operating cash flows from finance leases		704		534
Financing cash flows from finance leases		2,545		2,294
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	11,371	$	9,512
Finance leases		3,127		11,622

XML

RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)

6 Months Ended

Jun. 30, 2020

RETIREMENT AND DEFERRED COMPENSATION PLANS

Components of net periodic benefit cost

	Domestic Plans				Foreign Plans
Three Months Ended June 30,	2020		2019		2020		2019
Service cost	$	3,562	$	2,775	$	1,767	$	1,445
Interest cost		1,536		1,846		340		495
Expected return on plan assets		(2,702)		(3,095)		(631)		(586)
Amortization of net loss		1,294		489		514		359
Amortization of prior service cost		—		—		95		113
Net periodic benefit cost	$	3,690	$	2,015	$	2,085	$	1,826

	Domestic Plans				Foreign Plans
Six Months Ended June 30,	2020		2019		2020		2019
Service cost	$	7,139	$	5,548	$	3,535	$	2,905
Interest cost		3,523		3,691		680		996
Expected return on plan assets		(6,124)		(6,189)		(1,265)		(1,178)
Amortization of net loss		2,842		978		1,028		722
Amortization of prior service cost		—		—		192		226
Net periodic benefit cost	$	7,380	$	4,028	$	4,170	$	3,671

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)

6 Months Ended

Jun. 30, 2020

ACCUMULATED OTHER COMPREHENSIVE INCOME

Changes in Accumulated Other Comprehensive Income/(Loss) by Component

	Foreign		Defined Benefit
	Currency		Pension Plans		Derivatives		Total
Balance - December 31, 2018	$	(248,401)	$	(60,463)	$	(1,640)	$	(310,504)
Other comprehensive (loss) income before reclassifications		(197)		—		3,727		3,530
Amounts reclassified from accumulated other comprehensive income (loss)		—		1,437		(4,599)		(3,162)
Net current-period other comprehensive (loss) income		(197)		1,437		(872)		368
Balance - June 30, 2019	$	(248,598)	$	(59,026)	$	(2,512)	$	(310,136)
Balance - December 31, 2019	$	(257,124)	$	(83,147)	$	(1,677)	$	(341,948)
Other comprehensive (loss) income before reclassifications		(23,134)		—		1,758		(21,376)
Amounts reclassified from accumulated other comprehensive income (loss)		—		3,076		(1,008)		2,068
Net current-period other comprehensive (loss) income		(23,134)		3,076		750		(19,308)
Balance - June 30, 2020	$	(280,258)	$	(80,071)	$	(927)	$	(361,256)

Reclassifications Out of Accumulated Other Comprehensive (Loss) Income

Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:

	Amount Reclassified from
Details about Accumulated Other	Accumulated Other				Affected Line in the Statement
Comprehensive Income Components	Comprehensive Income				Where Net Income is Presented
Three Months Ended June 30,	2020		2019
Defined Benefit Pension Plans
Amortization of net loss	$	1,808	$	848	(1)
Amortization of prior service cost		95		113	(1)
		1,903		961	Total before tax
		(463)		(245)	Tax benefit
	$	1,440	$	716	Net of tax
Derivatives
Changes in cross currency swap: interest component	$	(525)	$	(1,552)	Interest Expense
Changes in cross currency swap: foreign exchange component		3,060		3,084	Miscellaneous, net
	$	2,535	$	1,532	Net of tax
Total reclassifications for the period	$	3,975	$	2,248

	Amount Reclassified from
Details about Accumulated Other	Accumulated Other				Affected Line in the Statement
Comprehensive Income Components	Comprehensive Income				Where Net Income is Presented
Six Months Ended June 30,	2020		2019
Defined Benefit Pension Plans
Amortization of net loss	$	3,870	$	1,700	(1)
Amortization of prior service cost		192		226	(1)
		4,062		1,926	Total before tax
		(986)		(489)	Tax benefit
	$	3,076	$	1,437	Net of tax
Derivatives
Changes in cross currency swap: interest component	$	(1,288)	$	(3,006)	Interest Expense
Changes in cross currency swap: foreign exchange component		280		(1,593)	Miscellaneous, net
	$	(1,008)	$	(4,599)	Net of tax
Total reclassifications for the period	$	2,068	$	(3,162)

(1) These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)

6 Months Ended

Jun. 30, 2020

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

Schedule of Fair Value of Derivative Instruments in the Consolidated Balance Sheets

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019

		June 30, 2020				December 31, 2019
				Derivatives				Derivatives
		Derivatives		not		Derivatives		not
		Designated		Designated		Designated		Designated
	Balance Sheet	as Hedging		as Hedging		as Hedging		as Hedging
	Location	Instruments		Instruments		Instruments		Instruments
Derivative Assets
Foreign Exchange Contracts	Prepaid and other	$	—	$	747	$	—	$	206
Cross Currency Swap Contract (1)	Prepaid and other		3,052		—		2,552		—
		$	3,052	$	747	$	2,552	$	206
Derivative Liabilities
Foreign Exchange Contracts	Accounts payable, accrued and other liabilities	$	—	$	137	$	—	$	401
		$	—	$	137	$	—	$	401

(1) This cross currency swap contract is composed of both an interest component and a foreign exchange component.

Schedule of Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended June 30, 2020 and 2019

						Amount of Gain (Loss)				Total Amount
	Amount of Gain (Loss)				Location of (Loss)	Reclassified from				of Affected
Derivatives in Cash	Recognized in				Gain Recognized	Accumulated				Income
Flow Hedging	Other Comprehensive				in Income on	Other Comprehensive				Statement
Relationships	Income on Derivative				Derivatives	Income on Derivative				Line Item
	2020		2019			2020		2019
Cross currency swap contract:
Interest component	$	(208)	$	1,080	Interest expense	$	525	$	1,552	$	(8,734)
Foreign exchange component		(3,060)		(3,084)	Miscellaneous, net		(3,060)		(3,084)		(923)
	$	(3,268)	$	(2,004)		$	(2,535)	$	(1,532)

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Six Months Ended June 30, 2020 and 2019

						Amount of Gain (Loss)				Total Amount
	Amount of Gain (Loss)				Location of (Loss)	Reclassified from				of Affected
Derivatives in Cash	Recognized in				Gain Recognized	Accumulated				Income
Flow Hedging	Other Comprehensive				in Income on	Other Comprehensive				Statement
Relationships	Income on Derivative				Derivatives	Income on Derivative				Line Item
	2020		2019			2020		2019
Cross currency swap contract:
Interest component	$	2,038	$	2,472	Interest expense	$	1,288	$	3,006	$	(17,122)
Foreign exchange component		(280)		1,593	Miscellaneous, net		(280)		1,593		(2,335)
	$	1,758	$	4,065		$	1,008	$	4,599

Schedule of Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2020 and 2019

		Amount of (Loss) Gain
Derivatives Not Designated	Location of (Loss) Gain Recognized	Recognized in Income
as Hedging Instruments	in Income on Derivatives	on Derivatives
		2020		2019
Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	(940)	$	(251)
		$	(940)	$	(251)

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2020 and 2019

		Amount of (Loss) Gain
Derivatives Not Designated	Location of (Loss) Gain Recognized	Recognized in Income
as Hedging Instruments	in Income on Derivatives	on Derivatives
		2020		2019
Foreign Exchange Contracts	Other (Expense) Income: Miscellaneous, net	$	807	$	(514)
		$	807	$	(514)

Schedule of offsetting derivative assets and liabilities

						Gross Amounts not Offset
			Gross Amounts	Net Amounts		in the Statement of
			Offset in the	Presented in		Financial Position
	Gross		Statement of	the Statement of		Financial	Cash Collateral	Net
	Amount		Financial Position	Financial Position		Instruments	Received	Amount
Description
June 30, 2020
Derivative Assets	$	3,799	—	$	3,799	—	—	$	3,799
Total Assets	$	3,799	—	$	3,799	—	—	$	3,799
Derivative Liabilities	$	137	—	$	137	—	—	$	137
Total Liabilities	$	137	—	$	137	—	—	$	137
December 31, 2019
Derivative Assets	$	2,758	—	$	2,758	—	—	$	2,758
Total Assets	$	2,758	—	$	2,758	—	—	$	2,758
Derivative Liabilities	$	401	—	$	401	—	—	$	401
Total Liabilities	$	401	—	$	401	—	—	$	401

XML

FAIR VALUE (Tables)

6 Months Ended

Jun. 30, 2020

FAIR VALUE

Schedule of fair values of financial assets and liabilities

As of June 30, 2020, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
Assets
Foreign exchange contracts (1)	$	747	$	—	$	747	$	—
Cross currency swap contract (1)		3,052		—		3,052		—
Total assets at fair value	$	3,799	$	—	$	3,799	$	—
Liabilities
Foreign exchange contracts (1)	$	137	$	—	$	137	$	—
Contingent consideration obligation		24,710		—		—		24,710
Total liabilities at fair value	$	24,847	$	—	$	137	$	24,710

As of December 31, 2019, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
Assets
Foreign exchange contracts (1)	$	206	$	—	$	206	$	—
Cross currency swap contract (1)		2,552		—		2,552		—
Total assets at fair value	$	2,758	$	—	$	2,758	$	—
Liabilities
Foreign exchange contracts (1)	$	401	$	—	$	401	$	—
Contingent consideration obligation		5,930		—		—		5,930
Total liabilities at fair value	$	6,331	$	—	$	401	$	5,930

(1) Market approach valuation technique based on observable market transactions of spot and forward rates.

XML

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2020

STOCK-BASED COMPENSATION

Summary of option activity

	Stock Awards Plans					Director Stock Option Plans
			Weighted Average				Weighted Average
		Options	Exercise Price			Options	Exercise Price
Outstanding, January 1, 2020		5,044,180	$	68.32		135,251	$	58.45
Granted		—		—		—		—
Exercised		(460,243)		58.21		(30,751)		51.22
Forfeited or expired		(14,200)		76.07		—		—
Outstanding at June 30, 2020		4,569,737	$	69.38		104,500	$	60.58
Exercisable at June 30, 2020		4,416,415	$	68.62		104,500	$	60.58
Weighted-Average Remaining Contractual Term (Years):
Outstanding at June 30, 2020		5.0				3.1
Exercisable at June 30, 2020		4.9				3.1
Aggregate Intrinsic Value:
Outstanding at June 30, 2020	$	194,684			$	4,902
Exercisable at June 30, 2020	$	190,936			$	4,902
Intrinsic Value of Options Exercised During the Six Months Ended:
June 30, 2020	$	26,027			$	1,973
June 30, 2019	$	65,944			$	722

Weighted-average assumptions used to estimate fair value of restricted stock units

Six Months Ended June 30,		2020			2019
Fair value per stock award	$	94.98		$	134.97
Grant date stock price	$	83.93		$	104.51
Assumptions:
Aptar's stock price expected volatility		23.80	%		16.50	%
Expected average volatility of peer companies		48.50	%		31.90	%
Correlation assumption		63.50	%		37.40	%
Risk-free interest rate		0.31	%		2.19	%
Dividend yield assumption		1.72	%		1.30	%

Summary of restricted stock unit activity

	Time-Based RSUs			Performance-Based RSUs
		Weighted Average			Weighted Average
	Units	Grant-Date Fair Value		Units	Grant-Date Fair Value
Nonvested at January 1, 2020	480,729	$	95.45	181,680	$	117.26
Granted	229,033		85.57	417,313		93.08
Vested	(125,020)		85.55	—		—
Forfeited	(5,692)		99.08	(6,714)		108.10
Nonvested at June 30, 2020	579,050	$	92.14	592,279	$	100.29

XML

EARNINGS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2020

EARNINGS PER SHARE

Reconciliation of Basic and Diluted Earnings Per Share

	Three Months Ended
	June 30, 2020				June 30, 2019
	Diluted		Basic		Diluted		Basic
Consolidated operations
Income available to common stockholders	$	41,839	$	41,839	$	73,915	$	73,915
Average equivalent shares
Shares of common stock		64,262		64,262		63,471		63,471
Effect of dilutive stock-based compensation
Stock options		1,661		—		2,533		—
Restricted stock		461		—		228		—
Total average equivalent shares		66,384		64,262		66,232		63,471
Net income per share	$	0.63	$	0.65	$	1.12	$	1.16

	Six Months Ended
	June 30, 2020				June 30, 2019
	Diluted		Basic		Diluted		Basic
Consolidated operations
Income available to common stockholders	$	97,092	$	97,092	$	136,919	$	136,919
Average equivalent shares
Shares of common stock		64,135		64,135		63,219		63,219
Effect of dilutive stock-based compensation
Stock options		1,734		—		2,411		—
Restricted stock		377		—		212		—
Total average equivalent shares		66,246		64,135		65,842		63,219
Net income per share	$	1.47	$	1.51	$	2.08	$	2.17

XML

SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2020

SEGMENT INFORMATION

Financial information regarding the Company's reportable segments

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Total Sales:
Beauty + Home	$	306,469	$	349,253	$	636,935	$	722,756
Pharma		303,885		284,577		603,475		559,071
Food + Beverage		99,023		119,095		199,324		223,822
Total Sales		709,377		752,925	$	1,439,734	$	1,505,649
Less: Intersegment Sales:
Beauty + Home	$	6,683	$	7,173	$	12,589	$	13,017
Pharma		2,626		2,638		5,020		4,431
Food + Beverage		763		453		1,267		1,080
Total Intersegment Sales	$	10,072	$	10,264	$	18,876	$	18,528
Net Sales:
Beauty + Home	$	299,786	$	342,080	$	624,346	$	709,739
Pharma		301,259		281,939		598,455		554,640
Food + Beverage		98,260		118,642		198,057		222,742
Net Sales	$	699,305	$	742,661	$	1,420,858	$	1,487,121
Adjusted EBITDA (1):
Beauty + Home	$	23,974	$	48,745	$	58,221	$	101,936
Pharma		104,099		101,428		212,441		198,785
Food + Beverage		17,785		20,944		33,192		37,635
Corporate & Other, unallocated		(9,279)		(10,630)		(23,107)		(23,385)
Acquisition-related costs (2)		(3,592)		(1,059)		(5,866)		(1,059)
Restructuring Initiatives (3)		(7,331)		(1,737)		(12,170)		(11,267)
Depreciation and amortization		(56,429)		(47,867)		(107,235)		(95,356)
Interest Expense		(8,734)		(8,756)		(17,122)		(17,970)
Interest Income		175		1,033		350		2,781
Income before Income Taxes	$	60,668	$	102,101	$	138,704	$	192,100

(1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs.

(2) Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 17 – Acquisitions and Note 18 – Investment in Equity Securities for further details).

(3) Restructuring Initiatives includes expense items for the three and six months ended June 30, 2020 and 2019 as follows (see Note 19 – Restructuring Initiatives for further details):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Restructuring Initiatives by Segment
Beauty + Home	$	7,324	$	1,259	$	12,231	$	9,528
Pharma		(111)		(113)		(142)		213
Food + Beverage		75		112		178		622
Corporate & Other		43		479		(97)		904
Total Restructuring Initiatives	$	7,331	$	1,737	$	12,170	$	11,267

Restructuring Initiatives

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Restructuring Initiatives by Segment
Beauty + Home	$	7,324	$	1,259	$	12,231	$	9,528
Pharma		(111)		(113)		(142)		213
Food + Beverage		75		112		178		622
Corporate & Other		43		479		(97)		904
Total Restructuring Initiatives	$	7,331	$	1,737	$	12,170	$	11,267

XML

ACQUISITIONS (Tables)

6 Months Ended

Jun. 30, 2020

ACQUISITIONS

Summary of assets acquired and liabilities assumed at estimated fair value

	2020		2019
Assets
Cash and equivalents	$	1,010	$	3,427
Accounts receivable		4,380		3,504
Inventories		386		—
Prepaid and other		1,090		2,478
Property, plant and equipment		2,885		4,267
Goodwill		99,644		59,143
Intangible assets		79,900		52,980
Operating lease right-of-use assets		4,744		—
Other miscellaneous assets		65		430
Liabilities
Accounts payable, accrued and other liabilities		5,641		5,388
Deferred income taxes		—		2,592
Operating lease liabilities		4,207		—
Deferred and other non-current liabilities		322		1,598
Net assets acquired	$	183,934	$	116,651

Summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date

	2020			2019
	Weighted-Average	Estimated		Weighted-Average	Estimated
	Useful Life	Fair Value		Useful Life	Fair Value
	(in years)	of Asset		(in years)	of Asset
Acquired technology	4	$	4,600	8	$	9,160
Customer relationships	13		62,300	11		39,379
Trademarks and trade names	4		10,300	4		2,457
License agreements and other	0.25		2,700	1		1,984
Total		$	79,900		$	52,980

Schedule of unaudited pro forma financial information

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Net Sales	$	699,305	$	762,148	$	1,428,821	$	1,525,826
Net Income Attributable to AptarGroup Inc.		45,989		75,811		96,350		139,003
Net Income per common share — basic		0.72		1.19		1.50		2.20
Net Income per common share — diluted		0.69		1.14		1.45		2.11

XML

INVESTMENT IN EQUITY SECURITIES (Tables)

6 Months Ended

Jun. 30, 2020

Equity Method and Other Investments [Abstract]

Schedule of investments in equity securities

	June 30,		December 31,
	2020		2019
Equity Method Investments:
BTY	$	30,894	$	119
Sonmol		4,969		—
Kali Care		3,691		3,881
Desotec GmbH		845		858
Other Investments		3,794		3,538
	$	44,193	$	8,396

XML

RESTRUCTURING INITIATIVES (Tables)

6 Months Ended

Jun. 30, 2020

RESTRUCTURING INITIATIVES.

Activity associated with the entity's restructuring initiatives

	Beginning		Net Charges for						Ending
	Reserve at		the Six Months				Interest and		Reserve at
	12/31/2019		Ended 6/30/2020		Cash Paid		FX Impact		6/30/2020
Employee severance	$	7,090	$	8,190	$	(2,324)	$	192	$	13,148
Professional fees and other costs		3,609		3,980		(4,595)		(17)		2,977
Totals	$	10,699	$	12,170	$	(6,919)	$	175	$	16,125

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) - Argentina - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Foreign currency, gain recognized	$ 1.0
Maximum | Consolidated net revenues | Geographic concentration risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage		2.00%

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020 USD ($) $ / shares	Jun. 30, 2019 USD ($) shares	Jun. 30, 2020 USD ($) segment $ / shares	Jun. 30, 2019 USD ($) shares	Jan. 01, 2020 USD ($)	Dec. 31, 2019 USD ($) $ / shares
Number of reportable segments | segment			3
Total Restructuring Initiatives	$ 7,331	$ 1,737	$ 12,170	$ 11,267
INVESTMENTS IN EQUITY SECURITIES
Proceeds from sale of investment in equity securities				$ 16,487
Investment in unconsolidated affiliate			34,044
GOODWILL
Impairment of goodwill			$ 0
RETIREMENT OF COMMON STOCK
Common stock repurchased (retired and held in treasury) (in shares) | shares		34		193
Common stock, par value (in dollars per share) | $ / shares	$ 0.01		$ 0.01			$ 0.01
ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS
Retained earnings	$ 1,573,392		$ 1,573,392			$ 1,523,820
Adjustment | Accounting Standards Update 2016-13
ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS
Retained earnings					$ (1,400)
Beauty + Home
Total Restructuring Initiatives	7,324	$ 1,259	12,231	$ 9,528
Pharma
Total Restructuring Initiatives	(111)	(113)	(142)	213
Food + Beverage
Total Restructuring Initiatives	75	112	178	622
Corporate & Other
Total Restructuring Initiatives	43	479	(97)	904
Business Transformation
Total Restructuring Initiatives	$ 7,300	$ 1,700	$ 12,200	$ 11,300

XML

REVENUE - Revenue by Geographic Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
REVENUE
Net revenue	$ 699,305	$ 742,661	$ 1,420,858	$ 1,487,121
Beauty + Home
REVENUE
Net revenue	299,786	342,080	624,346	709,739
Pharma
REVENUE
Net revenue	301,259	281,939	598,455	554,640
Food + Beverage
REVENUE
Net revenue	98,260	118,642	198,057	222,742
Europe
REVENUE
Net revenue	382,066	425,531	787,915	856,899
Europe | Beauty + Home
REVENUE
Net revenue	152,412	202,541	339,362	418,774
Europe | Pharma
REVENUE
Net revenue	201,813	190,654	391,943	374,828
Europe | Food + Beverage
REVENUE
Net revenue	27,841	32,336	56,610	63,297
North America
REVENUE
Net revenue	229,925	215,175	460,325	429,046
North America | Beauty + Home
REVENUE
Net revenue	94,349	73,973	176,194	160,952
North America | Pharma
REVENUE
Net revenue	81,098	76,042	172,063	147,814
North America | Food + Beverage
REVENUE
Net revenue	54,478	65,160	112,068	120,280
Latin America
REVENUE
Net revenue	43,369	57,738	94,163	115,920
Latin America | Beauty + Home
REVENUE
Net revenue	29,893	41,449	66,074	84,091
Latin America | Pharma
REVENUE
Net revenue	6,987	7,078	13,566	14,734
Latin America | Food + Beverage
REVENUE
Net revenue	6,489	9,211	14,523	17,095
Asia
REVENUE
Net revenue	43,945	44,217	78,455	85,256
Asia | Beauty + Home
REVENUE
Net revenue	23,132	24,117	42,716	45,922
Asia | Pharma
REVENUE
Net revenue	11,361	8,165	20,883	17,264
Asia | Food + Beverage
REVENUE
Net revenue	$ 9,452	$ 11,935	$ 14,856	$ 22,070

XML

REVENUE - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
REVENUE.
Contract asset (current)	$ 15,113	$ 16,245
Increase / (decrease) in contract asset (current)	(1,132)
Contract liability (current)	70,708	79,305
Increase / (decrease) in contract liability (current)	(8,597)
Contract liability (long-term)	20,662	9,779
Increase / (decrease) in contract liability (long-term)	10,883
Revenue recognized previously included in current contract liabilities	27,300
Revenue recognized previously included in current contract liabilities at beginning of the year	21,600
Unearned revenue associated with outstanding contracts	410	515
Estimated revenue to be recognized in 2020	111
Estimated revenue to be recognized in 2021	125
Estimated revenue to be recognized after 2021	174
Allowance for Credit Loss [Abstract]
Accounts and note receivable	575,655	558,428
Accounts and notes receivable, allowance for doubtful accounts (in dollars)	$ 6,080	$ 3,626

XML

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventories, by component
Raw materials	$ 112,287	$ 111,653
Work in process	123,710	123,750
Finished goods	145,942	140,392
Total	$ 381,939	$ 375,795

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Goodwill) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Changes in the carrying amount of goodwill
Goodwill	$ 863,543	$ 765,076
Accumulated impairment losses	(1,615)	(1,615)
Goodwill, Total	861,928	763,461
Acquisition	100,107
Foreign currency exchange effects	(1,640)
Impairment of goodwill	0
Operating segment | Beauty + Home
Changes in the carrying amount of goodwill
Goodwill	320,829	221,658
Goodwill, Total	320,829	221,658
Acquisition	99,644
Foreign currency exchange effects	(473)
Operating segment | Pharma
Changes in the carrying amount of goodwill
Goodwill	412,938	413,650
Goodwill, Total	412,938	413,650
Acquisition	463
Foreign currency exchange effects	(1,175)
Operating segment | Food + Beverage
Changes in the carrying amount of goodwill
Goodwill	128,161	128,153
Goodwill, Total	128,161	128,153
Foreign currency exchange effects	8
Corporate Non-Segment
Changes in the carrying amount of goodwill
Goodwill	1,615	1,615
Accumulated impairment losses	$ (1,615)	$ (1,615)

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Summary of Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Amortized intangible assets:
Gross Carrying Amount	$ 454,420		$ 454,420		$ 372,417
Accumulated Amortization	(101,680)		(101,680)		(81,333)
Net Value	352,740		352,740		291,084
Aggregate amortization expense	12,320	$ 6,386	20,334	$ 12,388
Future estimated amortization expense
2020	19,192		19,192
2021	37,723		37,723
2022	37,443		37,443
2023	37,362		37,362
2024 and thereafter	221,020		$ 221,020
Weighted Average
Amortized intangible assets:
Amortization Period			12 years 7 months 6 days
Patents
Amortized intangible assets:
Gross Carrying Amount	2,703		$ 2,703		2,804
Accumulated Amortization	(1,334)		(1,334)		(1,318)
Net Value	1,369		$ 1,369		1,486
Patents | Weighted Average
Amortized intangible assets:
Amortization Period			7 years 1 month 6 days
Acquired technology
Amortized intangible assets:
Gross Carrying Amount	105,020		$ 105,020		100,511
Accumulated Amortization	(29,907)		(29,907)		(25,430)
Net Value	75,113		$ 75,113		75,081
Acquired technology | Weighted Average
Amortized intangible assets:
Amortization Period			12 years 7 months 6 days
Customer relationships
Amortized intangible assets:
Gross Carrying Amount	279,709		$ 279,709		217,934
Accumulated Amortization	(43,561)		(43,561)		(33,924)
Net Value	236,148		$ 236,148		184,010
Customer relationships | Weighted Average
Amortized intangible assets:
Amortization Period			13 years 6 months
Trademarks and trade names
Amortized intangible assets:
Gross Carrying Amount	44,508		$ 44,508		35,015
Accumulated Amortization	(13,568)		(13,568)		(11,003)
Net Value	30,940		$ 30,940		24,012
Trademarks and trade names | Weighted Average
Amortized intangible assets:
Amortization Period			6 years
License agreements and other
Amortized intangible assets:
Gross Carrying Amount	22,480		$ 22,480		16,153
Accumulated Amortization	(13,310)		(13,310)		(9,658)
Net Value	$ 9,170		$ 9,170		$ 6,495
License agreements and other | Weighted Average
Amortized intangible assets:
Amortization Period			15 years 6 months

XML

INCOME TAXES QTR (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
INCOME TAXES
Effective income tax rate (as a percent)	31.00%	27.60%	30.00%	28.70%
Tax benefits from employee share-based compensation		$ 9.1	$ 4.6	$ 11.6
Additional foreign valuation allowance		6.3		7.0
Impact of other discrete and non-discrete tax items		$ 2.9		$ 4.1

XML

DEBT - Short-term Debt Obligations (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 150,831	$ 44,259
Notes payable
Short-term Debt [Line Items]
Interest rate (as a percent)	8.00%
Notes payable, revolving credit facility and overdrafts	$ 831	1,436
Revolving credit facility
Short-term Debt [Line Items]
Interest rate (as a percent)	1.28%
Notes payable, revolving credit facility and overdrafts	$ 150,000	25,000
Overdrafts
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts		$ 17,823
Overdrafts | Minimum
Short-term Debt [Line Items]
Interest rate (as a percent)	5.68%
Overdrafts | Maximum
Short-term Debt [Line Items]
Interest rate (as a percent)	7.82%

XML

DEBT (Details) $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 EUR (€)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 EUR (€)
Components of the company's debt obligations
Consolidated Leverage Ratio		1.98	1.98
Consolidated Interest Coverage Ratio		15.50	15.50
Long-term obligations gross including current maturities		$ 1,150,942		$ 1,153,682
Current maturities of long-term obligations		(66,248)		(65,988)
Total long-term obligations		1,084,694		1,087,694
Deferred Finance Costs, Net, Total		1,952		2,241
Deferred debt issuance costs noncurrent		1,952		2,241
Long-term obligations including current maturities		1,148,990		1,151,441
Current maturities of long-term obligations		(66,248)		(65,988)
Long-term obligations, net of unamortized debt issuance costs		1,082,742		1,085,453
Aggregate long-term maturities, excluding finance lease obligations
Year One		62,259
Year Two		59,990
Year Three		133,859
Year Four		338,967
Year Five		274,900
After Year Five		$ 250,404
Minimum
Components of the company's debt obligations
Consolidated Interest Coverage Ratio		3.00	3.00
Maximum
Components of the company's debt obligations
Consolidated Leverage Ratio		3.50	3.50
5-year revolving credit facility maturing in July 2022
Components of the company's debt obligations
Revolving credit facility maximum borrowing capacity		$ 300,000	€ 150.0
Compensating balance requirement		0
Amount outstanding under line of credit		150,000	€ 0.0	25,000	€ 0.0
Notes payable
Components of the company's debt obligations
Proceeds from debt	$ 280,000
Long-term obligations gross including current maturities		168,000		168,000
Deferred Finance Costs, Net, Total		315		390
Long-term obligations including current maturities		$ 167,685		$ 167,610
Interest rate on notes (as a percent)	1.36%	1.36%	1.36%	1.36%	1.36%
Floating interest rate prior to conversion to a fixed interest rate		2.40%	2.40%	3.20%	3.20%
Notes payable 0.00% - 10.90%, due in monthly and annual installments through 2028
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 15,358		$ 19,220
Long-term obligations including current maturities		$ 15,358		$ 19,220
Notes payable 0.00% - 10.90%, due in monthly and annual installments through 2028 | Minimum
Components of the company's debt obligations
Interest rate on notes (as a percent)		0.00%	0.00%	0.00%	0.00%
Notes payable 0.00% - 10.90%, due in monthly and annual installments through 2028 | Maximum
Components of the company's debt obligations
Interest rate on notes (as a percent)		10.90%	10.90%	10.90%	10.90%
Senior unsecured notes 3.2%, due in 2022
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 75,000		$ 75,000
Deferred Finance Costs, Net, Total		52		64
Long-term obligations including current maturities		$ 74,948		$ 74,936
Interest rate on notes (as a percent)		3.20%	3.20%	3.20%	3.20%
Senior unsecured notes 3.5%, due in 2023
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 125,000		$ 125,000
Deferred Finance Costs, Net, Total		126		144
Long-term obligations including current maturities		$ 124,874		$ 124,856
Interest rate on notes (as a percent)		3.50%	3.50%	3.50%	3.50%
Senior unsecured notes 0.98%, due in 2023
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 112,340		$ 112,170
Deferred Finance Costs, Net, Total		326		356
Long-term obligations including current maturities		$ 112,014		$ 111,814
Interest rate on notes (as a percent)		1.00%	1.00%	1.00%	1.00%
Senior unsecured notes 3.4%, due in 2024
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 50,000		$ 50,000
Deferred Finance Costs, Net, Total		56		63
Long-term obligations including current maturities		$ 49,944		$ 49,937
Interest rate on notes (as a percent)		3.40%	3.40%	3.40%	3.40%
Senior unsecured notes 3.5%, due in 2024
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 100,000		$ 100,000
Deferred Finance Costs, Net, Total		126		144
Long-term obligations including current maturities		$ 99,874		$ 99,856
Interest rate on notes (as a percent)		3.50%	3.50%	3.50%	3.50%
Senior unsecured notes 1.17%, due in 2024
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 224,680		$ 224,340
Deferred Finance Costs, Net, Total		661		742
Long-term obligations including current maturities		$ 224,019		$ 223,598
Interest rate on notes (as a percent)		1.20%	1.20%	1.20%	1.20%
Senior unsecured notes 3.6%, due in 2025
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 125,000		$ 125,000
Deferred Finance Costs, Net, Total		145		169
Long-term obligations including current maturities		$ 124,855		$ 124,831
Interest rate on notes (as a percent)		3.60%	3.60%	3.60%	3.60%
Senior unsecured notes 3.6%, due in 2026
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 125,000		$ 125,000
Deferred Finance Costs, Net, Total		145		169
Long-term obligations including current maturities		$ 124,855		$ 124,831
Interest rate on notes (as a percent)		3.60%	3.60%	3.60%	3.60%
Financial lease liabilities
Components of the company's debt obligations
Long-term obligations gross including current maturities		$ 30,564		$ 29,952
Long-term obligations including current maturities		$ 30,564		$ 29,952

XML

LEASE COMMITMENTS - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Components of lease expense:
Operating lease cost	$ 5,841	$ 5,437	$ 11,095	$ 11,441
Finance lease cost:
Amortization of right-of-use assets	906	1,004	2,105	1,876
Interest on lease liabilities	369	325	717	640
Total finance lease cost	1,275	1,329	2,822	2,516
Short-term lease and variable lease costs	$ 2,430	$ 2,328	$ 4,878	$ 4,270

XML

LEASE COMMITMENTS - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 11,662	$ 10,249
Operating cash flows from finance leases	704	534
Financing cash flows from finance leases	2,545	2,294
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	11,371	9,512
Finance leases	$ 3,127	$ 11,622

XML

RETIREMENT AND DEFERRED COMPENSATION PLANS (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
United States
Change in benefit obligation:
Service cost	$ 3,562	$ 2,775	$ 7,139	$ 5,548
Interest cost	1,536	1,846	3,523	3,691
Change in plan assets:
Employer contribution			204
Components of net periodic benefit cost:
Service cost	3,562	2,775	7,139	5,548
Interest cost	1,536	1,846	3,523	3,691
Expected return on plan assets	(2,702)	(3,095)	(6,124)	(6,189)
Amortization of net loss	1,294	489	2,842	978
Net periodic benefit cost	3,690	2,015	7,380	4,028
Minimum funding requirements			0
Expected contribution in current fiscal year	200		200
Foreign Plans
Change in benefit obligation:
Service cost	1,767	1,445	3,535	2,905
Interest cost	340	495	680	996
Change in plan assets:
Employer contribution			1,100
Components of net periodic benefit cost:
Service cost	1,767	1,445	3,535	2,905
Interest cost	340	495	680	996
Expected return on plan assets	(631)	(586)	(1,265)	(1,178)
Amortization of net loss	514	359	1,028	722
Amortization of prior service cost	95	113	192	226
Net periodic benefit cost	$ 2,085	$ 1,826	$ 4,170	$ 3,671

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Accumulated other comprehensive income activity
Balance at the beginning of the period	$ 1,571,916
Balance at the end of the period	1,645,631
Foreign Currency
Accumulated other comprehensive income activity
Balance at the beginning of the period	(257,124)	$ (248,401)
Other comprehensive income (loss) before reclassifications	(23,134)	(197)
Net current-period other comprehensive income (loss)	(23,134)	(197)
Balance at the end of the period	(280,258)	(248,598)
Defined Benefit Pension Plans
Accumulated other comprehensive income activity
Balance at the beginning of the period	(83,147)	(60,463)
Amounts reclassified from accumulated other comprehensive income	3,076	1,437
Net current-period other comprehensive income (loss)	3,076	1,437
Balance at the end of the period	(80,071)	(59,026)
Derivatives
Accumulated other comprehensive income activity
Balance at the beginning of the period	(1,677)	(1,640)
Other comprehensive income (loss) before reclassifications	1,758	3,727
Amounts reclassified from accumulated other comprehensive income	(1,008)	(4,599)
Net current-period other comprehensive income (loss)	750	(872)
Balance at the end of the period	(927)	(2,512)
Accumulated Other Comprehensive Income/(Loss)
Accumulated other comprehensive income activity
Balance at the beginning of the period	(341,948)	(310,504)
Other comprehensive income (loss) before reclassifications	(21,376)	3,530
Amounts reclassified from accumulated other comprehensive income	2,068	(3,162)
Net current-period other comprehensive income (loss)	(19,308)	368
Balance at the end of the period	$ (361,256)	$ (310,136)

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (Reclassifications From Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Amount Reclassified from Accumulated Other Comprehensive Income
Miscellaneous, net	$ (923)	$ (49)	$ (2,335)	$ 417
Interest expense	8,734	8,756	17,122	17,970
Total before tax	(60,668)	(102,101)	(138,704)	(192,100)
Tax benefit	18,808	28,180	41,594	55,180
Total reclassifications for the period	(41,839)	(73,915)	(97,092)	(136,919)
Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Total reclassifications for the period	3,975	2,248	2,068	(3,162)
Defined Benefit Pension Plans | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Amortization of net loss	1,808	848	3,870	1,700
Amortization of prior service cost	95	113	192	226
Total before tax	1,903	961	4,062	1,926
Tax benefit	(463)	(245)	(986)	(489)
Total reclassifications for the period	1,440	716	3,076	1,437
Derivatives | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Total reclassifications for the period	2,535	1,532	(1,008)	(4,599)
Derivatives | Cross Currency Swap Contract: Interest Component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Interest expense	(525)	(1,552)	(1,288)	(3,006)
Derivatives | Cross Currency Swap Contract: Foreign Exchange Component | Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Miscellaneous, net	$ 3,060	$ 3,084	$ 280	$ (1,593)

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Cash Flow Hedge) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2017	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Net after-tax loss included in accumulated other comprehensive earnings	$ 733	$ 479	$ (750)	$ 872
Derivatives in Cash Flow Hedging Relationships
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	(3,268)	$ (2,004)	1,758	$ 4,065
Cross Currency Swap Contract | Derivatives in Cash Flow Hedging Relationships
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount hedged					$ 280,000
Net after-tax loss included in accumulated other comprehensive earnings			900
Fair value of derivative asset	3,100		3,100
Cross Currency Swap Contract: Interest Component | Derivatives in Cash Flow Hedging Relationships
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount expected to be recognized in earnings in next twelve months related to cross currency swap contract	$ 300		$ 300
Notes payable
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Proceeds from debt					$ 280,000
Interest rate on notes (as a percent)	1.36%		1.36%		1.36%	1.36%

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Fair Value of Derivative Instruments in the Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Fair Value of Derivative Instruments
Derivative Assets	$ 3,799		$ 3,799		$ 2,758
Derivative Liabilities	137		137		401
Foreign Exchange Contract, Amount of Gain (Loss) Recognized in Income on Derivative, not designated as hedging instruments	(940)	$ (251)	807	$ (514)
Foreign Exchange Contracts
Fair Value of Derivative Instruments
Aggregate amount of forward exchange contracts	49,400		49,400
Foreign Exchange Contract, Amount of Gain (Loss) Recognized in Income on Derivative, not designated as hedging instruments	(940)	$ (251)	807	$ (514)
Derivative Contracts Not Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	747		747		206
Derivative Liabilities	137		137		401
Derivative Contracts Not Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	747		747		206
Derivative Contracts Not Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable and accrued liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	137		137		401
Derivative Contracts Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	3,052		3,052		2,552
Derivative Contracts Designated as Hedging Instruments | Cross Currency Swap Contract | Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	$ 3,052		$ 3,052		$ 2,552

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Effect of Derivative Instruments on the Consolidated Statements of Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Derivative instruments, gain or (loss)
Foreign Exchange Contract, Amount of Gain (Loss) Recognized in Income on Derivative, not designated as hedging instruments	$ (940)	$ (251)	$ 807	$ (514)
Miscellaneous, net	(923)	(49)	(2,335)	417
Interest expense	(8,734)	(8,756)	(17,122)	(17,970)
Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	(3,268)	(2,004)	1,758	4,065
Amount of Gain (Loss) Reclassified from AOCI on Derivative	(2,535)	(1,532)	1,008	4,599
Foreign Exchange Contracts
Derivative instruments, gain or (loss)
Foreign Exchange Contract, Amount of Gain (Loss) Recognized in Income on Derivative, not designated as hedging instruments	(940)	(251)	807	(514)
Cross Currency Swap Contract: Interest Component | Interest expense | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	(208)	1,080	2,038	2,472
Amount of Gain (Loss) Reclassified from AOCI on Derivative	525	1,552	1,288	3,006
Interest expense	(8,734)		(17,122)
Cross Currency Swap Contract: Foreign Exchange Component | Other Income (Expense): Miscellaneous, net | Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	(3,060)	(3,084)	(280)	1,593
Amount of Gain (Loss) Reclassified from AOCI on Derivative	(3,060)	$ (3,084)	(280)	$ 1,593
Miscellaneous, net	$ (923)		$ (2,335)

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Schedule of Derivative Assets and Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Derivative Assets
Gross Amount	$ 3,799	$ 2,758
Net Amounts Presented in the Statement of Financial Position	3,799	2,758
Net Amount	3,799	2,758
Derivative Liabilities
Gross Amount	137	401
Net Amounts Presented in the Statement of Financial Position	137	401
Net Amount	$ 137	$ 401

XML

FAIR VALUE (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Apr. 01, 2020	Dec. 31, 2019	Oct. 31, 2019	May 31, 2019
Liabilities
Fair value of long-term obligations	$ 1,100,000	$ 1,100,000		$ 1,100,000
Payment of contingent consideration		1,500
Fusion Packaging
Liabilities
Fair value of contingent consideration arrangement	20,300	20,300	$ 19,100
Gateway Analytical
Liabilities
Fair value of contingent consideration arrangement	1,500	1,500		3,000		$ 3,000
Payment of contingent consideration	1,500
Noble
Liabilities
Fair value of contingent consideration arrangement	2,900	2,900		2,900	$ 2,900
Assets and liabilities measured at fair value on recurring basis
Assets
Foreign exchange contracts, assets	747	747		206
Cross currency swap contract, asset	3,052	3,052		2,552
Total assets at fair value	3,799	3,799		2,758
Liabilities
Foreign exchange contracts, liabilities	137	137		401
Fair value of contingent consideration arrangement	24,710	24,710		5,930
Total liabilities at fair value	24,847	24,847		6,331
Assets and liabilities measured at fair value on recurring basis | Level 2
Assets
Foreign exchange contracts, assets	747	747		206
Cross currency swap contract, asset	3,052	3,052		2,552
Total assets at fair value	3,799	3,799		2,758
Liabilities
Foreign exchange contracts, liabilities	137	137		401
Total liabilities at fair value	137	137		401
Assets and liabilities measured at fair value on recurring basis | Level 3
Liabilities
Fair value of contingent consideration arrangement	24,710	24,710		5,930
Total liabilities at fair value	$ 24,710	$ 24,710		$ 5,930

XML

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Mar. 31, 2019	Mar. 31, 2017
Brazil
Commitments and contingencies
Accrual for Environmental Loss Contingencies	$ 400,000			$ 1,500,000
Payments to settle environmental loss contingency	100,000	$ 600,000
Brazil | Reduction of gross receipts tax
Commitments and contingencies
Recovery of part of claim	700,000		$ 2,700,000
Brazil | Reduction of gross receipts tax | Cost of Sales
Commitments and contingencies
Recovery of part of claim	700,000		1,700,000
Brazil | Reduction of gross receipts tax | Interest Income
Commitments and contingencies
Recovery of part of claim			$ 1,000,000.0
Brazil | Minimum | Reduction of gross receipts tax
Commitments and contingencies
Estimated potential gain contingency, recoveries	1,500,000
Brazil | Maximum | Reduction of gross receipts tax
Commitments and contingencies
Estimated potential gain contingency, recoveries	7,500,000
Indemnification agreements
Commitments and contingencies
Liabilities recorded under indemnification agreements	0	0
Tax Assessment | Brazil
Commitments and contingencies
Estimated loss contingency		6,100,000
Loss contingency liability recorded	0
Tax Assessment, Interest | Brazil
Commitments and contingencies
Estimated loss contingency		2,300,000
Tax Assessment, Penalites | Brazil
Commitments and contingencies
Estimated loss contingency		$ 800,000
Fire damage | France
Commitments and contingencies
Estimated potential gain contingency, recoveries	0
Insurance receivable	$ 0

XML

STOCK REPURCHASE PROGRAM (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2020	Apr. 18, 2019
Stock repurchase program
Aggregate amount of share repurchases (in dollars)	$ 4,096	$ 19,096
Common stock repurchased (retired and held in treasury) (in shares)	34	193
Common stock repurchased (retired and held in treasury)	$ 4,100	$ 19,100
Remaining authorized repurchase amount			$ 278,500
Stock Repurchase Program April 18, 2019
Stock repurchase program
Share repurchases authorized amount				$ 350,000

XML

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
STOCK-BASED COMPENSATION
Proceeds from stock option exercises	$ 30,058	$ 70,712
Stock options
STOCK-BASED COMPENSATION
Award vesting period	3 years
Expiration period	10 years
Compensation expense	$ 1,300	3,200
Compensation expense, net of tax	1,000	2,700
Fair value of shares vested	7,600	12,200
Proceeds from stock option exercises	30,100
Actual tax benefit realized for the tax deduction from option exercises	6,400
Unrecognized compensation cost expected to be recognized in future periods	$ 1,000
Weighted-average period over which compensation cost is expected to be recognized	8 months 12 days
Stock options | Selling, research & development and administrative expenses
STOCK-BASED COMPENSATION
Compensation expense	$ 1,100	2,700
Restricted stock units
STOCK-BASED COMPENSATION
Compensation expense	16,300	9,800
Actual tax benefit realized for the tax deduction from option exercises	3,000
Unrecognized compensation cost expected to be recognized in future periods	$ 58,800
Weighted-average period over which compensation cost is expected to be recognized	2 years 2 months 12 days
Weighted-Average Grant-Date Fair Value
Fair value of units vested	$ 10,700	4,100
Intrinsic value of units vested	$ 12,800	$ 4,800
Restricted stock units (time-based)
STOCK-BASED COMPENSATION
Award vesting period	3 years
Restricted stock unit activity
Balance at the beginning of the period (in shares)	480,729
Granted (in shares)	229,033
Vested (in shares)	(125,020)
Forfeited (in shares)	(5,692)
Balance at the end of the period (in shares)	579,050
Weighted-Average Grant-Date Fair Value
Nonvested at the beginning of the period (in dollars per share)	$ 95.45
Granted (in dollars per share)	85.57
Vested (in dollars per share)	85.55
Forfeited (in dollars per share)	99.08
Nonvested at the end of the period (in dollars per share)	$ 92.14
Restricted stock units (performance-based)
STOCK-BASED COMPENSATION
Award vesting period	3 years
Assumptions used to estimate fair value of stock options granted
Dividend Yield (as a percent)	1.72%	1.30%
Expected Stock Price Volatility (as a percent)	23.80%	16.50%
Risk-free Interest Rate (as a percent)	0.31%	2.19%
Assumptions used to estimate fair value of restricted stock units granted
Fair value per stock award (in dollars per share)	$ 94.98	$ 134.97
Grant date stock price (in dollars per share)	$ 83.93	$ 104.51
Expected Stock Price Volatility (as a percent)	23.80%	16.50%
Expected average volatility of peer companies (as a percent)	48.50%	31.90%
Correlation assumption (as a percent)	63.50%	37.40%
Risk-free Interest Rate (as a percent)	0.31%	2.19%
Dividend Yield (as a percent)	1.72%	1.30%
Restricted stock unit activity
Balance at the beginning of the period (in shares)	181,680
Granted (in shares)	417,313
Forfeited (in shares)	(6,714)
Balance at the end of the period (in shares)	592,279
Weighted-Average Grant-Date Fair Value
Nonvested at the beginning of the period (in dollars per share)	$ 117.26
Granted (in dollars per share)	93.08
Forfeited (in dollars per share)	108.10
Nonvested at the end of the period (in dollars per share)	$ 100.29
Stock Awards Plans | Stock options
Stock options activity
Outstanding at the beginning of the period (in shares)	5,044,180
Exercised (in shares)	(460,243)
Forfeited or expired (in shares)	(14,200)
Outstanding at the end of the period (in shares)	4,569,737
Exercisable at the end of the period (in shares)	4,416,415
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 68.32
Exercised (in dollars per share)	58.21
Forfeited or expired (in dollars per share)	76.07
Outstanding at the end of the period (in dollars per share)	69.38
Exercisable at the end of the period (in dollars per share)	$ 68.62
Weighted-Average Remaining Contractual Term (Years):
Outstanding at the end of the period	5 years
Exercisable at the end of the period	4 years 10 months 24 days
Aggregate Intrinsic Value:
Outstanding at the end of the period	$ 194,684
Exercisable at the end of the period	190,936
Intrinsic Value of Options Exercised	$ 26,027	$ 65,944
Director Stock Option Plans | Stock options
Stock options activity
Outstanding at the beginning of the period (in shares)	135,251
Exercised (in shares)	(30,751)
Outstanding at the end of the period (in shares)	104,500
Exercisable at the end of the period (in shares)	104,500
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 58.45
Exercised (in dollars per share)	51.22
Outstanding at the end of the period (in dollars per share)	60.58
Exercisable at the end of the period (in dollars per share)	$ 60.58
Weighted-Average Remaining Contractual Term (Years):
Outstanding at the end of the period	3 years 1 month 6 days
Exercisable at the end of the period	3 years 1 month 6 days
Aggregate Intrinsic Value:
Outstanding at the end of the period	$ 4,902
Exercisable at the end of the period	4,902
Intrinsic Value of Options Exercised	$ 1,973	$ 722
Director Stock Option Plans | Restricted stock units
STOCK-BASED COMPENSATION
Award vesting period	1 year
Director Stock Option Plans | Restricted stock units (time-based)
Restricted stock unit activity
Granted (in shares)	12,379
Vested (in shares)	(11,490)

XML

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Earning per share
Authorized common stock (in shares)	199,000		199,000		199,000
Common stock, par value (in dollars per share)	$ 0.01		$ 0.01		$ 0.01
Income (Numerator)
Income available to common stockholders, basic (in dollars)	$ 41,839	$ 73,915	$ 97,092	$ 136,919
Income available to common stockholders, diluted (in dollars)	$ 41,839	$ 73,915	$ 97,092	$ 136,919
Shares (Denominator)
Basic (in shares)	64,262	63,471	64,135	63,219
Total average equivalent shares	66,384	66,232	66,246	65,842
Per Share Amount
Net income per share, basic (in dollars per share)	$ 0.65	$ 1.16	$ 1.51	$ 2.17
Net income per share, diluted (in dollars per share)	$ 0.63	$ 1.12	$ 1.47	$ 2.08
Stock options
Shares (Denominator)
Effect of dilutive stock based compensation (in shares)	1,661	2,533	1,734	2,411
Restricted stock units
Shares (Denominator)
Effect of dilutive stock based compensation (in shares)	461	228	377	212

XML

SEGMENT INFORMATION (Summary of Reportable Segments) (Details) $ in Thousands	3 Months Ended		6 Months Ended		30 Months Ended
	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) segment	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Financial information regarding the Company's reportable segments
Number of reportable segments | segment			3
Net sales	$ 699,305	$ 742,661	$ 1,420,858	$ 1,487,121
Acquisition related costs	(3,592)	(1,059)	(5,866)	(1,059)
Total Restructuring Initiatives	7,331	1,737	12,170	11,267
Depreciation and amortization	56,429	47,867	107,235	95,356
Interest expense	(8,734)	(8,756)	(17,122)	(17,970)
Interest income	175	1,033	350	2,781
Income before Income Taxes	60,668	102,101	138,704	192,100
Capital Expenditures			122,986	124,774
Total Assets	3,814,016		3,814,016		$ 3,814,016	$ 3,562,119
Employee severance
Financial information regarding the Company's reportable segments
Total Restructuring Initiatives			8,190
Business Transformation
Financial information regarding the Company's reportable segments
Total Restructuring Initiatives	7,300	1,700	12,200	11,300
Capital Expenditures					$ 43,000
Beauty + Home
Financial information regarding the Company's reportable segments
Net sales	299,786	342,080	624,346	709,739
Adjusted EBITDA	23,974	48,745	58,221	101,936
Total Restructuring Initiatives	7,324	1,259	12,231	9,528
Pharma
Financial information regarding the Company's reportable segments
Net sales	301,259	281,939	598,455	554,640
Adjusted EBITDA	104,099	101,428	212,441	198,785
Total Restructuring Initiatives	(111)	(113)	(142)	213
Food + Beverage
Financial information regarding the Company's reportable segments
Net sales	98,260	118,642	198,057	222,742
Adjusted EBITDA	17,785	20,944	33,192	37,635
Total Restructuring Initiatives	75	112	178	622
Corporate & Other
Financial information regarding the Company's reportable segments
Adjusted EBITDA	(9,279)	(10,630)	(23,107)	(23,385)
Total Restructuring Initiatives	43	479	(97)	904
Operating segment
Financial information regarding the Company's reportable segments
Net sales	709,377	752,925	1,439,734	1,505,649
Operating segment | Beauty + Home
Financial information regarding the Company's reportable segments
Net sales	306,469	349,253	636,935	722,756
Operating segment | Pharma
Financial information regarding the Company's reportable segments
Net sales	303,885	284,577	603,475	559,071
Operating segment | Food + Beverage
Financial information regarding the Company's reportable segments
Net sales	99,023	119,095	199,324	223,822
Intersegment
Financial information regarding the Company's reportable segments
Net sales	10,072	10,264	18,876	18,528
Intersegment | Beauty + Home
Financial information regarding the Company's reportable segments
Net sales	6,683	7,173	12,589	13,017
Intersegment | Pharma
Financial information regarding the Company's reportable segments
Net sales	2,626	2,638	5,020	4,431
Intersegment | Food + Beverage
Financial information regarding the Company's reportable segments
Net sales	$ 763	$ 453	$ 1,267	$ 1,080

XML

ACQUISITIONS (Details) - USD ($) $ in Thousands						1 Months Ended	3 Months Ended			6 Months Ended
	Apr. 01, 2020	Oct. 31, 2019	Aug. 02, 2019	Jun. 05, 2019	May 31, 2019	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Acquisitions
Acquisition of business, net of cash received										$ 159,570	$ 49,131
Payment of contingent consideration										1,500
Acquisition related costs							$ (3,592)		$ (1,059)	(5,866)	$ (1,059)
Restricted cash included in prepaid and other							9,738			9,738
Assets
Goodwill							861,928			861,928			$ 763,461
Carrying amount adjustments related to fair value adjustments
Investment impairment										0
Bapco
Acquisitions
Ownership interest previously held														20.00%
Fusion Packaging
Acquisitions
Percentage of interest acquired	100.00%
Acquisition of business, net of cash received	$ 163,800
Fair value of contingent consideration arrangement	19,100						20,300			20,300
Sales of acquiree during the reporting period							13,800
Pretax income of acquiree during the reporting period							(3,300)
Fair value adjustment for inventory sold during the quarter							2,700
Restricted cash included in prepaid and other							5,700			5,700
Goodwill expected to be tax deductible												$ 82,300
Assets
Cash and equivalents	$ 1,000											1,010
Accounts receivable												4,380
Inventories												386
Prepaid and other												1,090
Property, plant and equipment												2,885
Goodwill												99,644
Intangible assets												79,900
Operating lease right-of-use assets												4,744
Other miscellaneous assets												65
Liabilities
Accounts payable, accrued and other liabilities												5,641
Operating lease liabilities												4,207
Deferred and other non-current liabilities												322
Net assets acquired												$ 183,934
Fusion Packaging | Subsequent Events
Acquisitions
Working capital escrow released						$ 2,000
2019 Acquisitions
Acquisitions
Goodwill expected to be tax deductible													31,100
Assets
Cash and equivalents													3,427
Accounts receivable													3,504
Prepaid and other													2,478
Property, plant and equipment													4,267
Goodwill													59,143
Intangible assets													52,980
Other miscellaneous assets													430
Liabilities
Accounts payable, accrued and other liabilities													5,388
Deferred income taxes													2,592
Deferred and other non-current liabilities													1,598
Net assets acquired													116,651
Noble
Acquisitions
Percentage of interest acquired		100.00%
Acquisition of business, net of cash received		$ 62,300						$ 463
Fair value of contingent consideration arrangement		2,900					2,900			2,900			2,900
Restricted cash included in prepaid and other													5,000
Working capital escrow released								$ 1,000
Assets
Cash and equivalents		$ 1,600
Gateway Analytical
Acquisitions
Acquisition of business, net of cash received					$ 7,000
Fair value of contingent consideration arrangement					$ 3,000		1,500			1,500			$ 3,000
Payment of contingent consideration							1,500
Contingent consideration liability, current							$ 1,500			$ 1,500
Nanopharm
Acquisitions
Acquisition of business, net of cash received				$ 38,100
Assets
Cash and equivalents				$ 1,800
Bapco
Acquisitions
Percentage of interest acquired			80.00%
Acquisition of business, net of cash received			$ 3,800
Assets
Cash and equivalents			$ 2,900

XML

ACQUISITIONS (Acquired Intangibles) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
2019 Acquisitions
Acquired finite-lived intangible assets
Estimated Fair Value of Asset		$ 52,980
2019 Acquisitions | Acquired technology
Acquired finite-lived intangible assets
Weighted average useful life		8 years
Estimated Fair Value of Asset		$ 9,160
2019 Acquisitions | Customer relationships
Acquired finite-lived intangible assets
Weighted average useful life		11 years
Estimated Fair Value of Asset		$ 39,379
2019 Acquisitions | Trademarks and trade names
Acquired finite-lived intangible assets
Weighted average useful life		4 years
Estimated Fair Value of Asset		$ 2,457
2019 Acquisitions | License agreements and other
Acquired finite-lived intangible assets
Weighted average useful life		1 year
Estimated Fair Value of Asset		$ 1,984
Fusion Packaging
Acquired finite-lived intangible assets
Estimated Fair Value of Asset	$ 79,900
Fusion Packaging | Acquired technology
Acquired finite-lived intangible assets
Weighted average useful life	4 years
Estimated Fair Value of Asset	$ 4,600
Fusion Packaging | Customer relationships
Acquired finite-lived intangible assets
Weighted average useful life	13 years
Estimated Fair Value of Asset	$ 62,300
Fusion Packaging | Trademarks and trade names
Acquired finite-lived intangible assets
Weighted average useful life	4 years
Estimated Fair Value of Asset	$ 10,300
Fusion Packaging | License agreements and other
Acquired finite-lived intangible assets
Weighted average useful life	3 months
Estimated Fair Value of Asset	$ 2,700

XML

ACQUISITIONS (Pro Forma) (Details) - Fusion Packaging - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Unaudited pro forma financial information
Net Sales	$ 699,305	$ 762,148	$ 1,428,821	$ 1,525,826
Net Income Attributable to AptarGroup, Inc.	$ 45,989	$ 75,811	$ 96,350	$ 139,003
Net Income per common share - basic	$ 0.72	$ 1.19	$ 1.50	$ 2.20
Net Income per common share - diluted	$ 0.69	$ 1.14	$ 1.45	$ 2.11

XML

INVESTMENT IN EQUITY SECURITIES (Details) € in Thousands, $ in Thousands			6 Months Ended		12 Months Ended
	Apr. 01, 2020 USD ($)	Oct. 01, 2019	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2009 EUR (€)	Jan. 01, 2020 USD ($)	Dec. 31, 2019 USD ($)	Aug. 31, 2019 USD ($)
Other Investments			$ 3,794					$ 3,538
Total equity method and other investments			44,193					8,396
Investment in unconsolidated affiliate			34,044
Proceeds from sale of investment in equity securities				$ 16,487
Investment impairment			0
Preferred equity stocks
Other Investments									$ 3,500
Number of preferred equity investments									2
Sonmol
Equity method investments			4,969
Investment in unconsolidated affiliate	$ 5,000
Ownership percentage of equity method investment	30.00%
BTY
Equity method investments			30,894				$ 32,000	119
Ownership percentage of equity method investment							49.00%
Payment for equity method investment			28,800
Obligation associated with an agreement to acquire equity method investement			3,200
BTY | Strategic Definitive Agreement
Ownership percentage of equity method investment		49.00%
Initial lock-up period		5 years
Second lock-up period		3 years
BTY | Strategic Definitive Agreement | Call Option | Minimum
Ownership percentage of equity method investment		26.00%
BTY | Strategic Definitive Agreement | Call Option | Maximum
Ownership percentage of equity method investment		31.00%
Kali Care
Equity method investments			3,691					3,881
Investment in unconsolidated affiliate					$ 5,000
Ownership percentage of equity method investment					20.00%
Desotec GmbH
Equity method investments			$ 845					$ 858
Investment in unconsolidated affiliate | €						€ 574
Ownership percentage of equity method investment						23.00%

XML

RESTRUCTURING INITIATIVE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		30 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020
Restructuring initiatives
Capital Expenditures			$ 122,986	$ 124,774
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			10,699
Expense recognized related to the plan	$ 7,331	$ 1,737	12,170	11,267
Cash paid			(6,919)
Interest and FX impact			175
Restructuring reserve, balance at the end of the period	16,125		16,125		$ 16,125
Employee severance
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			7,090
Expense recognized related to the plan			8,190
Cash paid			(2,324)
Interest and FX impact			192
Restructuring reserve, balance at the end of the period	13,148		13,148		13,148
Professional fees and other costs
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			3,609
Expense recognized related to the plan			3,980
Cash paid			(4,595)
Interest and FX impact			(17)
Restructuring reserve, balance at the end of the period	2,977		2,977		2,977
Business Transformation
Restructuring initiatives
Expected implementation costs	125,000		125,000		125,000
Expected capital investments related to transformation plan	50,000		50,000		50,000
Cumulative expense incurred	98,700		98,700		98,700
Capital Expenditures					$ 43,000
Restructuring reserve
Expense recognized related to the plan	7,300	1,700	12,200	11,300
Beauty + Home
Restructuring reserve
Expense recognized related to the plan	7,324	1,259	12,231	9,528
Pharma
Restructuring reserve
Expense recognized related to the plan	(111)	(113)	(142)	213
Food + Beverage
Restructuring reserve
Expense recognized related to the plan	75	112	178	622
Corporate & Other
Restructuring reserve
Expense recognized related to the plan	$ 43	$ 479	$ (97)	$ 904